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Abstract 
This thesis details the applications of a class of chiral-at-metal iridium(III) and rhodium(III) 
complexes for asymmetric catalysis. 
A rhodium-based asymmetric catalyst Δ-RhO is introduced which derives its optical activity from 
octahedral centrochirality. Besides serving as the exclusive source of chirality, the rhodium center 
functions as a Lewis acid to activate α,-unsaturated 2-acyl imidazoles by two point binding and thereby 
catalyzes the asymmetric Michael addition of CH-acidic -dicarbonyl compounds, for which the 
rhodium catalyst is found to be superior to its iridium congener (chapter 3.1). Due to its straightforward 
proline-mediated synthesis, high catalytic activity, and tolerance towards moisture and air, this chiral-
at-rhodium complex has been used as chiral Lewis acid catalyst for many other asymmetric 
transformations in the Meggers group. 
The chiral-at-metal complexes Δ-IrO and Δ-IrS are investigated as highly efficient dual function 
photoredox/chiral Lewis acid catalysts in asymmetric photoactivated reactions. A simple chiral iridium 
complex Δ-IrO is capable of catalyzing the visible light activated α-aminoalkylation of 2-acyl-1-phenyl 
imidazoles, thereby serving as a “2-in-1” catalyst by combining photoinduced oxidation with 
asymmetric alkylation (chapter 3.2). Moreover, its derivative Δ-IrS is successfully utilized to the 
catalytic enantio- and diastereoselective redox coupling of trifluoromethyl ketones with tertiary amines 
to form 1,2-diamino alcohols (chapter 3.3). This single catalyst strategy provides new avenues for the 
synthesis of non-racemic molecules. 
An alternative strategy of merging the chiral Lewis acid Δ-RhS with photoredox catalyst fac-[Ir(ppy)3] 
is well applied to the asymmetric photoredox-mediated C(sp3)-H functionalization. This synthetic 
strategy exploits a radical translocation (1,5-hydrogen transfer) from an oxygen-centered to a carbon-
centered radical with a subsequent stereocontrolled radical addition, affording C-C bond formation 
products with high enantioselectivities (up to 97% ee). Notably, the previously developed dual function 
catalyst Δ-IrS is not applicable for this asymmetric transformation (chapter 3.4). 
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Zusammenfassung 
In der vorliegenden Dissertation wird die Anwendung neuer Iridium(III)- und Rhodium(III)-
Komplexe mit metallzentrierter Chiralität in der asymmetrischen Katalyse erläutert. 
Es wird eine neue Klasse chiraler Rhodium(III)-Komplexe vorgestellt, die ihre optische Aktivität 
ausschließlich durch ihre oktaedrische metallzentrierte Chiralität erhält. Darüber hinaus wirkt das 
Metallzentrum nicht nur exklusiv als Quelle der Chiralität, sondern als reaktives, LEWIS-saures Zentrum. 
Zum Einsatz kommt Δ-RhO bei der Aktivierung von α,β-ungesättigten 2-Acylimidazolen in der 
asymmetrischen Michael-Addition mit CH-aciden β-Dicarbonylen. In dieser Reaktion zeigt Δ-RhO im 
Vergleich zu seinem Δ-IrO-Analogon überlegene Aktivität (Kapitel 3.1). Bedingt durch seine einfache 
Prolin-vermittelte Synthese, seine hohe katalytische Aktivität, die hohe Stabilität an Luft und einer 
Toleranz gegenüber Feuchtigkeit, wird der „chiral-at-metal“ Komplex Δ-RhO in der Arbeitsgruppe 
MEGGERS mittlerweile in einer Vielzahl asymmetrischer Katalysen als chiraler LEWIS-Säure-
Katalysator eingesetzt. 
Weitere Untersuchungen hinsichtlich der Eignung von Δ-IrO und Δ-IrS als bifunktionelle 
Photoredox/LEWIS-Säure Katalysatoren in asymmetrischen, durch Licht aktivierte Reaktionen, wurden 
in den folgenden Projekten durchgeführt. Der einfach gehaltene chirale Iridium(III)-Komplex Δ-IrO ist 
in der Lage, die durch sichtbares Licht aktivierte α-Aminoalkylierung von 2-Acyl-1-phenylimidazol zu 
katalysieren. Dabei fungiert Δ-IrO als "2-in-1"-Katalysator durch die Kombination von 
photoinduzierter Oxidation und asymmetrischer Alkylierung (Kapitel 3.2). Des Weiteren wurde das 
Derivat Δ-IrS erfolgreich für die enantio- und diastereoselektive Redox-Kupplung von 
Trifluormethylketonen mit tertiären Aminen zur Synthese von 1,2-Diaminoalkoholen eingesetzt 
(Kapitel 3.3). Die gezeigte Strategie, einen einzelnen multifunktionellen Katalysator zu verwenden, 
ebnet neue Wege zur Synthese nicht-racemischer Verbindungen.  
Als alternative konnte der chirale LEWIS-Säure-Katalysator Δ-RhS mit dem Photoredox-Katalysator 
fac-[Ir(ppy)3] in der asymmetrischen, photoredox-vermittelten C(sp3)-H Funktionalisierung eingesetzt 
werden. In dieser Strategie wird eine 1,5-Wasserstoff-Verschiebung genutzt, um ein Sauerstoffradikal in 
ein Kohlenstoffradikal zu überführen, welches unter katalysatorkontrollierter C-C-Bindungsknüpfung 
VIII 
 
Produkte mit hohem Enantiomerenüberschuss erzeugt (bis zu 97% ee). Beachtenswert ist, dass der 
analoge bifunktionelle Iridiumkomplex Δ-IrS nicht für diese Reaktion geeignet ist (Kapitel 3.4). 
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Chapter 1: Theoretical Part 
1.1 Introduction 
Asymmetric catalysis is a fundamental methodology in modern chemistry and is particularly 
important in the field of pharmaceuticals, as the different enantiomers or diastereomers of a molecule 
often have different biological activity.1 Thalidomide is a striking example that illustrates the difference 
in which the (R)-enantiomer acts as a sedative in contrast to deformities caused by the (S)-enantiomer 
(Figure 1).2 Therefore, the asymmetric synthesis of enantiomerically pure compounds is under intense 
scrutiny. 
 
Figure 1 Structures of (R)-thalidomide and (S)-thalidomide. 
Photocatalysis has seen growing interest not only in the reactions of small molecules such as H2O 
(water splitting)3 and CO2 (forming solar fuels)4, but also in organic synthesis.5 Particularly, the recent 
progress in this area has been promoted by using visible light as a driving force, providing a number of 
otherwise unachievable modes of molecular transformations.6 
Combining these two aspects, visible light induced 
asymmetric photocatalysis is appreciated as a powerful tool to 
achieve high efficiency and selectivity in asymmetric 
synthesis.7 Whereas asymmetric catalysis is considered as an 
economic strategy to obtain enantiopure compounds, visible 
light can assist in generating highly reactive intermediates under mild conditions and at the same time 
providing an environmentally friendly and sustainable source of energy for activating chemical reactions. 
This chapter will be divided into two parts: 1) summarize some typical examples of asymmetric 
catalysis with octahedral chiral only-at-metal complexes; 2) discuss two systems of visible light 
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activated asymmetric catalysis, namely dual catalyst systems based on the combined use of photoredox 
with chiral catalyst or single chiral catalyst systems.  
1.2 Asymmetric Catalysis with Octahedral Chiral only-at-Metal Complexes 
A crucial role in asymmetric catalysis is the development of efficient chiral catalysts. Octahedral 
chiral only-at-metal complexes are an emerging class of catalysts for catalytic asymmetric synthesis of 
non-racemic compounds.8 For the developed octahedral chiral only-at-metal complexes, the central 
transition metal always serves as a structural anchorpoint and provides metal centrochirality, catalysis 
is mediated through the ligand sphere, thereby merging organocatalysis with transition metal catalysis. 
1.2.1 Octahedral Chiral only-at-Metal Ruthenium(II) and Cobalt(III) Complexes for 
Asymmetric Catalysis 
In 2003, the Fontecave group reported asymmetric oxidation of sulfide with an octahedral 
ruthenium(II) complex Λ-Ru1 in which the ruthenium ion is coordinated by two 2,9-dimethyl-1,10-
phenanthroline ligands and two labile acetonitrile molecules (Figure 2). Despite the low 
enantioselectivity obtained (18% ee), this study reveals the first experimental validation of the concept 
that an octahedral chiral only-at-metal complex has the potential to catalyze enantioselective 
oxidations.9 Later, they reported asymmetric transfer hydrogenation with a dinuclear ruthenium catalyst 
Λ-Ru2, in which the Λ-[Ru(2,2'-bipyridine)2(2,2'-bipyrimidine)]2+ moiety serves as a chiral bidentate 
ligand for a second, catalytically active ruthenium complex. The low enantioselective (26% ee) can be 
rationalized by the large distance between the chiral and catalytic centers.10 
 
Figure 2 Asymmetric catalysis by octahedral chiral-at-metal ruthenium(II) complexes. 
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In 2008, Gladysz and co-workers demonstrated asymmetric conjugate addition with a simple 
octahedral chiral-at-metal Werner complex.11 As shown in Figure 3, the enantiopure chiral-at-metal 
cobalt(III) complex Δ-Co is capable of catalyzing the Michael addition of dimethyl malonate to 
cyclopentenone in CH2Cl2 to afford the adduct in 78% yield, albeit with a low enantioselectivity of just 
33% ee. The chirality induction in this reaction relies on the stereogenic octahedral cobalt center and N-
H bonds (H-bonding donors). 
 
Figure 3 Asymmetric Michael addition by a chiral-at-metal Werner complex. 
1.2.2 Octahedral Chiral only-at-Metal Iridium(III) Complexes for Asymmetric Catalysis 
For the past several years, the Meggers group has successfully designed and synthesized a series of 
octahedral chiral-at-metal iridium(III) complexes for asymmetric catalysis. 
In 2013, the Meggers group reported a chiral-at-metal iridium(III) complex Λ-Ir1 for the highly 
efficient catalytic asymmetric transfer hydrogenation of β,β-disubstituted nitroalkenes (Figure 4).12 The 
design of the substitutionally inert biscyclometalated iridium complex Λ-Ir1 was inspired by the non-
covalent organocatalyst thiourea.13 While the pyrazole moiety acts as a double H-bonding donor for the 
nitroalkene, a hydroxy group serves as a H-bonding acceptor for the Hantzsch ester (Figure 5). Notably, 
although the iridium complex relies only on the formation of three hydrogen bonds, it exceeds the 
performance of most organocatalysts with respect to enantioselectivitities (up to 99% ee) and catalyst 
loadings (down to 0.1 mol%). This work is of great significance as it reveals the potential of octahedral 
metal complexes as chiral scaffolds for the design of high-performance asymmetric catalysts. 
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Figure 4 Asymmetric transfer hydrogenation catalyzed by a chiral-at-metal iridium(III) complex. 
 
Figure 5 Proposed transition state of Λ-Ir1 in asymmetric transfer hydrogenation. 
This non-covalent metal-templated complex was further applied to a more challenging transformation, 
namely enantioselective Friedel-Crafts alkylation of indoles to β,β-disubstituted nitroolefins. By using 
1 mol% of Λ-Ir2, all-carbon quaternary centers can be created in high enantioselectivities of up to 98% 
ee (Figure 6). Since the iridium catalyst functions completely as a H-bonding catalyst, the high reactivity 
and enantioselectivity of Λ-Ir2 are superior to the performance of Λ-Ir1 (70% ee with 5 mol% catalyst 
loading) which can be rationalized by the H-bonding affinity of the carboxamide (-CONEt2, Λ-Ir2) over 
the hydroxyl group (-OH, Λ-Ir1) in combination with the preferred conformation of the amide group, 
thereby placing the amide oxygen in an ideal position for H-bonding with the indole nucleophile. 
Notably, tested thiourea organocatalysts only provided very low enantioselectivities for this challenging 
formation.14 
 
Figure 6 Asymmetric Friedel-Crafts alkylation catalyzed by a chiral-at-metal iridium(III) complex. 
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Inert octahedral metal complexes are general, powerful templates for the efficient design of 
bifunctional catalysts. The developed octahedral 3-aminopyrazolato iridium(III) complexes Λ-Ir3 and 
Λ-Ir4 as chiral Brønsted base catalysts are suitable for highly effective asymmetric sulfa-Michael 
addition and aza-Henry reactions, permitting catalyst loadings down to 0.02 and 0.25 mol%, respectively 
(Figure 7). The observed high reactivity and stereoselectivity can be rationalized by the bifunctional 
mode of action in which the iridium catalyst, after the initial proton transfer, controls a ternary complex 
through defined H-bonding interactions (Figure 8).15  
 
Figure 7 Asymmetric sulfa-Michael and aza-Henry reactions catalyzed by chiral Brønsted base catalysts. 
 
Figure 8 Proposed ternary complex for the asymmetric sulfa-Michael addition catalyzed by Λ-Ir3. 
Asymmetric enamine/H-bonding dual activation catalyst is presented as another successful example 
for the power for a metal-templated design of ‘‘organocatalyst’’ (Figure 9). An octahedral chiral-at-
metal complex Λ-Ir5 catalyzes the enantioselective α-amination of aldehydes with high 
enantioselectivies of up to 97% ee and catalyst loadings down to 0.1 mol%. Mechanistically, this highly 
efficient chiral iridium complex can be rationalized by a dual activation catalysis which converts the 
aldehyde into a nucleophilic enamine, while at the same time activating the azodicarboxylate 
electrophile through H-bonding with one OH-group (Figure 10).16 Notably, Λ-Ir5 constitutes one of the 
most efficient catalysts for the enantioselective α-amination of aldehydes to date.  
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Figure 9 Asymmetric catalysis by enamine/H-bonding dual activation chiral-at-metal Iridium(III) 
catalyst. 
 
Figure 10 Proposed enamine/H-bonding mechanism model of the asymmetric α-amination catalyzed by 
iridium complex Λ-Ir5. 
Having demonstrated several remarkable asymmetric transformations directed by the ligand sphere 
of the stereogenic iridium center, the Meggers group further modified the metal-templated system to 
Lewis acid catalysts. In 2014, the Meggers group introduced a substitutionally labile chiral-at-metal 
iridium(III) complex Λ-IrO. As shown in Figure 11, the catalytic activity investigation demonstrated 
that the chiral complex Λ-IrO can effectively catalyze the enantioselective Friedel-Crafts addition of 
indoles to α,β-unsaturated 2-acyl imidazoles with high yields (75-99%) and excellent 
enantioselectivities (90-98% ee) at low catalyst loadings (0.25-2 mol%).17 
 
Figure 11 Asymmetric Friedel-Crafts reaction by a simple chiral-at-metal Lewis acid catalyst. 
The iridium complex Λ-IrO serves as a chiral Lewis acid by activating α,β-unsaturated 2-acyl 
imidazoles through bidentate N,O-coordination. Despite its substitutional lability, the metal-centered 
chirality is maintained throughout the catalysis. A proposed model for the asymmetric induction in the 
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course of the indole addition by using Λ-IrO as catalyst is shown in Figure 12 and demonstrates that Re 
face of the alkene is sterically shielded effectively by one tert-butyl group, and the Si face is leaving 
open for the approach of nucleophile. This novel class of reactive chiral-at-metal complexes has been 
proven to be of high value for a variety of asymmetric transformations in the Meggers group.18 
 
Figure 12 Proposed reaction model of enantioselective Friedel-Crafts addition with Λ-IrO.  
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1.3 Asymmetric Photocatalysis Activated by Visible Light 
In homogeneous photocatalysis, photoredox catalysis employs small quantities of a light-sensitive 
compound (photocatalyst) that, when excited by light, can mediate the transfer of electron or energy 
between chemical compounds.18 Desired features of common photocatalysts are as follows: 1) 
photostability; 2) long excited-state lifetime; 3) strong absorption in the visible region; 4) high reduction 
or oxidation potential to achieve electron transfer to substrates. Alongside organic dyes and inorganic 
semiconductors, the most widely-applied and effective photocatalysts are coordinatively saturated 
transition-metal-pyridyl complexes which are outlined in Figure 13.19 
 
Figure 13 The common classic transition metal photocatalysts (vs. SCE). 
1.3.1 Dual Catalyst Systems in Asymmetric Photoredox Catalysis 
The combination of visible light redox catalysts with chiral catalysts has enabled a number of highly 
enantioselective photoinduced reactions. The following section summarized some representative 
catalytic asymmetric transformations utilizing dual photoredox organocatalysis or transition-metal 
catalysis. 
1) Dual photoredox organocatalysis: covalent interactions 
In 2008, MacMillan’s group reported the first example of the combination of visible light induced 
photoredox catalysis and asymmetric organocatalysis.20 Accordingly, the reaction of aldehydes with 
bromo diethylmalonates or phenacyl bromides in the presence of [Ru(bpy)3]Cl2, chiral imidazolidinone 
and 15 W compact fluorescent lamp (CFL) afforded α-alkylation products with highly 
enantioselectivities of up to 99% ee (Figure 14). The generality of this dual photoredox organocatalytic 
protocol was demonstrated by further investigating the enantioselective α-trifluoromethylation21 and α-
benzylation of aldehydes.22 
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A mechanism for this transformation combining an enamine catalytic cycle and a photoredox catalytic 
cycle is shown in Figure 14. It is generally accepted that a photoredox catalytic cycle results in the 
reductive, heterolytic cleavage of the benzyl bromide or phenacyl bromide to afford electron deficient 
carbon radical which rapidly added to the electron rich double bond of chiral intermediate enamine in a 
stereocontrolled fashion. The generated α-aminoalkyl radical is oxidized to iminium ion via single 
electron transfer (SET). The iminium ion intermediate is further hydrolyzed to form the α-alkylation 
product, and thereby regenerate the amine catalyst for a new catalytic cycle. It is most likely that product-
forming step would be chain-propagating reduction of the alkyl electrophile substrates by the 
intermediate α-amino radical.23 
 
Figure 14 Enantioselective α-functionalization of aldehydes via dual photoredox enamine catalysis.  
Following MacMillan’s initial work, several other research groups have merged enamine catalysis 
with photocatalysis. For example, Zeiter, König, and Pericàs revealed that transition metal 
photocatalysts could be replaced by organic dyes and inorganic semiconductors in this asymmetric 
photoredox enamine catalysis system.24 Luo and co-workers extended this strategy and applied to the 
enantioselective α-alkylation of β-ketocarbonyls by merging photoredox catalysis with chiral primary 
amine catalysis (Figure 15).25 The reactions enable the creation of all-carbon stereocenters with excellent 
enantioselectivities (up to 99% ee) and a broad substrate scope (28 examples). The author proposed that 
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the high asymmetric induction can be rationalized by a hydrogen bond in the transition state between 
the protonated tertiary amine (N-H as hydrogen bond donor) of the intermediate enamine and the 
intermediate phenacyl radical (C=O as hydrogen bond accepter). 
 
Figure 15 Asymmetric α-photoalkylation of -ketocarbonyls with a combination of chiral primary 
amine and photoredox catalyst. 
Recently, Melchiorre and co-workers reported an excellent work about the enantioselective radical 
conjugate addition to β,β-disubstituted cyclic enones driven by UV light (365 nm) or visible light.26 The 
outlined visible light activated iminium dual catalysis platform enables challenging quaternary carbon 
stereocenters to be constructed in a highly enantioselective manner (Figure 16). The critical to their 
success is the design of a chiral organic catalyst, containing a redox-active carbazole moiety, which 
drives the formation of iminium ion intermediates and the stereoselective trapping of photogenerated 
carbon-centred radicals. The key step in the catalytic transformation is the rapid intramolecular electron 
transfer between the electron-rich carbazole and the α-iminyl radical cation, thereby forging the 
corresponding enamine and avoiding the undesired β-scission event. 
 
Figure 16 Asymmetric radical conjugate addition by photoredox iminium dual catalysis. 
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In 2012, the Rovis group identified a productive dual catalysis mode which enables the catalytic 
asymmetric α-acylation of tertiary amines.27 Through the powerful combination of chiral N-heterocyclic 
carbene (NHC) catalyst and photoredox catalyst [Ru(bpy)3]Cl2, the α-acylation products could be 
produced in high yields (up to 94% yield) with high enantioselectivies (up to 92% ee). Mechanistically, 
single-electron oxidation of a tertiary amine followed by hydrogen atom abstraction results in the 
formation of iminium ion. Meanwhile, interaction of a chiral NHC catalyst with an aldehyde generates 
the nucleophilic Breslow-type complex. The chiral Breslow intermediate intercepts the newly formed 
iminium ion, thereby forming the non-racemic α-amino ketone product. The stoichiometric amount of 
oxidant m-dinitrobenzene (m-DNB) are needed for this asymmetric transformation (Figure 17). 
 
Figure 17 Asymmetric α-acylation of tertiary amines by photoredox carbene dual catalysis. 
2) Dual photoredox organocatalysis: noncovalent interactions 
In 2013, the Knowles group reported a photoinduced proton-coupled electron transfer (PCET) 
protocol for the asymmetric reductive coupling of ketones and hydrazones.28 Accordingly, the exposure 
of ɛ-hydrazino arylketones to blue light in the presence of [Ir(ppy)2(dtbbpy)]PF6, the chiral phosphoric 
acid, and Hantzsch ester (HE) provided the syn 1,2-amino alcohols with 45-96% yield and 77-95% ee 
(Figure 18). Mechanistically, photoactivated [IrIII]* accepts an electron from Hantzsch ester to generate 
[IrIII]• ‾. The phosphoric acid forms a H-bonding with the aryl ketone, followed by an electron transfer 
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from the [IrIII]• ‾ to the aryl ketone in concert with proton transfer from the Brønsted acid to the oxygen 
of the formed ketyl radical. The enantioselective radical cyclization is based on the H-bonding between 
the chiral phosphate anion and the OH-group of the ketyl. Hantzsch ester acts as a terminal reduction 
agent in the catalytic cycle.  
 
Figure 18 Enantioselective aza-pinacol cyclizations by a chiral phosphoric acid catalyst and a 
photoredox catalyst. 
In 2014, Stephenson and Jacobsen reported a sequential two-step asymmetric Mukaiyama Mannich 
reaction.29 With the employment of a chiral thiourea H-bonding catalyst combined with a photoredox 
catalyst [Ru(bpy)3]Cl2 under the irradiation of blue LEDs, single-electron oxidation of N-aryl 
tetrahydroisoquinolines followed by nucleophilic addition with silyl enol ethers afforded α-alkylated 
products in 11-72% yields and 42-99% ee (Figure 19). In the first step, 1-chlorinated products are 
generated from 1,2,3,4-tetrahydroisoquinolines by photooxidation with stoichiometric oxidant carbon 
tetrachloride. In the second step, the addition of the chiral thiourea results in the formation of an 
intermediate contact ion pair (a H-bonded chloride anion and the iminium ion), which enantioselectively 
reacts with the silyl enol ether to provide the non-racemic compounds with moderate to high 
enantioselectivities. 
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Figure 19 Asymmetric α-acylation of tertiary amines by photoredox hydrogen bonding dual catalysis. 
Recently, the Ooi group developed a redox neutral, highly enantioselective α-coupling of N-
arylaminomethanes with N-sulfonyl imines under visible light irradiation. By using chiral 
arylaminophosphonium ion and iridium complex [Ir(ppy)2(Me2Phen)]BAr (Ar = 3,5-(CF3)2C6H3) as co-
catalyst, the coupling products were achieved with 60-90% yields and 85-98% ee.30 In their proposed 
mechanism (Figure 20), photoexcited iridium catalyst is reductively quenched by N-arylamine. The 
thereby generated [IrII] serves as a strong reducing agent and transfers a single electron to imine under 
formation of a prochiral radical anion. The chiral aminophosphonium ion (H-bonding donor) undergoes 
counterion exchange with the prochiral radical anion to form a chiral ion pair, thereby reacting with 
deprotonated α-aminoalkyl radical to afford the coupling product. The critical success factor is that 
chiral ion controls the enantiofacial approach of the oxidatively generated α-aminoalkyl radical.  
 
Figure 20 Enantioselective radical coupling reaction with chiral arylaminophosphonium ion catalyst 
and iridium photoredox catalyst. 
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3) Dual photoredox transition-metal catalysis: Lewis acid catalyst 
In 2014, the Yoon group developed a dual catalysis strategy in asymmetric [2+2] photocycloadditions 
of α,β-unsaturated ketones to the corresponding cyclobutanes.31 Employing 1 mol% of [Ru(bpy)3]Cl2 
and 10 mol% Eu(OTf)3 with 20 mo% of dipeptide-derived chiral ligand led to form the 1,2-trans-
cycloadducts with high enantioselectivities of up to 97% ee. Interestingly, by simply switching to 
saturated dipeptide ligand, the 1,2-cis-cycloadducts were generated as the major products (Figure 21). 
Mechanistically, the crucial step is the single-electron reduction of a chiral Lewis acid coordinated aryl 
enone to generated radical anion. The intermediate radical anion can react with another Michael acceptor 
to form a chiral Lewis acid mediated radical which subsequently undergoes intermolecular cyclization. 
In this protocol, the requirement of the Lewis acid catalyst for both reactivity and stereoselectivity 
prevents undesired background reaction. And recently, the author extended this strategy for the 
asymmetric [3+2] photocycloaddition of aryl cyclopropyl ketones, which enables the enantiocontrolled 
construction of densely substituted cyclopentane structures not synthetically accessible using other 
catalytic methods.32  
 
Figure 21 Enantioselective [2+2] photocycloadditions with a photoredox catalyst and a 
stereocontrolling Lewis acid. 
The principle of cooperative Lewis acid-photoredox catalysis was further applied to the asymmetric 
Giese addition of photogenerated α-amino radicals to Michael acceptors by Yoon’s group.33 Chiral 
pybox ligand and relay auxiliary are two key points for achieving the radical addition products with high 
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levels of enantiocontrol (up to 96% ee). Notably, the Lewis acid here is not directly involved in the 
photoinduced electron transfer step. Rather, the chiral Lewis acids control the rate and selectivity of a 
step independent of the photoredox process itself (Figure 22). 
 
Figure 22 Enantioselective radical addition with cooperative Lewis acid-photoredox catalysis. 
4) Dual photoredox transition-metal catalysis: Nickel catalyst 
In 2016, MacMillan and Fu performed an elegant work of the enantioselective decarboxylative 
C(sp3)-C(sp2) cross-coupling reaction of α-amino acids with aryl halides by interfacing photoredox and 
nickel catalysis.34 This method is very practical and useful because non-racemic benzylic amine products 
can be formed by using low-cost α-amino acids as radical precursors (Figure 23). Mechanistically, 
photocatalyst-mediated oxidation and decarboxylation of an α-amino acid produce a prochiral α-amino 
radical. Meanwhile, activation of an aryl halide via oxidative addition lead to a chiral Ni(II)-aryl 
complex, which intercept the newly generated α-amino radical. The resulting diorganonickel(III) adduct 
then undergoes reductive elimination to achieve the C-C bond formation. The presence of a chiral ligand 
induces enantioselectivity and the last reductive elimination of diorganonickel(III) intermediate is 
proposed as the stereocontrol step.  
 
Figure 23 Enantioselective C(sp3)-C(sp2) cross-coupling reaction by interfacing photoredox and nickel 
catalysis.  
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1.3.2 Single Catalyst Systems in Asymmetric Photoredox Catalysis 
1) Organocatalysis with electron donor-acceptor (EDA) complex 
Melchiorre’s group demonstrated that the synthetic potential of chiral enamines is not limited to the 
ground-state domain (enamines as nucleophlies or SOMO activation)35, but can be further expanded by 
exploiting their photochemical activity. In 2013, Melchiorre and co-workers reported visible light 
induced asymmetric α-alkylation of aldehydes with electron deficient benzyl bromides and phenacyl 
bromides in the presence of the chiral secondary amine (Figure 24, pathway a).36 Although the 
compounds used in the reaction system do not contain any photoactive unit, they guide the 
photoactivation of the substrate by inducing the in-situ formed chiral electron donor-acceptor (EDA) 
complex. The EDA complex is able to absorb visible light and triggers a single electron transfer (SET) 
from the enamine to the organobromide substrate. In addition, quantum yield measurements established 
that a radical chain propagation mechanism is operative. 
Interestingly, the recent mechanistic studies from the Melchiorre group show another radical initiation 
pathway (Figure 24, pathway b) that the chiral enamine can directly reach an electronically excited state 
upon light absorption and then act as an effective photoinitiator to induce carbon-centered radical 
formation by reduction of the bromomalonate through SET process.37  
 
Figure 24 Visible light induced asymmetric α-alkylation of aldehydes via radical initiation step and 
chain process. 
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2) Organocatalysis with hydrogen bonding catalyst 
The Bach group recently reported an organocatalyst for enantioselective intramolecular [2+2]-
photocycloaddition reactions induced by visible light.38 By using the enantiopure thioxanthone as single 
catalyst, the intramolecular cycloaddition products were achieved with good yields (79-95%) and high 
enantioselectivities (87-94% ee).  
With respect to the organocatalyst, it is based on a 1,5,7-trimethyl-3-azabicyclo[3.3.1]nonan-2-one 
scaffold connected to a thioxanthone chromophore via an oxazole moiety. The mechanistic model 
assumes the binding of the 4-substituted chinolones to the catalyst through a double H-bonding as 
depicted in Figure 25. The thioxanthone not only serves as the light-absorbing molecule and transfers 
the energy to the chinolone, but also provides the asymmetric induction by allowing the attack of the 
double bond only from one prochiral face, thereby affording the cycloaddition product in an 
enantioselective fashion. The author mentioned that the enantiopure thioxanthone catalyst can be 
recovered in high yields after the reaction which demonstrate that visible light induced catalyst 
decomposition is not severe. 
 
Figure 25 Photoinduced asymmetric [2+2] intramolecular cycloaddition via energy transfer process. 
  
Chapter 1: Theoretical Part 
18 
 
3) Metal catalysis: chiral-at-metal iridium(III) complex 
In 2014, the Meggers group reported a highly efficient chiral-at-metal iridium Λ-IrS for the visible 
light induced enantioselective α-alkylation of 2-acyl imidazoles.39 As shown in Figure 26, under visible 
light irradiation, 2 mol% of iridium catalyst Λ-IrS is able to catalyze the reaction between 2-aryl 
imidazoles and electron deficient benzyl bromides in high yields (up to 100% yield) and with high 
enantioselectivities (up to 99% ee). 
Mechanistically, the catalysis is initiated by the coordination of 2-acyl imidazole to the iridium 
catalyst, followed by deprotonation to form the iridium enolate complex. The subsequent addition of the 
reductively generated electrophilic carbon radical to form the ketyl radical intermediate. Oxidation of 
the ketyl radical to the carbonyl group by single electron transfer (SET) provides the iridium-coordinated 
product, which is subsequently released. The SET process either regenerates the iridium photoredox 
catalyst or leads to the reduction of another organobromide substrate, thereby initiating a chain process. 
Proposed key intermediate is the iridium enolate complex, which not only provides the crucial 
asymmetric induction but also serves as the in-situ generated active photoredox catalyst. 
 
Figure 26 Enantioselective α-alkylation of 2-acyl imidazoles with a single chiral-at-metal iridium 
catalyst. PC = photoredox catalyst. 
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4) Metal catalysis: chiral copper(I) complex 
Very recently, the Fu group described a copper-based chiral catalyst derived from commercially 
available components can achieve asymmetric C-N cross-coupling reactions of racemic tertiary alkyl 
chlorides with high enantioselectivities of up to 99% ee (Figure 27).40 In this method, an in-situ formed 
chiral cooper(I) complex in which cooper cation is coordinated with two chiral phosphine ligands and 
one monoanionic carbazolide is responsible for the photocatalysis and the enantioselective C-N bond 
construction.  
Mechanistically, the first step is the binding of the nucleophile to copper to form a copper-nucleophile 
complex. Irradiation of the copper-nucleophile complex leads to an excited-state copper adduct which 
then engages in electron transfer with the alkyl halide to generate an alkyl radical. Then, C-N bond 
formation between the nucleophile and the alkyl radical occurs through an inner sphere pathway 
involving a copper-nucleophile complex. This work is of great significance because it stands at a 
previously unexplored intersection of asymmetric synthesis, catalysis with earth-abundant metals, 
visible light induced processes, and cross-coupling reactions of alkyl electrophiles, each of them 
represents an important current theme in organic synthesis. 
 
Figure 27 Enantioselective C-N cross-coupling with an in-situ chiral copper catalyst.  
  
Chapter 1: Theoretical Part 
20 
 
1.4 Conclusions 
Octahedral chiral-at-metal complexes have developed not only because of their importance in 
fundamental stereochemistry but also because of their application as asymmetric catalysts in organic 
synthesis. 
In above examples of asymmetric catalysis, several inert octahedral transition-metal complexes are 
presented as chiral templates, in which the transition metal serves as a structural center, whereas catalytic 
transformation is mediated through the organic ligand sphere. Among them, chiral-at-metal iridium 
complexes developed by the Meggers group exhibited impressive properties, achieving high 
enantioselectivities with low catalyst loadings. Remarkably, a chiral Lewis acid iridium catalyst should 
be of high practical value since it provides an excellent substrate scope for the highly enantioselective 
Friedel-Crafts addition of indoles to α,β-unsaturated 2-acyl imidazoles at low catalyst loadings. This 
high performance indicates the value of a direct chirality transfer from the chiral metal center to the 
coordinated substrate. 
Under irradation with visible light, highly enantioselective transformations could be achieved by 
merging photocatalyst with chiral catalyst or using a single catalyst. A variety of reaction types are 
developed via photoinduced electron transfer or energy transfer processes. The highly reactive 
intermediates, directed asymmetric induction and the tolerance of the reaction conditions to a wide range 
of functional groups enable the application of these reactions to the synthesis of various enantiopure 
compounds. The encouraging work from the Meggers group, a single chiral-at-metal iridium complex 
catalyzed the visible light activated asymmetric α-alkylation, provide new opportunities to realize 
different kinds of enantioselective photoredox catalysis with single chiral-at-metal complexes. 
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Chapter 2: Aim of the Work 
1) Synthesis and catalytic activity of chiral rhodium Lewis acid catalyst 
The inert octahedral chiral-at-iridium complexes provide ideal environments to induce asymmetry. 
However, efforts to exploit highly desirable features of chiral-at-rhodium complexes have met with great 
challenges, mainly due to limited methods to synthesize enantiopure rhodium complexes.1 
The Meggers group has recently introduced a substitutionally labile yet configurational stable chiral-
at-metal iridium Lewis acid catalyst. The iridium center serves as a dual function of activating a substrate 
through bidentate coordination and at the same time provides the asymmetric induction.2 In this work, 
we wish to accomplish the first isostructural synthesis of chiral-at-metal rhodium(III) complex, and 
subsequently, we would like to search for different reactions for the comparison of the catalytic 
properties of the homologous chiral iridium and rhodium Lewis acid catalysts. Stability and the potential 
racemization of such rhodium complex should be considered. 
2) Development of visible light induced asymmetric photoredox catalysis with chiral-at-
metal complexes  
General solutions for interfacing visible light induced photoredox chemistry and asymmetric catalysis 
with single catalysts are highly desirable. The Meggers group has recently reported a single chiral-at-
metal iridium complex catalyzed the visible light induced asymmetric α-alkylation of 2-acyl 
imidazoles.3 Several useful information can be obtained: 1) the chiral-at-metal iridium complex can 
serve as “2-in-1” catalyst by combining photoinduced reduction with asymmetric alkylation; 2) the 
chiral catalyst can not be dissociated or racemized under visible light irradiation; 3) highly effective 
asymmetric induction can be mediated by the propeller-like C2-symmetrical ligand sphere. All these 
informations potentially provide opportunities for reaction design by having a closer control over the 
entire reaction path. 
The aim of this research part is the development of new and efficient visible light mediated 
asymmetric reactions with newly developed chiral-at-metal iridium or rhodium complexes. For instance, 
the activation of α-C(sp3)-H bond of tertiary amines represents an important organic synthesis process. 
Although oxidation of amines into iminium ions or α-aminoalkyl radicals via photoinduced electron 
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transfer has been extensively studied,4 only a few asymmetric methodologies are available. Whether the 
oxidation potentials of such chiral-at-metal iridium complexes are positive for activing α-C(sp3)-H 
bonds need further investigation. 
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Chapter 3: Results and Discussion 
3.1 Asymmetric Lewis Acid Catalysis Directed by Octahedral Rhodium 
Centrochirality 
3.1.1 Catalyst Design 
Chiral Lewis acid catalysts play a significant role in asymmetric catalysis because many reactions are 
amenable to Lewis acid activation.1 Recently, the Meggers group has developed a chiral-at-metal 
iridium(III) complex (Δ-IrO)2 as a novel type of chiral Lewis acid catalyst in which the metal center is 
cyclometalated by two achiral bidentate ligands in a propeller type fashion and thereby provides the sole 
source of chirality. Herein, we wish to synthesize an octahydral chiral-at-metal rhodium(III) complex. 
The designed structure of Δ-RhO, like its congener Δ-IrO, consists of two cyclometalating 
benzoxazoles and two coordinated acetonitrile ligands. We hope the rhodium center can also serve as 
the source of centrochirality and Lewis acidity in the catalytic asymmetric reactions (Figure 28).  
 
Figure 28 Catalyst design for the chiral-at metal rhodium complex. 
3.1.2 Catalyst Synthesis 
The study was started by developing a synthesis of the complex Δ-RhO. The methodology was 
developed by the Meggers group.3 Accordingly, RhCl3 hydrate was reacted with tert-butyl-2-
phenylbenzoxazole (1) in a mixture of 2-ethoxyethanol and water under reflux to provide the rhodium 
dimer complex rac-2 (Scheme 1). The subsequent reaction with D-proline afforded the prolinato-
rhodium complexes -(R)-3 and -(R)-3 as a mixture of diastereomers, and -(R)-3 is isolable in a 
straightforward fashion in a yield of 40% with high purity by just washing the mixture of diastereomers 
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with CH2Cl2/Et2O. Exposure of -(R)-3 to NH4PF6 in acetonitrile at 50 ºC for 12 h resulted in a 
substitution of D-proline by two acetonitrile ligands under complete retention of configuration to afford 
-RhO in a yield of 90%. Notably, -RhO is air stable, moisture tolerant and can be purified by standard 
flash silica gel chromatography. The mirror-imaged complex -RhO is accessible in an analogous 
fashion by using the chiral auxiliary L-proline instead.  
 
Scheme 1 Proline-mediated synthesis of the enantiomerically pure rhodium(III) complexes -RhO and 
-RhO. 
It is worth noting that the prolinato-rhodium complexes -(R)-3 and -(R)-3 can not be separated by 
chromatography due to a limited stability of the complexes. The isolation of -(R)-3 or its enantiomer 
Λ-(S)-3 is based on the different solubilities of the diastereomers in solutions. Whereas Λ-(R)-3 is very 
soluble in a mixture of CH2Cl2/Et2O, its diastereomer -(R)-3 is insoluble. Thus, -(R)-3 could be 
obtained by washing with CH2Cl2/Et2O (for details, see experimental part). The structure of -(R)-3 is 
demonstrated by single crystal X-ray crystallography (Figure 29).4 Notably, other tested auxiliaries5 did 
not provide rhodium auxiliary complexes with distinct solubilities and were not stable enough for a 
resolution via silica gel chromatography. Chiral proline here serves as a cheap and readily available 
powerful chiral auxiliary for the synthesis of enantiopure rhodium complexes. This method provides 
opportunity for the large-scale synthesis of enantiomerically pure transition metal complexes. 
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Figure 29 Crystal structure of -(R)-3. Hydrogen atoms are omitted for clarity. ORTEP drawing with 
50% probability thermal ellipsoids. 
Thus, following this convenient proline-mediated synthesis, Λ- and Δ-RhO can be obtained in a non-
racemic fashion as verified by CD-spectroscopy (Figure 30). HPLC on a chiral stationary phase 
demonstrates that the chiral-at-rhodium complexes are virtually enantiopure (Figure 31). Furthermore, 
time dependent stability tests by 1H NMR and HPLC confirm that the relative and absolute metal-
centered configuration is completely retained in solution over many days (for details, see experimental 
part).  
 
Figure 30 CD spectra (0.2 mM in CH3OH) of - and -RhO. 
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Figure 31 Chiral HPLC traces demonstrating the enantiopurity of synthesized - and -RhO. HPLC 
conditions: Daicel Chiralpak IB (250 × 4.6 mm), flow rate = 0.6 mL/min, 0.1% aq. TFA with MeCN as 
eluent (30% to 41% in 60 min). 
A structure of -RhO was obtained by single crystal X-ray diffraction and verifies the -configuration 
at the rhodium center (Figure 32, left). As expected, affected by the lanthanide contraction, the period 5 
transition metal complex -RhO and its period 6 congener -IrO (Figure 32, right) possess almost 
identical structures. For example, the lengths of the bonds between the transition metals and the 
cyclometalating benzoxazoles differ just in the range of 0.009 and 0.022 Å. However, the bonds to the 
coordinated acetonitrile ligands are notably longer in -RhO compared to -IrO by 0.041–0.043 Å, 
thereby indicating more exchange labile acetonitrile ligands in -RhO. 
 
Figure 32 Crystal structures of -RhO (left) and -IrO (right). The hexafluorophosphate counteranion 
and hydrogen atoms are omitted for clarity. Selected bond lengths (Å): N1-Rh1 = 2.056(2), N20-Rh1 = 
2.044(2), N39-Rh1 = 2.142(3), N42-Rh1 = 2.155(3); N1-Ir1 = 2.054(9), N20-Ir1 = 2.044(6), N39-Ir1 = 
2.111(6), N42-Ir1 = 2.100(9). 
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3.1.3 Catalytic Reactions  
With the novel Lewis acid catalyst -RhO in hand, we next searched for different reactions for the 
comparison of the homologous catalysts -IrO and -RhO. Preliminary works of the following 
asymmetric conjugate additions by using -IrO as catalyst were explored by Haohua Huo (a former 
Ph.D. student in the Meggers group). 
1) Asymmetric Friedel-Crafts alkylation 
First reaction is the enantioselective Friedel-Crafts addition of indoles to α,β-unsaturated 2-acyl 
imidazoles which is effectively catalyzed by -IrO.2 As shown in Figure 33, although 1 mol% -RhO 
catalyzes the addition of indole to α,β-unsaturated 2-acyl imidazole 4a affording the Friedel-Crafts 
product (R)-5a with 94% yield and respectable 95% ee after 40 h, reaction time, yield, and 
enantioselectivity can not quite match the performance of the homolog -IrO (96% yield and 96% ee 
after 20 h).  
 
Figure 33 Asymmetric Friedel-Crafts alkylation catalyzed by -IrO and -RhO. 
2) Asymmetric addition of malononitrile 
Next, the Michael addition of 2-acyl imidazoles 4a with malononitrile was investigated. As shown in 
Table 1, the addition of malononitrile to 4a catalyzed by 1 mol% -RhO in THF at room temperature 
afforded the adduct (R)-5b with a significantly higher ee value of 88% (entry 2) compared to 70% using 
-IrO (entry 1). After a brief survey of reaction conditions (entries 3-8), THF (0.5 M) and malononitrile 
(1.2 eq.) are favorable to get a high enantioselectivity of 92% ee (entry 8). It is worth noting that the 
rhodium catalyst is tolerant towards moisture and air, and the presence of 1 mol% H2O and air 
atmosphere did neither affect the yield nor the enantioselectivity (entries 9 and 10). Upon the best 
conditions (entry 8), the addition of malononitrile to substrate 4b catalyzed by -RhO afforded the 
product (R)-5c with 91% yield and 95% ee after 28 h, reaction time, yield, and enantioselectivity are 
superior to the performance of the homolog -IrO (entries 11 and 12). 
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Table 1 Asymmetric addition of malononitrile.a 
 
entry catalystb substrate solventc malononitrile t (h) yield (%)d ee(%)e 
1 Δ-IrO 4a THF (1 M) 3.0 eq. 16 99 70 
2 Δ-RhO 4a THF (1 M) 3.0 eq. 16 98 88 
3 Δ-RhO 4a DCM (1 M) 3.0 eq. 16 96 87 
4 Δ-RhO 4a MeOH (1 M) 3.0 eq. 16 97 83 
5 Δ-RhO 4a THF (0.5 M) 3.0 eq. 16 97 91 
6 Δ-RhO 4a THF (0.25 M) 3.0 eq. 16 97 91 
7 Δ-RhO 4a THF (0.5 M) 2.0 eq. 16 96 91 
8 Δ-RhO 4a THF (0.5 M) 1.2 eq. 16 96 92 
9f Δ-RhO 4a THF (0.5 M) 1.2 eq. 16 96 92 
10g Δ-RhO 4a THF (0.5 M) 1.2 eq. 16 96 92 
11 Δ-RhO 4b THF (0.5 M) 1.2 eq. 28 91 95 
12 Δ-IrO 4b THF (0.5 M) 1.2 eq. 96 40 88 
a Reaction conditons: 2-acyl imidazole 4a or 4b (0.20 mmol), malononitrile (0.24 mmol or 0.40 mmol 
or 0.60 mmol) in solvent with catalyst -IrO or -RhO (1 mol%) under nitrogen atmosphere at room 
temperature. b Catalyst loadings in brackets given in mol%. c Concentration of solvents are given in 
brackets. d Isolated yields. e Enantioselectivities were determined by HPLC analysis. f under air. g with 
1% H2O. 
3) Asymmetric addition of Meldrum’s acid 
Meldrum’s acid is widely used as a nucleophile in organic synthesis due to its adequate acidity (pKa 
= 4.83).6 As shown in Table 2, by using -RhO (1 mol%) as catalyst, the Michael addition of Meldrum’s 
acid with 2-acyl imidazole 4a provided the expected product (R)-5d with 85% ee compared to just 68% 
ee with -IrO (entries 1 and 2). The enantioselectivity for the -RhO catalyzed reaction can be further 
improved significantly by either reducing the temperature to 5 ºC (entry 4, 94% ee) or increasing the 
catalyst loading to 2 mol% (entry 5, 95% ee), as both ways can inhibit the background reaction 
efficiently (entry 3). 
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Table 2 Asymmetric addition of Meldrum’s acid.a 
 
entry catalystb T (ºC) t (h) yield (%)c ee (%)d 
1 Δ-IrO (1 mol%) 25 16 99 68 
2 Δ-RhO (1 mol%) 25 16 99 85 
3 none 25 16 8.5 n.d. 
4 Δ-RhO (1 mol%) 5 16 97 94 
5 Δ-RhO (2 mol%) 25 6 96 95 
a Reaction conditons: 2-acyl imidazole 4a (0.20 mmol), Meldrum’s acid (0.60 mmol) in THF (0.2 mL) 
with catalyst -IrO or -RhO under nitrogen atmosphere at room temperature. b Catalyst loadings in 
brackets given in mol%. c Isolated yields. d Enantioselectivities were determined by HPLC analysis. n.d. 
= not determined. 
4) Asymmetric addition of β-ketoesters 
Interestingly, -RhO (1 mol%) is even capable of catalyzing the formation of an all-carbon 
quaternary stereocenter (Table 3). The reaction of tert-butyl 2-oxocyclopentane-1-carboxylate with acyl 
imidazole 4a yields 5e with 99% ee and 4:1 dr (entry 1). Under the same conditions, -IrO displays 
inferior performance with 97% ee and 3:1 dr and a low yield of just 41%. -RhO (1 mol%) also 
catalyzes the addition of 2,3-dihydro-1-oxo-1H-indene-2-carboxylic acid tert-butyl ester to acyl 
imidazole 4a providing the adduct 5f in 92% yield with 96% ee and 14:1 dr. -IrO performs similar for 
this transformation although the catalysis rate is somewhat sluggish and requires an elongated reaction 
time (72 h) for a complete conversion (entry 2). 
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Table 3 Asymmetric addition of β-ketoesters.a 
 
entry β-ketoester  product catalystb t (h) yield (%)c ee (%)d 
1 
 
 
-IrO (1 mol%) 
-RhO (1 mol%) 
96 
48 
41 
83 
97 (3:1 dr) 
99 (4:1 dr) 
2 
 
 
-IrO (1 mol%) 
-RhO (1 mol%) 
 
72 
20 
 
89 
92 
 
97 (10:1 dr) 
96 (14:1 dr) 
 
a Reaction conditons: 2-acyl imidazole 4a (0.20 mmol), β-ketoester (0.40 mmol) in THF (0.4 mL) with 
catalyst -IrO or -RhO under nitrogen atmosphere at room temperature. b Catalyst loadings in 
brackets given in mol%. c Isolated yields. d Enantioselectivities were determined by HPLC analysis; 
diastereoselectivities were determined by 1H NMR analysis of the crude products. 
5) Asymmetric cascade reactions 
Asymmetric cascade sequences provide an ecologically and economically desirable approach to 
organic synthesis.7 Taking into account that the asymmetric additions of α,β-unsaturated 2-acyl 
imidazoles are efficiently catalyzed by the iridium and rhodium complexes, and this class of catalysts 
exhibits impressive catalytic activity in the asymmetric α-amination of 2-acyl imidazoles through 
enolate activation mode (Liang-A. Chen’s work, a former Ph.D. student in the Meggers group)8, we 
were wondering if the cascade reaction could be realized which combine two intermolecular and 
stereoselective steps involving a Michael addition/amination pathway (Figure 34).  
 
Figure 34 Reaction design of the asymmetric cascade reaction. 
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The asymmetric cascade strategy was first examined by the mixture of α,β-unsaturated 2-acyl 
imidazole 4a, malononitrile and diethyl azodicarboxylate in isopropanol with rac-IrO as catalyst, to our 
disappointment, only Michael addition product 5b was observed (Table 4, entry 1). Encouragingly, by 
using rac-RhO (2 mol%) as catalyst (entry 2), the desired product 6 was provided with 40% yield 
(mixture of two diastereoisomers). After a brief screen of solvents, a high yield of 82% and 
diastereoselectivity of 4:1 dr can be achieved (entry 4). The enantioselectivity of the major 
diastereoisomer was observed as 92% ee when Δ-RhO was used as chiral catalyst (entry 5).  
Table 4 Asymmetric cascade reaction.a 
 
entry solventb catalyst (2 mol%) yield (%)c ee (%)d 
1 iPrOH (2 M)  rac-IrO 0 n.d. 
2 iPrOH (2 M)  rac-RhO 40 n.d. 
3 CH2Cl2 (1 M) rac-RhO 48 n.d. 
4 THF (1 M)  rac-RhO 83 n.d. 
5 THF (1 M)  Δ-RhO 82 92 (dr 4:1)e 
a Reaction conditons: 2-acyl imidazole 4a (0.2 mmol), malononitrile (0.24 mmol) and (E)-dibenzyl 
diazene-1,2-dicarboxylate (0.4 mmol) in solvent with catalyst -IrO or -RhO under nitrogen 
atmosphere at room temperature. b Concentration of solvents are given in brackets. c Isolated yields. d 
Enantioselectivities were determined by HPLC analysis. e Diastereoselectivity was determined by the 
isolated yield of each isomer. n.d. = not determined. 
The above described alkene alkylation and amination processes afford straightforward access to the 
product 6 which have two adjacent stereogenic centers with high enantioselectivty. However, the 
substrate scope of this catalytic tandem reaction is narrow. For example, only the Michael addition 
product (step 1) was afforded when replacing malononitrile to indole or switching diethyl 
azodicarboxylate to imine electrophile (Scheme 2). It is probably because either the intermediate enolate 
complexes are difficult to generate or the in-situ formed enolate complexes could not efficiently attack 
to other electron deficient double bonds. 
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Scheme 2 Some limitations for asymmetric cascade reaction. 
3.1.4 Mechanistic Investigations 
1) Proposed mechanism and reaction model 
A plausible mechanism of asymmetric conjugate additions is outlined in Figure 34. -RhO, 
analogous to -IrO, apparently serves as a chiral Lewis acid which coordinates in a bidentate fashion 
to the α,-unsaturated 2-acyl imidazole, forming intermediate rhodium complex I. The activated double 
bond in complex I could be attacked by the nucleophile, thereby forging the intermediate enolate 
complex II. After protonation, the rhodium coordinated product III is subsequently released the product 
upon coordination to a new substrate molecule, thereby starting a new catalytic cycle. 
In the stereocontrol model, -RhO coordinates in two-point fashion to the α,-unsaturated acyl 
imidazole, thereby shielding Si prochiral face of the alkene and raising its electrophilicity, so that an 
asymmetric induction is provided in the course of the addition of the deprotonated carbon nucleophiles 
to the prochiral -carbon (Figure 35). 1H NMR spectra recorded in CD2Cl2 at room temperature after 
the addition of substrate 4a to catalyst Δ-RhO support the fast bidentate coordination of 4a to the 
rhodium complex (see experimental part). The mode of reaction is also supported by a crystal structure 
of RhO-I, which was obtained upon mixing of the racemic rhodium catalyst with an α,-unsaturated 2-
acyl imidazole substrate 4b at room temperature, confirming the anticipated two-point coordination of 
the acyl imidazole to the rhodium center upon replacement of the two labile acetonitrile ligands (Figure 
36).  
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Figure 35 Proposed mechanism for Δ-RhO catalyzed asymmetric additions and reaction model for the 
asymmetric induction in the transition state in which one face of the alkene is shielded by the C2-
symmetrical ligand sphere. 
 
Figure 36 Crystal structure of substrate-coordinated rhodium intermediate complex RhO-I. Hydrogen 
atoms and the hexafluorophosphate counteranion are omitted for clarity. ORTEP drawing with 50% 
probability thermal ellipsoids. 
2) The acetonitrile exchange experiments 
It is quite intriguing that the congeners Δ-RhO and Δ-IrO differ in their catalytic performance despite 
their isostructural nature, with the iridium catalyst being superior for the asymmetric Friedel-Crafts 
reaction, whereas the rhodium congener providing higher turnover frequencies and, in most cases, 
higher enantioselectivities for the shown Michael additions of β-dicarbonyl compounds. 1H NMR 
experiments of -RhO/-IrO with bipyridine reveal that the acetonitrile exchange rates are much faster 
in -RhO compared to -IrO which is consistent with longer coordinative bonds of the metal-
coordinated acetonitrile ligands in -RhO compared to -IrO (Figure 37).  
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Figure 37 The acetonitrile exchange experiments of -RhO and -IrO in the presence of bipyridine. 
It is therefore plausible that the superior catalytic activity of the more coordinatively labile -RhO 
over the more inert -IrO for the Michael additions with -dicarbonyl compounds is due to substrate 
coordination and/or release being the rate limiting steps in the catalytic cycle, while it is the nucleophile 
addition step for the Friedel-Crafts reaction in which the aromaticity of the pyrrole ring is lost temporary 
in the course of the addition. The observed higher turnover frequencies for the rhodium-catalyzed 
Michael additions may also contribute to the observed higher enantioselectivities since a higher turnover 
frequency suppresses the undesired, uncatalyzed background reaction.10  
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3.1.5 Conclusions 
In conclusion, the first example of an asymmetric catalyst which derives both its optical activity and 
Lewis acidity from an octahedral rhodium stereocenter was developed. This novel, configurationally 
surprisingly stable chiral Lewis acid is conceptually very simple, as it just contains achiral mono- and 
bidentate ligands, and it can be accessed conveniently in an enantiomerically pure fashion through a 
proline-mediated synthesis. Interestingly, although isostructural to its iridium congener, the two 
homologs differ significantly in their catalytic Lewis acid activity, with the rhodium complex 
demonstrating advantages as catalyst for the Michael addition of CH-acidic β-dicarbonyl compounds to 
α,β-unsaturated 2-acyl imidazoles and the cascade reaction of α,β-unsaturated 2-acyl imidazole with 
malononitrile and diethyl azodicarboxylate. The superiority of the rhodium catalyst over its iridium 
congener can in large parts be attributed to a significantly higher lability of the two accessible rhodium 
coordination sites which allow higher turnover frequencies and turnover numbers.  
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3.2 Merger of Visible Light Induced Oxidation and Enantioselective 
Alkylation with Chiral Iridium Catalyst 
3.2.1 Reaction design 
The development of methods for fundamental functionalizations, as well as protocols for the 
construction of chiral molecules is an ongoing challenge. Recently, the Meggers group reported for the 
first time that a single chiral-at-metal complex Δ-IrS can serve as an effective catalyst for the visible 
light induced enantioselective α-alkylation of 2-acyl imidazoles with electron deficient benzyl bromides 
and phenacyl bromides under reductive activation.1 We were wondering whether this class of chiral 
iridium catalysts could also be capable of catalyzing asymmetric photoredox processes which instead 
proceed through oxidative chemistry. As shown in Figure 38, the designed reaction of the electrophilic 
iminium ion with the nucleophilic iridium enolate complex might produce a non-racemic compound. 
We hypothesized the intermediate iridium enolate complex could provide the crucial asymmetric 
induction as well as serve as the active photocatalytic species.  
 
Figure 38 Reaction design for photoactivated asymmetric catalysis with chiral iridium(III) Lewis acids. 
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3.2.2 Initial Experiments and Reaction Optimization 
The initial experiments were inspired by Stephenson and co-workers, who utilized the oxidation of 
N-phenyl tetrahydroisoquinolines with bromotrichloromethane (BrCCl3) to generate the iminium ion 
under photoredox conditions.2 This study was started by investigating the reaction of 2-acyl imidazole 
7a'' with dimethylaniline (Eox ≈ +0.78 V vs. SCE)3 and carbon tetrabromide (CBr4) under visible light 
irradiation. In the presence of the previously developed dual function photoredox/chiral Lewis acid 
catalyst Δ-IrO (3 mol%), the expected C-C bond formation product 8 was obtained in 34% yield after 
irradiation of 16 h (Figure 39). However, racemization was observed in the course of the reaction. The 
enantioselectivity of product 8 was dropped dramatically from 96% to 0% ee during the reaction time 
from 1 h to 16 h. Control experiment in the absence of iridium catalyst showed that about 10% of rac-8 
was observed after 16 h of the reaction. As the product 8 is stable in the solution, the observed 
racemization phenomenon might be explained by the reversibility of this Mannich reaction.4  
 
Figure 39 Asymmetric photoactivated α-aminoalkylation of 2-acyl imidazole7a'' with dimethylaniline. 
To get non-racemic product under mild conditions, we next used α-silylamines (Eox ≈ +0.44 V vs. 
NHE) as precursors. The silyl group in α-silylamines not only serves as a redox handle to facilitate a 
single electron oxidation, but also results in a subsequent rapid cleavage of the C-Si bond under release 
of α-aminoalkyl radicals, which then be involved in iminium chemistry after further oxidation.4 Thus, 
the reaction of 2-acyl imidazole 7a'' and N,N-diphenyl-N-(trimethylsilyl)methylamine 9a was carried 
out in the presence of the enantiomerically pure iridium complex Λ-IrO (2 mol%), while exposed to air 
(Scheme 3). Encouragingly, irradiation with visible light in form of a standard 12 W energy saving 
household lamp for 20 h afforded the expected product 10a'' in 34% yield and 91% ee. However, the 
reaction is not straightforward and the intermediate α-aminoalkyl radical can either form a dimer 11 via 
homocoupling or be oxidized to form amide 12 in the presence of oxygen.2 The isolated side products, 
on the other hand, provide good evidence in support of a radical pathway of the reaction.  
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Scheme 3 Asymmetric photoactivated α-aminoalkylation of 2-acyl imidazole 7a'' with α-silylamine 9a. 
Improved results were obtained after the modification of the 2-acyl imidazole substrate (Table 5). 
Accordingly, replacing the N-methyl imidazole moiety (7a'') with N-isopropyl imidazole (7a') provided 
the aminoalkylation product 10a' with an increased yield of 48% and 90% ee after 20 h of irradiation 
(entries 1 and 2). However, the best results were obtained with the N-phenyl imidazole substrate 7a, 
giving 92% yield and 97% ee after just 6.5 h of photolysis (entry 3). Notably, excess α-silylamine 9a is 
crucial for high yield of the product (entries 4 and 5). Control experiments in the absence of catalyst (no 
reaction) or performed in the dark (very sluggish and incomplete reaction after an elongated reaction 
time of 48 h) reveal that it is the combination out of chiral iridium complex -IrO and visible light that 
is required for an efficient reaction (entries 6 and 7). It is also worth noting that the catalyst -IrS,1 
which was found superior for the reported asymmetric photo-reductive C-C bond formation, turned out 
to be inferior for the here investigated photo-oxidative activation (entry 8 compared to entry 3). 
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Table 5 Optimization of the enantioselective photoactivated α-aminoalkylation of 2-acyl imidazoles.a 
 
entry substrate catalyst 
(2.0 mol%) 
hb ratio of 7 and 9a 
ratio 
t (h) yield (%)c ee (%)d 
1e 7a'' -IrO yes 1:3 20 34 91 
2 7a' -IrO yes 1:3 20 48 90 
3 7a -IrO yes 1:3 6.5 92 97 
4 7a -IrO yes 1:2 20 71 97 
5 7a -IrO yes 2:1 20 49 97 
6 7a none yes 1:3 20 0 n.d. 
7 7a -IrO no 1:3 48 18 94 
8 7a -IrS yes 1:3 20 51 97 
a Reaction conditions: Reactions performed in CH2Cl2 (0.5 mL) with 2-acyl imidazole (0.2 or 0.4 mmol) 
and α-silylamine 9a (0.2 or 0.4 or 0.6 mmol) in the presence of catalyst (2 mol% or none) at room 
temperature under an atmosphere of air. b 12 W white light energy saving lamp. c Isolated yield. d 
Determined by chiral HPLC analysis. e Shown for comparison. n.d. = not determined. 
3.2.3 Substrate Scope 
After the optimized conditions were identified, the scope of the asymmetric photoinduced α-
aminoalkylation with catalyst -IrO was then tested. Figure 40 shows that the reaction of a variety of 
2-acyl imidazoles with N,N-diaryl-N-(trimethylsilyl)methylamines in the presence of -IrO (2-4 mol%) 
and under air while illuminating with visible light provided the expected alkylation products in 61-93% 
yields and with excellent enantioselectivities of 90-98% ee. The 2-acyl-N-phenyl imidazole substrates 
tolerate steric (products 10b and 10c), electron donating (product 10d) and electron accepting (product 
10e) substituents in the phenyl moiety, and it can be replaced by the heteroaromatic thiophene (product 
10f). Furthermore, a 2-propionic imidazole (product 10g) as well as a 2-butyric imidazole (product 10h) 
were aminoalkylated in the α-postion of the carbonyl group with high enantioselectivities, although an 
increased catalyst loading of 4 mol% and more active silymethylamine are required to achieve 
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satisfactory results. With respect to silymethylamines, different substituents are tolerated in the phenyl 
groups (10i-k), and one phenyl can be replaced by a naphthyl group (10l).  
 
Figure 40 Substrate scope of the asymmetric photoinduced α-aminoalkylation. a Catalyst loading of 4 
mol%. 
Unfortunately, the application of this α-aminoalkylation technology to other substrates did not 
succeed (Figure 41). The α-silyl and the two aryl groups are required for this transformation. When one 
aryl group was replaced by aliphatic group (methyl, isopropyl or n-butyl group), both the yields and 
enantioselectivities dropped dramatically. Without α-silyl group or one aryl group was replaced by 
electron-withdrawing group (-COOMe), the expected product was not observed under the standard 
conditions. However, with additional 1.2 equivalent of oxidant CBr4, the C-C bond formation product 
was obtained, albeit in a low yield. These results support that the α-silyl and two aryl groups are crucial 
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for reducing the oxidation potential of amines.4 
 
Figure 41 Some limitations of the substrate scope with respect to silymethylamines. n.d. = not 
determined. 
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3.2.4 Plausible Mechanism  
A plausible mechanism in which photoredox catalysis intertwines with asymmetric catalysis is 
outlined in Figure 42. Herein, the catalytic cycle is initiated upon coordination of the 2-acyl imidazole 
substrate 7 to the iridium complex Δ-IrO in a bidentate fashion under release of the two labile 
monodentate acetonitrile ligands to provide the substrate coordinated intermediate A. The subsequent 
reversible deprotonation in α-position of the carbonyl group affords the nucleophilic iridium enolate 
intermediate B. Meanwhile, an electrophilic iminium ion is generated by an iridium-photoinduced 
oxidation of the α-silylamine 9 with oxygen serving as the terminal oxidant according to the generally 
accepted photoredox catalysis cycle.5 The reaction of the iminium ion with the iridium enolate complex 
B occurs in a stereocontrolled fashion dictated by the metal-centered chirality and provides the iridium 
coordinated product C, which is subsequently released the product 10 upon coordination to a new 
substrate molecule 7, thereby initiating a new catalytic cycle. A series of investigations have been 
executed to verify the proposed mechanism in the following section. 
 
Figure 42 Plausible mechanism for the photoinduced asymmetric catalysis. PC = iridium photoredox 
catalyst, most likely intermediates A and C. [O] = oxidant in form of molecular oxygen and superoxide 
anion. 
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3.2.5 Mechanistic Investigations 
1) Crystal structure analysis 
The catalytic cycle was firstly investigated by verifying the involvement of the proposed iridium 
intermediate A and enolate intermediate B. Accordingly, upon reaction of an excess substrate 7a with 
racemic /-IrO we could isolate the proposed intermediate A and subsequent deprotonation generated 
intermediate enolate B (Ar = Ph). A crystal structure of enolate intermediate B is shown in Figure 43 
and reveals that a -configuration at the iridium center shields the Si-face of the α-enolate carbon and 
directs the addition of the electrophile to the Re-face, thereby being consistent with the observed S-
configuration of the alkylation product when using the catalyst with -configuration at the metal. 
 
Figure 43 Crystal structure of the proposed complex B (left) and proposed model for the asymmetric 
photoinduced α-aminoalkylation (right). 
2) Evaluating the Catalytic Activities of Complexes A and B 
It is safe to assume that at the beginning of the reaction, due to the bidentate nature of the 2-acyl 
imidazole substrate and a high substrate/catalyst ratio of 50, all iridium catalyst will be captured by the 
imidazole substrate, while an equilibrium may exist between the cationic intermediate A and the 
deprotonated enolate intermediate B.6 The involvement of the enolate complex B as a photoredox 
catalyst in this reaction was excluded based on a simple experiment which is outlined in Figure 44. The 
replacement of -IrO with the enolate complex B showed that it was not capable of catalyzing the 
photoinduced reaction at all, whereas on the other hand the cationic intermediate A displayed almost the 
same catalytic activity compared to -IrO. Thus, the substrate-coordinated intermediate A must be the 
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active photoredox catalyst at the beginning of the reaction, probably complemented later by the related 
product-coordinated intermediate C.  
 
Figure 44 Evaluating the catalytic activities of complexes A and B. 
3) Control experiments 
Enolate chemistry 
The involvement of an enolate complex B in the catalytic cycle is further supported by a reaction of 
7a with the electrophile dibenzyl diazodicarboxylate catalyzed by -IrO which afforded the α-
amination product 13 in 87% yield and 89% ee, apparently through the intermediate formation of a 
nucleophilic iridium enolate complex (Scheme 4). Thus, -IrO is capable of catalyzing enolate 
chemistry as has been recently also demonstrated for a related iridium and rhodium complex7 and the 
observed enantioselective C-C bond formation can be explained with the stereoselective reaction 
between the chiral iridium enolate B and an intermediate iminium ion. 
 
Scheme 4 The control experiment with dibenzyl diazodicarboxylate. 
Iminium chemistry 
The formation of the electrophile through chemical oxidation replacing the photoinduced oxidation 
also provides the desired C-C bond formation product in an enantioselective fashion as shown for the 
oxidant tBuOOH (Scheme 5). The oxidative formation of the iminium ion intermediate starting from 
the oxidation of α-silylamine along the pathway of photoinduced single electron oxidation with a 
photoredox catalyst, followed by rapid desilylation, and further oxidation by air is well established8 and 
consistent with the observation that the absence of air completely suppresses the formation of the desired 
product.9 
Chapter 3: Results and Discussion 
48 
 
 
Scheme 5 The control experiments with tBuOOH in the dark or without air. 
4) The replacement of iridium catalyst -IrO with a dual catalyst system 
Next, the requirement for a photoredox process was verified. We thereby exploited the circumstance 
that, in contrast to biscyclometalated iridium complexes which are well established photoredox catalyst, 
there are few cases for the analogous rhodium complex -RhO.10 The replacement of iridium in catalyst 
-IrO with rhodium -RhO therefore allows us to dissect the catalytic and photoredox activity of -
IrO. Accordingly, the reaction of imidazole 7a with amine 9a in the presence of -RhO (2 mol%) under 
irradiation with visible light provided the C-C bond formation product 10a only in very low yield (6% 
after an elongated reaction time, compare entries 1 and 2 of Table 6). Revealingly, when combined -
RhO with the established photoredox catalyst [Ir(ppy)2(dtbbpy)]PF6 (1.0 mol%)11 or 
[Ru(bpy)3]Cl2∙6H2O (0.5 mol%),12 the reaction provided the product 10a with good conversions and 
high enantioselectivities. Consistent with our proposed mechanism, neither the Lewis acid catalyst -
RhO (entry 2) nor photocatalyst (entries 3 and 4) alone are capable of catalyzing the asymmetric 
photoreaction, apparently because asymmetric enolate catalysis and photoinduced amine oxidation have 
to proceed hand in hand, which can be achieved with a dual catalyst system (entries 5 and 6) or even 
more efficiently with the single catalyst -IrO. It is also worth noting that the weaker photooxidant but 
highly efficient singlet oxygen sensitizer meso-tetraphenylpropyhrin (TPP)13 provides only a reduced 
yield of 30% after an elongated reaction time (entry 7), thereby supporting the notion that singlet oxygen 
does not have a major contribution to the observed oxidation of the α-silylamines in this reaction scheme.  
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Table 6 Single versus dual catalysis for the photoactivated α-aminoalkylation of 2-acyl imidazoles.a 
 
entry catalyst t (h) conv.(%)b ee (%)c 
1d -IrO (2.0 mol%) 6.5 quant. 97 
2 -RhO (2.0 mol%) 16 6 n.d. 
3 [Ir(ppy)2(dtbbpy)]PF6 (1.0 mol%) 16 0 n.d. 
4 [Ru(bpy)3]Cl2∙6H2O (0.5 mol%) 16 0 n.d. 
5 -RhO (2.0 mol%) + [Ir(ppy)2(dtbbpy)]PF6 (1.0 mol%)  24 84 94 
6 -RhO (2.0 mol%) + [Ru(bpy)3]Cl2∙6H2O (0.5 mol%)  24 72 94 
7 -RhO (2.0 mol%) + TPPe (0.5 mol%) 24 30 90 
a Reaction conditions: Reactions performed in CH2Cl2 (0.5 mL) with 2-acyl imidazole 7a (0.2 mmol) 
and α-silylamine 9a (0.6 mmol) at room temperature under an atmosphere of air while illuminating with 
a 12 W white light energy saving lamp. b Determined by 1H NMR.  c Determined by chiral HPLC 
analysis; d Shown for comparison. e meso-Tetraphenylporphyrin. n.d. = not determined. 
5) UV/Vis-absorption spectra  
The absorbance spectra of the substrate 7a coordinated iridium complex A (Ar = Ph) and catalyst rac-
IrO were measured in solution of CH2Cl2. As shown in Figure 45, the intermediate A absorbs visible 
light with a longer wavelength absorbance band in the visible region (max,abs = 398 nm) compared to 
catalyst rac-IrO (max,abs = 375 nm). 
 
Figure 45 UV/Vis-absorbance spectra of intermediate complex A and racemic catalyst Δ/Λ-IrO. 
Measured as solution in CH2Cl2. a.u. = absorbance units. 
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6) Luminescence quenching experiments 
In order to further verify the potential photoredox catalyst involving in the photoredox cycle, rac-IrO 
and intermediate A and [Ir(ppy)2(dtbbpy)]PF6 were selected to perform the luminescence quenching 
experiments with quencher 9a (Figure 46). Notably, [Ir(ppy)2(dtbbpy)]PF6 is a photoredox catalyst that 
has been used for the photo-oxidative cleavage of C-Si bond.5e The iridium complex A 
photoluminescence (max,em = 516 and 552 nm) is efficiently quenched by the α-silylamine 9a in a dose 
dependent fashion as shown with a Stern-Volmer plot compared to catalyst rac-IrO and 
[Ir(ppy)2(dtbbpy)]PF6, which can be explained by a quenching of the excited state of A through electron 
transfer from the electron donor 9a. 
 
Figure 46 Stern-Volmer plots. I0 and I = luminescence intensities in the absence and presence of the 
indicated concentrations of the α-silylamine 9a, respectively. All experiments were performed in CH2Cl2. 
7) Cyclic voltammetry measurements 
The cyclic voltammetry was tested by Philipp Röse, a graduate student in Prof. Hilt group (Department 
of Chemistry, University of Marburg). From the DPV in combination with the emission spectrum 
(Figure 47), the excited state reduction potential (E*red = Ered + E00) of complex A (Ar = Ph) can be 
estimated according to the Rehm-Weller approximation, with the E00 transition energy calculated from 
the luminescence peak (max,em = 516 nm, 2.403 eV) and Ered from DPV measurements (0.98 V vs. 
Ag/AgCl): E*red =  +1.4 V vs. Ag/AgCl in THF. 
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Figure 47 Cyclic voltammograms (CV) and differential pulse voltammograms (DPV) of the complex 
A and the reference iridium complex [Ir(ppy)2(dtbbpy)]PF6 in THF containing 0.1 M nBu4NBF4. 
3.2.6 Conclusions  
In conclusion, a visible light activated asymmetric aerobic α-aminoalkylation of 2-acyl imidazoles 
has been developed. From the perspective of the catalyst, it is intriguing that the metal center is capable 
of serving multiple functions at the same time: it constitutes the exclusive center of chirality, the 
catalytically active Lewis acid center, and additionally functions as the key component of the photoredox 
catalyst that is formed in situ. From the perspective of the catalytic reaction, the photo-oxidative 
activation and net oxidation of the here featured asymmetric catalysis complements our previous work 
on a redox neutral reaction in which the photoactivation occurred in a reductive fashion. It is fascinating 
that the metal-centered configuration (the exclusive source of chirality in the catalyst) retains throughout 
the catalysis, considering the oxidative conditions and the exposure to light. This conceptionally simple 
reaction scheme may provide new avenues for the green synthesis of non-racemic molecules. 
  
DPVCV
CV DPV
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3.3 Asymmetric Radical-Radical Cross-Coupling through Visible Light 
Activated Iridium Catalysis 
3.3.1 Reaction Design 
A single chiral-at-metal iridium complex Δ-IrO has been proven to be very efficient dual function 
catalyst in visible light induced enantioselective α-aminoalkylation of 2-acyl imidazoles with 
silymethylamines (chapter 3.2).1 Despite its novelty, one may criticize that it is not atom economical 
reaction as a trimethylsilyl (TMS) group is released during the formation of α-aminoalkylation product. 
In this case, commercially available or easily prepared tertiary amines are more favorable as reducing 
agents in photoredox chemistry. Compared with the well established iminium ion, the application of α-
aminoalkyl radical to asymmetric coupling reaction or nucleophilic addition under photoredox 
conditions still remains challenging (Figure 48).2 
 
Figure 48 Two possible pathways for α-C(sp3)-H bond functionalization of tertiary amines by 
photoredox catalysis. 
On the other hand, the enantioselective radical-radical cross-coupling reaction, which is used as a 
powerful tool for asymmetric transformations, still remains in its infancy when compared with other 
highly developed reactions.3 Normally, in order to control the selective bond formation, a persistent 
radical and a transient radical should be engaged in the radical-radical cross-coupling reaction according 
to the persistent radical effect.4 Therefore, we envisioned that it is possible to transfer the reactive ketyl 
radical to a persistent one by stabilizing it through coordination to the chiral iridium Lewis acid catalyst 
after protonation. Then, once a transient carbon-centered radical is added, a selective radical-radical 
cross-coupling reaction could be achieved. Herein, we designed a catalytic and asymmetric process that 
closely interlocks a visible light activated single electron transfer between two substrates with the 
stereocontrolled radical-radical cross-coupling of an intermediate radical pair, namely the 
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enantioselective redox coupling of ketones with tertiary amines to 1,2-diaminoalcohols (Figure 49). A 
big challenge is whether the α-amino radical and ketyl radical could be simultaneously generated in a 
single photoredox catalytic cycle.  
 
Figure 49 Linking (photoinduced) single electron transfer between a donor substrate and an acceptor 
substrate to asymmetric radical-radical recombination with a single iridium catalyst. 
3.3.2 Initial Experiments and Reaction Optimization  
The study was started by investigating the reaction of 2-acetyl imidazole 14a' with tertiary amine 15a 
under photoredox conditions (Table 7). In the presence of the previously developed dual function 
photoredox/chiral Lewis acid catalyst Δ-IrO1 (3 mol%) under irradiation with a 23 W compact 
fluorescent lamp (CFL), the desired product 16a' was not observed (entry 1). Encouragingly, using 
instead the more electron-deficient trifluoroacetyl imidazole 14a provided the coupling product 16a with 
69% yield and 95% ee (entry 2). Replacing the solvent CH2Cl2 with CHCl3 improved the yield to 75%, 
albeit under the cost of slightly reduced enantioselectivity (entry 3). The reaction is very sensitive to 
solvent effect and other tested solvents did not provide satisfactory results (entries 4-6). With the catalyst 
-IrS instead of -IrO, yields and enantioselectivities could be further enhanced (entries 7 and 8). In 
CHCl3, 82% yield and excellent 98.6% ee were observed. Effects of N-substitutions on the 2-acyl 
imidazoles were also investigated (entries 9-11) and the best results were still obtained with the N-phenyl 
imidazole substrate 14a. Control experiments in the absence of the catalyst or in the dark demonstrate 
that this reaction crucially depends on the presence of the iridium catalyst and light, otherwise no traces 
of product were monitored (entries 12 and 13). It is also worth noting that no C-C coupling product is 
formed when using the common photoredox catalyst [Ru(bpy)3]Cl2∙6H2O or [Ir(ppy)2(dtbbpy)]PF6 or a 
dual catalyst system combining [Ir(ppy)2(dtbbpy)]PF6 and -RhO (entries 14-16).5  
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Table 7 Initial experiments and optimization of the visible light induced asymmetric C-C bond 
formation.a 
 
entry sub. catalyst hb solvent yield (%)c ee (%)d 
1 14a' -IrO (3.0) CFL CHCl3 0 n.d. 
2 14a -IrO (3.0) CFL CHCl3 75 95 
3 14a -IrO (3.0) CFL CH2Cl2 69 97 
4 14a -IrO (3.0) CFL EtOAc 42 68 
5 14a -IrO (3.0) CFL toluene 30 11 
6 14a -IrO (3.0) CFL MeCN 0 n.d. 
7 14a -IrS (3.0) CFL CH2Cl2 72 98.9 
8 14a -IrS (3.0) CFL CHCl3 82 98.6 
9 14b' Λ-IrS (3.0) CFL CHCl3 40 98 
10 14c' Λ-IrS (3.0) CFL CHCl3 66 90 
11 14d' Λ-IrS (3.0) CFL CHCl3 67 92 
12 14a -IrS (3.0) none CHCl3 0 n.d. 
13 14a none CFL CHCl3 0 n.d. 
14 14a [Ru(bpy)3]Cl2∙6H2O (0.5) CFL CHCl3 0 n.d. 
15 14a [Ir(ppy)2(dtbbpy)]PF6 (1.0) CFL CHCl3 0 n.d. 
16 14a [Ir(ppy)2(dtbbpy)]PF6 (1.0) +-RhO (3.0) CFL CHCl3 0 n.d. 
a Reaction conditions: 2-acyl imidazoles 14 (0.2 mmol), amine 15a (0.6 mmol), and catalyst (entries 1-
13, 16: 3.0 mol%, entry 14: 0.5 mol%, entry 15: 1.0 mol%) in the indicated solvent (0.4 mL) irradiated 
for 22 h under an atmosphere of nitrogen at room temperature. b Light source: 23 W compact fluorescent 
lamp (CFL) at a distance of approximately 5 cm from the Schlenk tube. c Isolated yields. d Determined 
by HPLC on chiral stationary phase. n.d. = not determined. 
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3.3.3 Substrate Scope 
Having identified the optimal conditions for this visible light activated asymmetric aminoalkylation 
of trifluoromethyl ketones, the scope of the amine partner was first examined (Figure 50). The reactions 
between 2-trifluoroacetyl imidazole 14a and various N-methyldiarylamines (15a-h) provided the 
respective 1,2-aminoalcohols (16a-h) in satisfactory yields (60-82%) and with high enantioselectivities 
(91-98% ee). Crystal structure of 16g was obtained to determine the absolute configuration of the 
products. However, the two aryl groups, which reduce the oxidation potential of amines, are required 
for obtaining satisfactory results. When one aryl group was replaced by heterocyclic group (-Py) or 
aliphatic group (-Me), the C-C bond formation products were obtained with very low yields (Figure 51). 
It is noteworthy that we found empirically that certain reactions provide better results under white light 
irradiation (CFL), whereas others prefer blue light (blue LEDs). 
 
Figure 50 Substrate scope with respect to N-methyldiarylamines. 
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Figure 51 Some limitations of substrate scope with respect to amines. 
Cyclic tertiary amines are relatively simple to synthesize and have been successfully utilized in the 
α-amino radical chemistry to generate α-heteroaryl amines by MacMillan and other research groups.6 
Herein, the reaction of substrate 14a with 2-phenylisoindoline was investigated. However, the expected 
α-aminoalkylation product was not observed. Encouragingly, by using a more reactive N-phenyl 
tetrahydroisoquinoline as radical precursor, the C-C bond formation product 18a was obtained with 
diastereoselectivity of 3:1 dr and enantioselectivity of 72% ee (the major diastereoisomer), and at a 
catalyst loading of 5 mol%, even 8:1 dr and 94% ee were reached (Figure 52).  
 
Figure 52 Reaction condition screening of cyclic tertiary amines. 
Thus, the substrate scope with respect to N-aryl tetrahydroisoquinolines was tested by using 5 mol% 
Λ-IrS (Figure 53). As expected, a series of C-C bond formation products (18a-f) were obtained with 
good diastereoselectivities (4:1 to 10:1 dr) and high enantioselectivities (94-98% ee) (Figure 53). 
Notably, a bromine (Br) substituent promoted the product excellent yield and enantioselectivity. 
However, a p-methoxyphenyl (PMP) substituent, which serves as a well-established protecting group 
for the nitrogen atom,7 can not be used here because of the limited stability of the product.  
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Figure 53 2-Aryl-1,2,3,4-tetrahydroisoquinolines as amine substrates for enantio- and 
diastereoselective reactions. Relative configurations are assigned based on a crystal structure of 18a. 
n.d. = not determined. 
Another interesting aspect to investigate with this aminoalkylation chemistry would be to extend the 
imidazole moiety to other coordination groups. Herein, 2-acyl pyridines were chosen due to the 
prevalence of pyridines and piperidines in bioactive compounds.8 The reaction of 2-trifluoroacetyl 
pyridine with amine 15a in the presence of catalyst Λ-IrS (3 mol%) under irradiation with a 24 W blue 
LEDs afforded the coupling product 20a with 74% yield and 93% ee. Steric effect of the pyridine 
substrates in this asymmetric aminoalkylation was then investigated. By using pyridine substrate with 
methyl substitute group at 4 and 5-position, the C-C bond coupling products 20b and 20c were afforded 
with moderate yields and good enantioselectivties, while 3-position substituted pyridine substrate was 
failed to convert to the desired product 20d efficiently. Further investigation of other coordination groups, 
such as thiazole and ester, did not give any satisfactory results (Figure 54). 
 
Figure 54 Asymmetric C-C bond cross coupling with other coordination groups. 
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3.3.4 Plausible Mechanism 
A plausible mechanism is shown in Figure 55. The catalytic process starts with the photoactivation 
of the iridium-coordinated trifluoromethyl ketone I to its excited state II (step 1), which induces a single 
electron transfer from a tertiary amine, thereby generating an amino radical cation in addition to a 
reduced iridium complex which can be described as an iridium-coordinated ketyl radical III (step 2). 
This is followed by a proton transfer (step 3) and a radical-radical cross-coupling between the electron-
rich α-amino radical and the electron-deficient ketyl IV (step 4) which is stereochemically controlled 
by the chiral iridium complex V. Finally, the product is replaced by a new substrate (step 5). Several 
investigations have been executed to verify the proposed mechanism in the following section. 
 
Figure 55 Putative mechanism for the visible light activated catalytic asymmetric process. 
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3.3.5 Mechanistic Investigations 
1) Substrate-coordinated iridium complex IrS-I 
To start with, the iridium intermediate complex IrS-I was synthesized by reacting of substrate 14a 
with Δ/Λ-IrS in toluene/CHCl3 at 50 ºC overnight. The freshly prepared complex IrS-I catalyzed the 
photoinduced C-C bond coupling reaction with an almost identical efficiency compared to Λ-IrS (Figure 
56). In addition, the absorbance spectra of racemic Δ/Λ-IrS and intermediate complex IrS-I were 
measured in solution of CHCl3 (0.2 mM). As shown in Figure 57, compared to Δ/Λ-IrS, the complex 
IrS-I displays a bathochromically shifted long wavelength absorbance maximum with an additional 
shoulder at around 600 nm. With the efficient catalytic reactivity and good absorption property, complex 
IrS-I is most likely the active photoredox catalyst in the catalytic cycle mentioned above. 
 
Figure 56 Evaluation of the catalytic activity of intermediate complex IrS-I. 
 
Figure 57 UV/Vis-absorbance spectra of Δ/Λ-IrS and intermediate complex IrS-I. Measured in solution 
of CHCl3 (0.2 mM). a.u. = absorbance units. 
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2) Control experiments 
Control experiment in the presence of air 
The reaction was performed in a 10 mL test tube under an atmosphere of air (air balloon), no C-C 
coupling product was formed (detected by crude 1H NMR of the mixture after 22 h of irradiation), being 
consistent with the presence of intermediate radicals which react with oxygen in a diffusion controlled 
fashion. 
 
Scheme 6 Control experiment in the presence of air. 
Control experiment in the dark with chemical initiator  
Can the reaction be chemically initiated, potentially with a chemical one-electron oxidant? If so, a 
reaction conducted in the dark but in the presence of the iridium complex as a Lewis acid might be able 
to determine whether there is turnover (a chain) or not.9 Thus, the reaction was performed in the dark in 
the presence of catalyst Δ/Λ-IrS and one-electron oxidant, like Cp2FePF6, (BrC6H4)3NSbCl6 and 
Ce(NH4)2(NO3)6. However, no C-C bond coupling product 16a was detected by 1H NMR after stirring 
at room temperature for 22 h. It provides good evidence that no chain process exists in the catalytic 
cycle (Figure 58). 
 
Figure 58 Control experiment in the dark with chemical initiators. 
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3) Trapping experiments 
Trapping experiments of α-aminomethyl radical  
Trapping experiments of electron-rich α-aminomethyl radicals have been well established.10 In the 
presence of dibenzyl azodicarboxylate, a hydrazone C-N coupling product is formed in high yield which 
can be traced back to a reaction of the proposed intermediate (nucleophilic) α-aminomethyl radical with 
the (electrophilic) N=N double bond, followed by reduction and protonation. Likewise, in the presence 
of EWG-alkene acrylonitrile or methyl acrylate, the addition/cyclization product 22a or 22b together 
with 16a are afforded, which again provide good evidence to demonstrate the existence of α-
aminomethyl radical (Figure 59).  
 
Figure 59 Trapping experiments of α-aminomethyl radical. 
Trapping experiment of ketyl radical 
Pinacol coupling product was not observed from the model reaction which probably because the 
resulting stabilized ketyl radical III is a persistent radical that possesses relatively little propensity 
towards homodimerization.4 To capture the ketyl radical, electron rich alkene, ethene-1,1-diyldibenzene, 
was used under the modified reaction conditions. Unfortunately, only the aminoalkylation product 16a 
was observed (Scheme 7). Since the evidence of ketyl radical is limited, radical addition pathway which 
electron-rich α-aminomethyl radical adds to the iridium-coordinated electron-deficient C=O double 
bond could not be completely excluded.11 
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Scheme 7 Trapping experiment of ketyl radical in the presence of ethene-1,1-diyldibenzene. 
4) Quantum yield  
The quantum yield was measured by standard ferrioxalate actinometry. The relevant data was 
collected and calculated by Xiaodong Shen (a former Ph.D. student in the Meggers group). The moles 
of products formed were determined by crude 1H NMR. The quantum yield of the model reaction 14a 
+ 15a  16a with ferrioxalate actinometry was determined to be 0.09. A quantum yield of ≤1 in 
agreement with the expected closed catalytic cycle. According to the control experiments in the presence 
of chemical one-electron oxidants and quantum yield, it is safety to say that no chain process is possible 
with one photon being required for each C-C bond formation event.12  
5) Stereochemistry model 
The photogenerated α-amino radical interacts with the persistent ketyl radical within the chiral 
environment of the iridium complex, which provides impressively high enantioselectivity. The observed 
absolute configuration of the C-C bond coupling reaction, providing S-configuration at the carbon next 
to the OH group when using -IrS, is consistent with this mechanistic picture in which the prochiral Si-
face of the iridium-coordinated ketyl is effectively shielded by one tert-butyl group of the propeller-type 
ligand sphere, providing an excellent stereochemical control of the radical process (Figure 60). 
 
Figure 60 Model for the asymmetric induction in the course of the radical-radical recombination shown 
for selected substrates.  
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3.3.6 Conclusions  
In conclusion, a unique catalytic asymmetric process in which a visible light driven single electron 
transfer reaction between a donor substrate and a catalyst-bound acceptor substrate is followed by a 
stereocontrolled radical-radical recombination was introduced. Using a chiral iridium complex as dual 
chiral Lewis acid/photoredox catalyst, 1,2-aminoalcohols are synthesized from trifluoromethylketones 
and tertiary amines with high enantioselectivities of up to 99% ee. Such non-racemic CF3-containing 
compounds might be useful building blocks for the synthesis of bioactive compounds.17 It is also worth 
noting that this mild method follows the spirit of sustainable chemistry, not only because the activation 
energy is provided by visible light as an abundant light source, but also since in the course of the C-C 
bond formation with the implementation of one or two new stereocenters, no waste products are 
generated, thereby constituting a perfect atom economy. 
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3.4 Catalytic Asymmetric C(sp3)-H Functionalization under Photoredox 
Conditions by Radical Translocation and Stereocontrolled Alkene Addition 
3.4.1 Reaction Design 
In chapter 3.3, we developed a catalytic asymmetric C(sp3)-H functionalization protocol that allows 
tertiary amines to undergo α-aminoalkylation of trifluoromethyl ketones to achieve 1,2-diamino alcohols 
(through radical-radical cross-coupling). Besides the functional group at its α-position, there are many 
other powerful strategies that have been emerged for the functionalization of C(sp3)-H bonds.1 
Recently, Chen and co-workers introduced a visible light induced release of alkoxyl radicals from N-
alkoxyphthalimides and applied it to the selective C(sp3)-H functionalization by exploiting an 1,5-
hydrogen atom transfer (1,5-HAT).2 Radical translocation3 has been used extensively for the 
functionalization of remote C(sp3)-H bonds, but to our knowledge the combination with a catalytic 
asymmetric C-C bond formation remains elusive. Therefore, we envisioned to merge this photoredox-
mediated C-H functionalization with asymmetric catalysis as shown in Figure 61 by trapping the 
intermediate (electron rich) carbon-centered radical in a stereocontrolled fashion with an acceptor-
substituted alkene catalyzed by a chiral Lewis acid. Challenges include the compatibility of the 
individual steps with respect to the reactivity of the radical intermediates and the kinetics of the 
individual steps, as well as the ability to control the relative and absolute stereochemistry of the radical 
reaction in a catalytic fashion. 
 
Figure 61 Reaction design of photoredox-mediated C-H functionalization with asymmetric catalysis. 
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3.4.2 Initial Experiments and Reaction Optimization 
This study was started by investigating the reaction of α,β-unsaturated acyl imidazole 24a' with N-
alkoxyphthalimide 25a and Hantzsch ester (HE) under photoredox conditions. In the presence of the 
previously developed dual function photoredox/chiral Lewis acid catalyst Δ-IrS4 (3 mol%), to our 
disappointment, the desired product 26a' was not achieved. Encouragingly, when α,β-unsaturated acyl 
pyrazole 24a was used as a Michael acceptor instead, the C-C bond formation product 26a was obtained 
in 85% yield after irradiation of 20 h. However, no enantioselectivity was observed (Figure 62).  
 
Figure 62 Initial experiments with two different Michael acceptors.  
Thus, the optimization began with the reaction of α,β-unsaturated acyl pyrazole 24a and N-
alkoxyphthalimide 25a under photoredox conditions (Table 8). When the dual catalyst system of a chiral 
Lewis acid Δ-RhO5 (3 mol%) in combination with a photoredox catalyst fac-[Ir(ppy)3] (1 mol%) was 
applied to this system, the reaction proceeded in 60% yield and 18% ee (entry 1). The enantioselectivity 
was improved to 79% ee when Δ-RhS6 (3 mol%) was used as the chiral Lewis acid (entry 2). At a 
catalyst loading of 8 mol%, even 92% ee was reached (entry 5). Other photoredox catalysts, such as 
[Ir(ppy)2(dtbbpy)]PF6 and [Ru(bpy)3](PF6)2, were inferior to fac-[Ir(ppy)3] (entries 3 and 4). The 
reaction is sensitive to solvent effects (entries 6 and 7) and the light source, as blue LEDs provided a 
somewhat lower enantioselectivity (entry 8). Control experiments verified that both visible light and 
Hantzsch ester are essential for product formation (entries 9 and 10). In the absence of the chiral Lewis 
acid Δ-RhS, product 26a was still formed (75% yield), albeit as a racemic mixture (entry 11). It is worth 
noting that in the absence of the additional photoredox catalyst fac-[Ir(ppy)3] (entry 12) or both fac-
[Ir(ppy)3] and Δ-RhS (entry 13), the product 26a was still generated but with significantly reduced 
efficiency. UV/Vis-absorbance spectra of the individual substrates and Hantzsch ester suggest that this 
should be due to the direct photoexcitation of the Hantzsch ester.7 
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Table 8 Reaction development.a 
 
entry catalyst photoredox catalyst hb solvent t (h) yield (%)c ee(%)d 
1 -RhO (3.0) fac-[Ir(ppy)3] (1.0) CFL THF 20 60 18 
2 -RhS (3.0) fac-[Ir(ppy)3] (1.0) CFL THF 20 61 79 
3 -RhS (3.0) [Ir(ppy)2(dtbbpy)]PF6 (1.0) CFL THF 20 76 36 
4 -RhS (3.0) [Ru(bpy)3](PF6)2 (1.0) CFL THF 20 < 5 n.d. 
5 -RhS (8.0) fac-[Ir(ppy)3] (1.0) CFL THF 40 70 92 
6 -RhS (8.0) fac-[Ir(ppy)3] (1.0) CFL CH2Cl2 40 13 86 
7 -RhS (8.0) fac-[Ir(ppy)3] (1.0) CFL DMF 40 21 60 
8 -RhS (8.0) fac-[Ir(ppy)3] (1.0) blue LEDs THF 40 69 86 
9 -RhS (8.0) fac-[Ir(ppy)3] (1.0) none THF 40 0 n.a. 
10e -RhS (8.0) fac-[Ir(ppy)3] (1.0) CFL THF 40 0 n.a. 
11 none fac-[Ir(ppy)3] (1.0) CFL THF 20 75 n.a. 
12 -RhS (8.0) none CFL THF 40 33 92 
13 none none CFL THF 20 56 n.a. 
a Reaction conditions: 2-Acyl pyrazole 24a (0.4 mmol), N-alkoxyphthalimide 25a (0.2 mmol), Hantzsch 
ester (none or 0.3 mmol) with chiral Lewis acid catalyst (none or 3 or 8 mol%) and photoredox catalyst 
(none or 1 mol%) in solvent (1.0 mL) at room temperature for 20-40 h under an atmosphere of nitrogen. 
b 23 W compact fluorescent lamp (CFL) or 6 W blue LEDs. c Isolated yield. d Enantiomeric excess 
determined by HPLC on chiral stationary phase. e Control experiment without Hantzsch ester. n.a. = not 
applicable, n.d. = not determined. 
It is worth noting that compared to N-alkoxyphthalimide 25a (n = 1), N-alkoxyphthalimide 25a' (n=0) 
and 25a'' (n=2) were not suitable for the reaction (Figure 63). The results are in agreement with Curran’s 
work8 and can be rationalized by the possible transition state involved in the HAT process. It is currently 
accepted that the ideal arrangement of the three atoms involved in the transition state of intramolecular 
HAT is linear (low energetic cost). The six-membered transition structure can readily accommodate a 
C-H-O angel close to 180º. Thus, 1,5-HAT is a more favorable process compare to 1,4-HAT or 1,6-HAT.  
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Figure 63 Transition-state of alkoxyl radicals. 
3.4.3 Substrate Scope 
After the optimized conditions were established, we next tested the substrate scope of the asymmetric 
photoinduced C(sp3)-H functionalization. Figure 64 shows that the reaction of a variety of 2-acyl 
pyrazoles 24a-j with N-alkoxyphthalimide 25a in the presence of Δ-RhS, fac-[Ir(ppy)3] and Hantzsch 
ester while illuminating with visible light provided the expected C-C bond formation products 26a-j in 
51-80% yields and 82-97% ee. The reaction was tolerant of aliphatic substituents, regardless of acyclic 
and cyclic paraffins (26a-f). Notably, ethoxy- and benzyloxy-substituted 24g and 24h are favorable here, 
affording the corresponding products 26g and 26h in good yields and high stereoselectivities, 
respectively. The electronic effects have a significant influence upon substituents on the aromatic 
moieties, and with electron-donating substituents, the radical addition products (26i and 26j) were 
obtained in moderate yields and good enantioselectivities. As for the aromatic moiety with no substituent 
or electron-withdrawing substituent, the undesired reductive homocoupling of alkene was the main 
process.9 
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Figure 64 Substrate scope with respect to α,β-unsaturated 2-acyl pyrazoles. 
To further expand the scope, a wide range of tertiary N-alkoxyphthalimides were applied to the 
reaction, affording the adducts in 54-85% yields and with 86-97% ee (26m-26u). Secondary N-
alkoxyphthalimide with aromatic substitutes were also suitable for the reaction and afforded the 
corresponding products (26v and 26w) with diastereoselectivities of up to 3:1 and enantioselectivities 
of up to 97% ee (Figure 65). The effort to improve the diastereoselectivity by changing reaction 
temperature or catalyst loadings of Δ-RhS was not succeeded. In addition, this α-heteroatom activation 
is not limited by oxygen, α-sulfur activated C-H bonds also work well under the standard condition 
(Figure 66), while α-nitrogen activated C-H bonds could not give satisfactory results. For unactivated 
C-H bonds, low yields may be rationalized by high reactivity of the intermediate alkoxyl radical or 
carbon-centered radical and once generated, it was rapidly trapped by Hantzsch ester, thereby forming 
alcohol as a side product. 
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Figure 65 Substrate scope with respect to N-alkoxyphthalimides. Crystal structure of 26t was obtained 
to determine the absolute configuration of the products. 
 
Figure 66 Limitation with respect to N-alkoxyphthalimides. 
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The formation of quaternary carbon stereocenters in a catalytic enantioselective fashion is promising 
and challenging. Unfortunately, the reactions of several 2-acyl pyrazoles with N-alkoxyphthalimide 25a 
for the construction of quaternary carbon stereocenters were not succeeded under standard conditions 
(Figure 67). Comparing to Melchiorre’s recent work10, we thought that the chiral Lewic acid catalyst Δ-
RhS might not efficiently activate 2-acyl pyrazoles with two substituted groups in β-position duo to its 
crowded coordination atmosphere. 
 
Figure 67 Some limitations for the construction of quaternary carbon stereocenters. 
It is noteworthy to mention that N-acyl pyrazole is a very useful precursor for the conversion into 
other functionality. As shown in Figure 68, the aminolysis of product 26s underwent smoothly to yield 
27 without compromise any of enantiopurity, while the treatment of 26s with NaBH4 afforded diol 28 
without detectable racemization.11 
 
Figure 68 Exemplary transformations starting with one N-acyl pyrazole. 
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3.4.4 Plausible Mechanism 
A plausible mechanism is shown in Figure 69 and starts with the photoactivation of fac-[Ir(ppy)3], whose 
excited state [Ir(ppy)3]* is reductively quenched by the Hantzsch ester.7 Thereby generated fac-[Ir(ppy)3]ˉ 
serves as a strong reducing agent and transfers a single electron to N-alkoxyphthalimide (redox handle) under 
formation of an N-alkoxyphthalimide radical anion, which is subsequently protonated by the oxidized 
Hantzsch ester (radical cation), and then undergoes a homolytic N-O bond cleavage under formation of an 
alkoxy radical. The alkoxyl radical engages in an intramolecular 1,5-hydrogen atom transfer (HAT) to yield 
a carbon-centered radical,12 which adds to N,O-rhodium-coordinated 2-acyl pyrazole substrate (RhS-I), 
thereby generating the secondary radical intermediate (RhS-II). This radical intermediate is further trapped 
by the Hantzsch ester radical to provide rhodium-bound product (RhS-III). The observed high 
enantioselectivity in this new process demonstrates that the chiral Lewis acid Δ-RhS strongly accelerates the 
radical addition so that it is capable of outcompeting the prevailing racemic background reaction.13  
 
Figure 69 Proposed mechanism which is consistent with the observed product formation and the 
mechanistic experiments.  
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3.4.5 Mechanistic Investigations 
1) Crystal structure analysis of the proposed rhodium intermediate RhS-I 
The catalytic cycle was first investigated by verifying the involvement of the proposed rhodium 
intermediate RhS-I. Accordingly, upon reaction of an excess substrate 24a with racemic /-RhS we 
could isolate the proposed intermediate RhS-I. A crystal structure of intermediate RhS-I is shown in 
Figure 70 (left). The stereocontrol model reveals that a -configuration at the rhodium center shields 
the Re-face of the carbon in β-position and directs the addition of the electron-rich radical to the Si-face, 
thereby being consistent with the observed R-configuration of the alkylation product when using the 
catalyst with -configuration at the metal (Figure 70, right). 
 
Figure 70 Crystal structure of proposed intermediate RhS-I (left, hydrogen atoms and the 
hexafluorophosphate counteranion are omitted for clarity) and stereochemical model (right). 
2) Isolation of byproducts and a side product  
Isolation of byproducts 
The expected byproducts diethyl 2,6-dimethylpyridine-3,5-dicarboxylate (29) and isoindoline-1,3-
dione (30) could be isolated under the standard conditions. Accordingly, compound 29 was generated 
by oxidation of Hantzsch ester, while compound 30 was formed by reduction of N-alkoxyphthalimide 
25a.  
 
Scheme 8 Isolation of byproducts 29 and 30. 
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Isolation of a side product  
2-((1-Tosylazetidin-3-yl)oxy)ethanol 31 was isolated as a side product with 15% yield in the relatively 
sluggish conversion reaction Scheme 9. This further supports our proposed mechanism and can be 
explained by a competing undesired reduction of the initial oxygen- or carbon-centered radicals. 
 
Scheme 9 Isolation of a side product 31. 
3) Control reactions 
The presence of air or the radical inhibitor BHT (5 eq.) results in a reduced yield and enantioselectivity 
of the C-C bond formation product 26a, which provides evidence for a radical pathway (Scheme 10). 
The intermediate carbon-centered radical serving as a relatively stabilized radical that could not be 
trapped efficiently by oxygen or BHT. These results are in agreement with Haohua Huo’s work13 and 
may explain why the product 26a was still formed with about 45% yield. 
 
Scheme 10 Probing radical pathway in the presence of air or BHT. 
4) Trapping experiments 
The proposed intermediate carbon-centered radical was verified by trapping experiments with 
competing electron deficient alkenes (Scheme 11). For example, when 2 equivalents of ((2-
phenylallyl)sulfonyl)benzene 32 were added to the reaction under standard conditions, the C(sp3)-H 
allylation adduct 33 was isolated with 18% yield. N-arylacrylamides are currently magic reagents for 
trapping carbon radicals by sequential intermolecular addition of radicals followed by intramolecular 
cyclization.14 When 2 equivalents of N-methyl-N-phenylmethacrylamide 34 were added to the reaction 
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under modified conditions, the addition/cyclization product 35 was isolated as a yield of 18%. 
 
Scheme 11 Trapping experiments in the presence of alkene 32 or 34. 
5) UV/Vis-absorption spectra 
The absorption spectra of the possible metal photoredox catalysts of the reaction were measured in 
THF. As shown in Figure 71, not only fac-[Ir(ppy)3] (λmax = 370 nm) but also the Lewis acid catalyst 
RhS (λmax = 395 nm) and the intermediate RhS-I (λmax = 390 nm) have absorption in the visible region.  
 
Figure 71 UV/Vis-absorption spectra of the used photoredox catalyst, the Lewis acid catalyst RhS and 
intermediate RhS-I. Measured as solutions in THF (0.2 mM). a.u. = absorbance units. 
The absorption spectra of the substrate 25a and Hantzsch ester were measured in THF as well. As 
shown in Figure 72, substrate 25a does not absorb in the visible part of the spectrum, while the Hantzsch 
ester exhibits an absorption band in the near UV, with a maximum at about 350 nm. Notably, the 
absorbance of the mixture of 25a and Hantzsch ester is the same as that of Hantzsch ester in the visible 
light region. The absorption spectrum of Hantzsch ester and control experiment (Table 8, entry 13) 
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support that the Hantzsch ester can also be photoexcited and reduce the N-alkoxyphthalimide in the absence 
of fac-[Ir(ppy)3] and RhS, but it is not the major pathway of the N-alkoxyphthalimide reduction. 
 
Figure 72 UV/Vis-absorption spectra of substrate 25a and Hantzsch ester. Measured as solutions in THF 
(2 mM). a.u. = absorbance units. 
6) Luminescence quenching experiments 
Quenching experiments with fac-[Ir(ppy)3] in the absence of intermediate RhS-I 
Stern-Volmer plots (Figure 73) illustrate that the luminescence emission of fac-[Ir(ppy)3] is quenched 
efficiently by the Hantzsch ester, in contrast to the substrates 2-acyl pyrazole 24a or N-
alkoxyphthalimide 25a, which supports the proposed catalytic mechanism in which electron transfer 
from Hantzsch ester to the excited state fac-[Ir(ppy)3]* occurs and is at the center of the redox process. 
This observation is also in agreement with recent studies by Chen.2 
 
Figure 73 Stern-Volmer plots. I0 and I are respective luminescence intensities in the absence and 
presence of the indicated concentrations of the corresponding quencher. 
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Quenching experiments with with fac-[Ir(ppy)3] in the presence of intermediate RhS-I 
When the quenching experiments were performed in the presence of intermediate RhS-I, a decreased 
luminescence of fac-[Ir(ppy)3] was observed. Despite the lower luminescence intensity of the iridium 
sensitizer, the quenching of the photoexcited state of fac-[Ir(ppy)3] by Hantzsch ester can be observed 
which is demonstrated by the emission intensity of the mixture solution of fac-[Ir(ppy)3] and 
intermediate RhS-I and Hantzsch ester (Figure 74).  
 
Figure 74 Emission spectra of the photoactive species. The photoactive species were measured as 
solutions in THF (0.2 mM). a.u. = arbitrary unit. 
7) Quantum yield measurement  
The quantum yield was measured by standard ferrioxalate actinometry. The moles of product formed 
was measured by GC analysis using dodecane as internal standard (for details, see experimental part). 
The quantum yield of the model reaction 24a + 25a  26a with ferrioxalate actinometry was determined 
to be 0.05 which is consistent with the proposed absence of a chain process.15 
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3.4.6 Conclusions 
In summary, this work shows how C(sp3)-H bond functionalization through radical translocation can be 
merged with a catalytic asymmetric C-C bond formation by combining visible light activated 
photoredox catalysis with chiral Lewis acid catalysis. By using dual catalysis strategy, radical addition 
products were achieved with enantioselectivities of up to 97% ee, and with some diastereoselectivity 
(3:1 dr). We believe that this method is practically valuable since it makes use of the functionalization 
of unactivated C(sp3)-H bonds, at the same time introduces two stereocenters, and employs simple 
activating groups, namely N-alkoxyphthalimides as known redox-active radical precursors, as well as 
N-acyl pyrazoles as Lewis-acid-activatable functional groups.  
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Chapter 4: Summary and Outlook 
4.1 Summary 
In this thesis, a class of octahedral chiral-at-metal complexes IrO(S) and RhO(S) have been 
successfully applied to asymmetric reactions (Figure 75). Accordingly, rhodium complexes Δ-RhO and 
Δ-RhS have been demonstrated as very efficient chiral Lewis acid catalysts in asymmetric Michael 
additions and visible light induced asymmetric Giese radical addition, respectively. Iridium complexes 
Δ-IrO and Λ-IrS have been proven to be capable of serving as dual chiral Lewis acid/photoredox 
catalysts in visible light activated asymmetric α-aminoalkylation and radical-radical cross-coupling 
reaction, respectively. These novel octahedral chiral-at-metal iridium and rhodium complexes provide 
new opportunities for the efficient and economical synthesis of highly enantioenriched molecules. 
 
Figure 75 An overview for the thesis. 
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1) Asymmetric Lewis acid catalysis directed by octahedral rhodium centrochirality 
 
Figure 76 Enantiomers of a substitutionally labile yet configurationally stable chiral-at-metal 
rhodium(III) Lewis acids -RhO and -RhO. 
A rhodium-based asymmetric catalyst which derives its optical activity from octahedral 
centrochirality was introduced (Figure 76). The chiral Lewis acid complexes -RhO and -RhO were 
synthesized according to chiral proline-mediated strategy developed by the Meggers group. 
Accordingly, the reaction of dimer rac-2 with D-proline afforded the prolinato-rhodium complexes -
(R)-3 and -(R)-3 as a mixture of diastereomers, and -(R)-3 is isolable in a straightforward fashion 
with high purity by just washing the mixture of diastereomers with CH2Cl2/Et2O. The virtually 
enantiopure -RhO was yielded after stereospecific substitution of D-proline by two acetonitrile 
ligands. The mirror-imaged complex -RhO is accessible in an analogous fashion by using the chiral 
auxiliary L-proline instead (Figure 77). 
 
Figure 77 Synthesis of the enantiomerically pure Lewis acid complexes -RhO and -RhO. 
Besides providing the exclusive source of chirality, the rhodium center serves as a Lewis acid by 
activating 2-acyl imidazoles through two-point-binding and enabling a very effective asymmetric 
induction mediated by the propeller-like C2-symmetrical ligand sphere. Applications of asymmetric 
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Michael additions as well as asymmetric cascade reaction are disclosed, for which the rhodium catalyst 
is found to be overall superior to its iridium congener (Figure 78). By virtue of its straightforward 
proline-mediated synthesis, high catalytic activity, and tolerance towards moisture and air, this novel 
class of chiral-at-rhodium catalysts has been proven to be of widespread use for a variety of asymmetric 
transformations in the Meggers group. 
 
 
Figure 78 Catalytic asymmetric conjugate additions and cascade reaction catalyzed by -IrO and -
RhO. 
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2) Merger of visible light induced oxidation and enantioselective alkylation with chiral iridium 
catalyst 
A visible light activated asymmetric α-aminoalkylation of 2-acyl imidazoles catalyzed by a single 
chiral iridium complex was developed. In the presence of a conventional household lamp and under an 
atmosphere of air, the oxidative coupling of 2-acyl-N-phenyl imidazoles with α-silylamines provide 
aminoalkylated products in 61-93% yields with high enantioselectivities (90-98% ee). Mechanistically, 
the catalytic cycle is started by the formation of the substrate coordinated intermediate A. The 
subsequent deprotonation in α-position of the carbonyl group affords the nucleophilic iridium enolate 
intermediate B. The reaction of the enolate complex B with the newly formed iminium ion (generated 
by an iridium-photocatalyzed oxidation of the α-silylamine with oxygen serving as the terminal oxidant) 
occurs in a stereocontrolled fashion dictated by the metal-centered chirality and provides the iridium 
coordinated product C. The intermediate C subsequently released the product upon coordination to a 
new substrate, thereby initiating a new catalytic cycle (Figure 79). This conceptionally simple reaction 
scheme may provide new avenues for the green synthesis of chiral molecules. 
 
Figure 79 Visible light activated asymmetric α-aminoalkylation of 2-acyl imidazoles with a chiral 
iridium complex Δ-IrO. PC = photoredox catalyst.   
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3) Asymmetric radical-radical cross-coupling through visible light activated iridium catalysis  
A catalytic process of asymmetric radical-radical cross-coupling through visible light activated 
iridium catalysis was introduced. Combining single electron transfer between a donor substrate and a 
catalyst-activated acceptor substrate with a stereocontrolled radical-radical recombination enables the 
catalytic enantio- and diastereoselective synthesis of 1,2-aminoalcohols from trifluoromethyl ketones 
and tertiary amines. With a dual function chiral iridium complex acting as both a Lewis acid and a 
photoredox catalyst, enantioselectivities of up to 99% ee and where applicable, with 
diastereoselectivities of up to 10:1 dr were achieved (Figure 80). A quantum yield of <1 supports the 
proposed catalytic cycle in which at least one photon is needed for each asymmetric CC bond formation 
mediated by single electron transfer. It is also worth noting that this mild method follows the spirit of 
sustainable chemistry, not only because the activation energy is provided by visible light as an abundant 
light source, but also since in the course of the C-C bond formation with the implementation of one or 
two new stereocenters, no waste products are generated, thereby constituting a perfect atom economy. 
 
Figure 80 Visible light activated asymmetric radical-radical cross-coupling with a chiral iridium 
complex Λ-IrS. 
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4) Catalytic asymmetric C(sp3)-H functionalization under photoredox conditions by radical 
translocation and stereocontrolled alkene addition 
How photoredox-mediated C(sp3)-H activation through radical translocation can be combined with 
asymmetric catalysis was demonstrated. Upon irradiation with visible light, α,β-unsaturated N-acyl 
pyrazoles react with N-alkoxyphthalimides in the presence of a rhodium-based chiral Lewis acid catalyst 
Δ-RhS and the photoredox catalyst fac-[Ir(ppy)3] to provide C-C bond-formation products with high 
enantioselectivities (up to 97% ee) and, where applicable, with some diastereoselectivities (3:1 dr). 
Mechanistically, the synthetic strategy exploits a radical translocation (1,5-hydrogen transfer) from an 
oxygen-centered to a carbon-centered radical with a subsequent stereocontrolled radical alkene addition. 
It is worth noting that N-acyl pyrazole is a very useful precursor for the conversion into other carbonyl 
functionality as shown for the representative conversion into a diol and an amide (Figure 81). 
 
Figure 81 Visible light activated asymmetric C(sp3)-H functionalization with a chiral Lewis acid Δ-
RhS and a photoredox catalyst fac-[Ir(ppy)3]. 
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4.2 Outlook 
The work described in this thesis contributes to the development of new catalysts and synthetic strategies. 
Further investigations can be focus on the following aspects: 
1) Nowadays, one of the most challenging projects in organic synthetic methodology is visible light 
induced asymmetric C(sp3)-H functionalization. Radical translocation is an old but very useful strategy 
which has been discussed in chapter 3.4. However, the complexity certainly limits the practical 
application. The simultaneous use of iridium and rhodium complexes and the stoichiometric amount of 
the Hantzsch ester required make the reaction less attractive for large scale synthesis. Very recently, the 
Knowles group and the Rovis group simultaneously reported symmetric photoredox catalyzed C-C bond 
formation by directed cleavage of traditionally non-reactive C(sp3)-H bonds (through intramolecular 
1,5-HAT) and their subsequent addition to readily available alkenes, no waste products are generated. 
These results suggest that enantioselectivity photoredox catalyzed C-C bond formation products can be 
formed by combining our chiral rhodium Lewis acid catalysts with the newly developed C(sp3)-H 
functionalization approaches. 
2) Although high enantioselectivities could be achieved by using chiral-at-metal complexes in chapter 
3.2-3.4, the substrates limitation is obvious and such imidazole or pyrazole coordination group is always 
required which makes the products less usable. How to make the products more general and practical? 
Maybe iridium-templated Brønsted acid or co-catalysts of the combination of rhodium-templated 
Brønsted acid with photocatalysis would give opportunities to activate carbonyl substrates, thereby 
reacting with intermediates in a stereocontrolled fashion under photoredox conditions. 
3) In recent years, ruthenium(II), iridium(III) and platinum(II) complexes with cyclometalated 
arylpyridines and related ligands have become the most studied systems because they display highly 
tunable emission energies and can reach very high quantum yields. The González-Herrero group 
recently developed a variety of platinum(IV) complexes with cyclometalated arylpyridines which 
exhibit impressively luminescence properties. However, the application of these platinum(IV) 
complexes in photoredox catalysis is rarely. Next work may focus on the synthesis of a platinum(IV) 
Lewis acid catalyst which contains two achiral bidentate ligands and two labile acetonitriles, and thereby 
investigates its catalytic properties in asymmetric photoredox catalysis.  
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Chapter 5: Experimental Part 
5.1 Materials and Methods 
All reactions were carried out under an atmosphere of nitrogen with magnetic stirring. The catalysis 
reactions were performed using standard Schlenk glassware techniques. 
 
Solvents and Reagents 
Solvents were distilled under nitrogen from calcium hydride (CHCl3, CH2Cl2, CH3CN and DMF), 
magnesium turnings/iodine (MeOH) or sodium/benzophenone (Et2O, THF and toluene). HPLC grade 
solvents, such as 2-methoxyethanol, ethanol and 1,4-dioxane used directly without further drying. All 
reagents were purchased from Acros, Alfa Aesar, Sigma Aldrich, TCI, ChemPur and Fluorochem and 
used without further purification. 
 
Chromatographic Methods 
The course of the reactions and the column chromatographic elution were monitored by thin layer 
chromatography (TLC) [Macherey-Nagel (ALUGRAM®Xtra Sil G/UV254)]. Flash column 
chromatography was performed with silica gel from Merck (particle size 0.040-0.063 mm). 
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
1H NMR, proton decoupled 13C NMR, and proton coupled 19F NMR spectra were recorded on Bruker 
Avance 300 system (1H NMR: 300 MHz, 13C NMR: 75 MHz, 19F NMR: 282 MHz) spectrometers at 
ambient temperature. Chemical shifts are given in ppm on the  scale, and were determined after 
calibration to the residual signals of the solvents, which were used as an internal standard. NMR 
standards were used are as follows: 1H NMR spectroscopy:  = 7.26 ppm (CDCl3),  = 5.32 ppm 
(CD2Cl2),  = 2.50 ppm (DMSO-d6),  = 3.31 ppm (CD3OD); 13C-NMR spectroscopy:  = 77.0 ppm 
(CDCl3),  = 53.8 ppm (CD2Cl2),  = 118.26, 1.32 ppm (CD3CN),  = 206.26,  = 39.52 ppm (DMSO-
d6),  = 49.0 ppm (CD3OD). 19F NMR spectroscopy:  = 0 ppm (CFCl3). The characteristic signals were 
specified from the low field to high field with the chemical shifts (δ in ppm). 1H NMR spectra peak 
Chapter 5: Experimental Part 
89 
 
multiplicities indicated as singlet (s), doublet (d), doublet of doublet (dd), doublet of doublet of doublet 
(ddd), triplet (t), doublet of triplet (dt), quartet (q), multiplet (m). The coupling constant J indicated in 
hertz (Hz).  
 
High-Performance Liquid Chromatography (HPLC) 
Chiral HPLC was performed with an Agilent 1200 Series or Agilent 1260 Series HPLC System. All the 
HPLC conditions were detailed in the individual procedures. The type of the columns, mobile phase and 
the flow rate were specified in the individual procedures. 
 
Infrared Spectroscopy (IR) 
IR measurements were recorded on a Bruker Alpha-P FT-IR spectrometer. The absorption bands were 
indicated a wave numbers v (cm1). All substances were measured as films or solids. 
 
Mass Spectrometry (MS) 
High-resolution mass spectra were recorded on a Bruker En Apex Ultra 7.0 TFT-MS instrument using 
ESI or APCI or FD technique. Ionic masses are given in units of m/z for the isotopes with the highest 
natural abundance. 
 
Circular Dichroism Spectroscopy (CD) 
CD spectra were recorded on a JASCO J-810 CD spectropolarimeter. The parameters we used as follows: 
from 600 nm to 200 nm; data pitch (0.5 nm); band with (1 nm); response (1 second); sensitivity 
(standard); scanning speed (50 nm/min); accumulation (5 times). The concentration of the compounds 
for the measurements was 0.2 mM. The formula for converting θ to ε is shown as below. 
 
)()/(32980
deg][
cmLLmolc
m



 
C = concentration of the sample; L = thickness of the measurement vessel 
 
Crystal Structure Analysis 
Crystal X-ray measurements and the crystal structure analysis were carried out by Dr. Klaus Harms 
(Chemistry Department, Philipps University of Marburg). X-ray data were collected with a Bruker 3 
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circuit D8 Quest diffractometer with MoKa radiation (microfocus tube with multilayer optics) and 
Photon 100 CMOS detector. Scaling and absorption correction was performed by using the SADABS1 
software package of Bruker. Structures were solved using direct methods in SHELXS2 and refined using 
the full matrix least squares procedure in SHELXL-20133 or SHELXL-20144. The Flack parameter is a 
factor used to estimate the absolute configuration of the coumounds.5 The hydrogen atoms were placed 
in calculated positions and refined as riding on their respective C atom, and Uiso(H) was set at 1.2 
Ueq(Csp2) and 1.5 Ueq(Csp3). Disorder of PF6 ions, solvent molecules or methylene groups was refined 
using restraints for both the geometry and the anisotropic displacement factors. 
 
UV/Vis Analysis Spectroscopy 
UV/Vis measurements were taken on a Spectra Max M5 microplate reader in a 10.0 mm quartz cuvette. 
 
Optical Rotation Polarimeter 
Optical rotations were measured on a Krüss P8000-T or Perkin-Elmer 241 polarimeter with []D20 or 
[]D25 values reported in degrees with concentrations reported in g/100 mL.  
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5.2 Asymmetric Lewis Acid Catalysis Directed by Octahedral Rhodium 
Centrochirality 
5.2.1 Synthesis of the Rhodium Catalysts -RhO and -RhO 
1) Synthesis of benzoxazole ligands 
5-tert-Butyl-2-phenylbenzo[d]oxazole (1) 
  
The compound 1 was synthesized following a published procedure with slight modifications.6 A solution 
of 2-amino-4-tert-butylphenol (0.825 g, 5.0 mmol) and benzaldehyde (0.5 mL, 5.0 mmol) in m-xylene 
(16.0 mL) was stirred at 120 ºC for 30 min. 4-Methoxy-TEMPO (46.5 mg, 5 mol%) was added to the 
mixture and the reaction was stirred at this temperature for further 8 h under an oxygen atmosphere. The 
reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue 
was purified by flash chromatography on silica gel (EtOAc/hexane = 1:20) to obtain the product 1 (1.152 
g, 4.6 mmol, yield: 92%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 8.29–8.22 (m, 2H), 7.81 (d, J = 1.8 Hz, 1H), 7.56–7.48 (m, 4H), 7.42 (dd, 
J = 8.6, 1.9 Hz, 1H), 1.40 (s, 9H). 
All spectroscopic data are in agreement with the literature.7 
 
2) Precursor rhodium complex rac-2 
 
The new complex rac-2 was synthesized according to a route reported by Mesmaeker for rhodium(III) 
μ-chloro-bridged dimers with related cyclometalated ligands.8 Accordingly, 5-tert-butyl-2-
phenylbenzo[d]oxazole 1 (1.030g, 4.1 mmol) was added to RhCl3•3H2O (526.6 mg, 2.0 mmol) in a 
mixture of 2-ethoxyethanol and water (3:1, 92.0 mL). The reaction mixture was heated at 120 °C for 24 
h under an atmosphere of nitrogen. The resulting precipitate was collected by centrifugation, washed 
with methanol and dried to obtain the product rac-2 (792.4 mg, 0.62 mmol, yield: 62%) as a pale yellow 
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solid. 
1H NMR (300 MHz, CD2Cl2) δ 8.38 (t, J = 1.2 Hz, 4H), 7.58 (dd, J = 7.6, 1.3 Hz, 4H), 7.31–7.20 (m, 
8H), 6.97 (td, J = 7.4, 0.9 Hz, 4H), 6.77 (td, J = 7.6, 1.5 Hz, 4H), 6.12 (d, J = 7.9 Hz, 4H), 1.22 (s, 36H). 
13C NMR (75 MHz, CD2Cl2) δ 170.4 (4C), 164.8 (4C), 164.4 (4C), 149.0 (4C), 148.0 (4C), 139.6 (4C), 
133.6 (4C), 131.4 (4C), 125.5 (4C), 124.1 (4C), 123.1 (4C), 115.8 (4C), 110.5 (4C), 35.4 (4C), 31.8 
(12C). 
IR (film): ν (cm1) 3055, 2957, 2870, 1589, 1526, 1441, 1373, 1271, 1196, 1120, 1075, 1027, 929, 892, 
808, 727, 702, 647, 448. 
HRMS (ESI, m/z) calcd for C68H64RhN4O4Cl [MCl]+: 1241.2721, found: 1241.2709. 
 
3) Rhodium auxiliary complexes -(S)-3 and -(R)-3 
 
The new rhodium auxiliary complexes Λ-(S)-3 and Δ-(R)-3 were synthesized according to a reported 
method9 with some modifications. To a solution of NaOMe (16.2 mg, 0.30 mmol) in methanol (16.0 
mL), L-proline (34.5 mg, 0.30 mmol) or D-proline (34.5 mg, 0.30 mmol) was added in one portion. The 
mixture was stirred for 10 min, to which a suspension of rhodium dimer (201.3 mg, 0.15 mmol) was 
added. The mixture was stirred and heated at 50 °C for 12 h. After the mixture cooled to room 
temperature, CH2Cl2 (16.0 mL) was added. The reaction mixture was stirred for a further 12 h to give a 
clear, yellow solution. The solvent was removed in vacuo and the mixture of two diastereoisomers was 
washed by dichloromethane/diethyl ether (1:6, v/v) until the filtrate was almost colorless. The residual 
insoluble solid was dried and collected as Λ-(S)-3 (77.4 mg, 36%) or Δ-(R)-3 (86.1 mg, 40%). The 
absolute configurations of the obtained Λ-(S)/Δ-(R) configured rhodium(III) complexes were assigned 
by an X-ray crystal structure of Δ-(R)-3. CD spectroscopy confirmed that they are enantiomers. 
1H NMR (300 MHz, CD2Cl2) δ 8.17 (d, J = 1.8 Hz, 1H), 7.84–7.79 (m, 2H), 7.73 (dd, J = 15.2, 8.8 Hz, 
2H), 7.63 (td, J = 9.0, 1.8 Hz, 2H), 7.36 (d, J = 1.6 Hz, 1H), 7.10–7.07 (m, 2H), 6.95 (td, J = 7.5, 1.5 
Hz, 2H), 6.76 (d, J = 7.7 Hz, 1H), 6.49 (d, J = 7.7 Hz, 1H), 4.34–4.17 (m, 2H), 2.80–2.67 (m, 1H), 2.30–
2.13 (m, 2H), 2.07–1.94 (m, 1H), 1.68–1.53 (m, 2H), 1.45 (d, J = 7.6 Hz, 18H). 
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13C NMR (75 MHz, CD2Cl2) δ 180.5, 172.7, 172.6, 171.5, 171.4, 167.4, 167.0, 166.1, 165.7, 151.4, 
150.6, 149.09, 149.06, 138.9, 138.3, 135.4, 134.4, 131.7, 131.3, 131.2, 131.0, 126.3, 126.0, 124.3, 124.2, 
123.5, 123.1, 115.7, 112.2, 111.5, 111.1, 64.3, 49.7, 35.8, 35.6, 32.0, 31.9, 30.4, 27.3. 
IR (film): ν (cm1) 3146, 3056, 2958, 1591, 1524, 1445, 1373, 1270, 1191, 1122, 1077, 1033, 928, 814, 
773, 648, 550, 449. 
Λ-(S)-3: 
HRMS (ESI, m/z) calcd for C39H41RhN3O4 [M+H]+: 718.2147, found: 718.2133. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 394 (18), 353 (+26), 295 (23), 253 (+15), 233 (4), 216 (+35), 203 
(53). 
Δ-(R)-3: 
HRMS (ESI, m/z) calcd for C39H40RhN3O4Na [M+Na]+: 740.1966, found: 740.1930. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 394 (+9), 353 (12), 295 (+14), 253 (6), 233 (+4), 216 (15), 203 
(+30). 
 
4) Synthesis of non-racemic rhodium catalysts 
 
A suspension of the rhodium auxiliary complex -(S)-3 (71.7 mg, 0.10 mmol) or -(R)-3 (71.7 mg, 0.10 
mmol) and NH4PF6 (163.0 mg, 1.00 mmol) in acetonitrile (20.0 mL) was heated at 50 C for 12 h under 
nitrogen in the dark. The reaction mixture was concentrated to dryness and subjected to flash silica gel 
chromatography (100% CH2Cl2 to CH2Cl2/CH3CN = 15:1) to give the enantiopure catalyst -RhO (72.2 
mg, 0.09 mmol, 87%) or -RhO (74.7 mg, 0.09 mmol, 90%) as a pale yellow solid. The absolute 
configurations of the obtained - and -configured rhodium(III) complexes were verified by CD 
spectroscopy and confirmed by an X-ray crystal structure of -RhO. The enantiomeric purity was 
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verified by HPLC analysis with a chiral stationary phase. 
1H NMR (300 MHz, CD2Cl2) δ 7.88 (d, J = 1.6 Hz, 2H), 7.80–7.74 (m, 6H), 7.09 (td, J = 7.5, 0.9 Hz, 
2H), 6.94 (td, J = 7.6, 1.5 Hz, 2H), 6.40 (d, J = 7.8 Hz, 2H), 2.31 (s, 6H), 1.46 (s, 18H). 
13C NMR (75 MHz, CD2Cl2) δ 171.5, 160.2, 159.8, 151.2, 148.9, 138.2, 133.5, 132.4, 130.6, 126.3, 
125.3, 124.6, 122.0, 113.4, 112.0, 35.7, 31.9, 3.7. 
IR (film): ν (cm1) 2957, 1593, 1528, 1446, 1381, 1274, 1193, 1126, 1081, 1033, 931, 835, 730, 649, 
555, 449. 
-RhO:  
HRMS (ESI, m/z) calcd for C38H38RhN4O2 [MPF6]+: 685.2044, found: 685.2036. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 390 (33), 350 (+69), 295 (61), 242 (+36), 228 (+3), 218 (+16), 204 
(30). 
-RhO:  
HRMS (ESI, m/z) calcd for C38H38RhN4O2 [MPF6]+: 685.2044, found: 685.2026. 
CD (MeOH): λ, nm (Δε, M-1cm-1) 390 (+34), 350 (70), 295 (+61), 242 (36), 228 (14), 218 (24), 
204 (+34). 
 
5.2.2 Catalytic Reactions with Δ-IrO and Δ-RhO 
1) General procedure for asymmetric Michael additions. To a solution of catalyst -IrO10 (1 mol%) 
or -RhO (1 or 2 mol%) in distilled, anhydrous THF was added the acylimidazole 4a or 4b (0.20 mmol) 
in a Schlenk tube. After being stirred at room temperature for 20 min, the corresponding nucleophile 
was added at room temperature or 5 C. The reaction was stirred at the indicated temperature for the 
indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:2 to 2:1) to afford the products 5a-f. The dr values were determined by 1H NMR 
analysis of the crude products, and the ee values were determined by chiral HPLC chromatography using 
a Chiralpak IC or AD-H column.  
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(R)-3-(1H-Indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)butan-1-one (5a) 
 
Starting from 4a (30.2 mg, 0.2 mmol) and 1H-indole (58.6 mg, 0.5 mmol) according to the general 
procedure to give 5a as a white solid (catalyzed by -IrO: 51.9 mg, yield: 97%, ee: 96%; catalyzed by 
-RhO: 50.2 mg, yield: 94%, ee: 95%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak IC column (HPLC: IC, 254 nm, hexane/isopropanol = 85:15, flow rate 0.5 mL/min, 40 C, tr 
(major) = 22.4 min, tr (minor) = 25.9 min); []D20 = +13.8 (c 0.5, CH2Cl2) for 95% ee of 5a ([]D20 = 
14.5 (c 2.7, CH2Cl2) for 96% ee of product with S-configuration)10.  
1H NMR (300 MHz, CDCl3) δ 8.41 (br s, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.34–7.28 (m, 1H), 7.22–7.05 
(m, 3H), 7.01–6.95 (m, 2H), 3.93 (s, 3H), 3.91–3.78 (m, 1H), 3.66–3.34 (m, 2H), 1.40 (d, J = 6.9 Hz, 
3H). 
13C NMR (75 MHz, CDCl3) δ 192.4, 143.4, 136.5, 128.9, 127.0, 126.7, 121.9, 121.5, 120.3, 119.3, 119.1, 
111.2, 46.8, 36.2, 27.2, 21.8. 
All spectroscopic data were in agreement with the literature.10  
 
(R)-2-(4-(1-Methyl-1H-imidazol-2-yl)-4-oxobutan-2-yl)malononitrile (5b) 
 
Starting from 4a (30.2 mg, 0.2 mmol) and malononitrile (15.8 mg, 0.24 mmol) according to the general 
procedure to give 5b as a colorless oil (catalyzed by -IrO: 41.5 mg, yield: 96%, ee: 89%; catalyzed by 
-RhO: 41.5 mg, yield: 96%, ee: 92%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 
25 C, tr (major) = 22.8 min, tr (minor) = 24.1 min); []D20 = 33.2 (c 0.4, CH2Cl2) for 92% ee of 5b. 
1H NMR (300 MHz, CDCl3) δ 7.15 (s, 1H), 7.08 (s, 1H), 4.37 (d, J = 4.9 Hz, 1H), 3.99 (s, 3H), 3.47 (dd, 
J = 18.0, 5.3 Hz, 1H), 3.28 (dd, J = 18.0, 8.2 Hz, 1H), 2.89–2.71 (m, 1H), 1.36 (d, J= 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 189.6, 142.4, 129.8, 127.9, 112.5, 111.5, 41.6, 36.2, 31.9, 28.2, 17.3. 
All spectroscopic data were in agreement with the literature.11 
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(R)-2-(3-(1-Isopropyl-1H-imidazol-2-yl)-3-oxo-1-phenylpropyl)malononitrile (5c) 
 
Starting from 4b (45.8 mg, 0.2 mmol) and malononitrile (15.8 mg, 0.24 mmol) according to the general 
procedure to give 5c as a colorless oil (catalyzed by -IrO: 24.7 mg, yield: 40%, ee: 88%; catalyzed by 
-RhO: 55.8 mg, yield: 91%, ee: 95%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column (HPLC: AD-H, 254 nm, hexane/isopropanol = 70:30, flow rate 0.8 mL/min, 
25 C, tr (minor) = 13.0 min, tr (major) = 23.6 min); []D20 = 0.4 (c 0.8, CH2Cl2) for 95% ee of 5c. 
1H NMR (300 MHz, CDCl3) δ 7.46–7.35 (m, 5H), 7.30 (d, J = 0.9 Hz, 1H), 7.19 (d, J = 0.8 Hz, 1H), 
5.42 (dt, J = 13.4, 6.7 Hz, 1H), 4.53–4.45 (m, 1H), 4.03–3.88 (m, 2H), 3.87–3.72 (m, 1H), 1.41 (dd, J = 
8.6, 6.7 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ 188.7, 141.5, 136.5, 130.2, 129.2, 129.0, 128.2, 122.1, 112.0, 111.7, 49.5, 
41.7, 41.2, 29.3, 23.55, 23.52. 
IR (film): ν (cm1) 3034, 2983, 2909, 2254, 1670, 1497, 1465, 1454, 1395, 1371, 1254, 1199, 1162, 
1087, 971, 914, 772, 731, 700, 671, 646, 591, 548, 488, 407. 
HRMS (ESI, m/z) calcd for C18H18N4ONa [M+Na]+: 329.1373, found: 329.1369. 
 
(R)-2,2-Dimethyl-5-(4-(1-methyl-1H-imidazol-2-yl)-4-oxobutan-2-yl)-1,3-dioxane-4,6-dione (5d) 
 
Starting from 4a (30.2 mg, 0.2 mmol) and 2,2-dimethyl-1,3-dioxane-4,6-dione (86.5 mg, 0.6 mmol) 
according to the general procedure to give 5d as a white solid (catalyzed by -IrO: 58.3 mg, yield: 99%, 
ee: 68%; catalyzed by -RhO: 58.3 mg, yield: 99%, ee: 85%). Enantiomeric excess established by 
HPLC analysis using a Chiralpak AD-H column (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, 
flow rate 0.8 mL/min, 40 C, tr (major) = 24.9 min, tr (minor) = 26.6 min); []D20 = 3.3 (c 0.8, CH2Cl2) 
for 95% ee of 5d (catalyzed by -RhO (2 mol%) at room temperature). 
1H NMR (300 MHz, CDCl3) δ 7.13 (d, J = 0.9 Hz, 1H), 7.03 (s, 1H), 4.22–4.16 (m, 1H), 3.98 (s, 3H), 
3.56 (dd, J = 7.2, 5.0 Hz, 2H), 3.24–3.10 (m, 1H), 1.77 (d, J = 5.8 Hz, 6H), 1.21 (d, J = 7.0 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.3, 165.2, 164.7, 142.9, 129.2, 127.2, 104.7, 49.3, 41.9, 36.2, 28.9, 
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28.4, 26.9, 17.3. 
IR (film): ν (cm1) 3136, 2928, 2883, 1780, 1739, 1667, 1459, 1408, 1298, 1200, 1151, 1086, 1053, 991, 
958, 914, 871, 787, 698, 670, 634, 596, 544, 496, 426. 
HRMS (ESI, m/z) calcd for C14H19N2O5 [M+H]+: 295.1288, found: 295.1282. 
 
(R)-tert-Butyl 1-((R)-4-(1-methyl-1H-imidazol-2-yl)-4-oxobutan-2-yl)-2-
oxocyclopentanecarboxylate (5e) 
 
Starting from 4a (30.2 mg, 0.2 mmol) and tert-butyl 2-oxocyclopentanecarboxylate (73.7 mg, 0.4 mmol) 
according to the general procedure to give 5e (major product) as a colorless oil (catalyzed by -IrO: 
27.4 mg, yield: 41%, ee: 97%, dr: 3:1; catalyzed by -RhO: 55.5 mg, yield: 83%, ee: 99%, dr: 4:1). 
The dr was determined by 1H NMR and the enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column (HPLC: AD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 0.5 mL/min, 
40 C, tr (minor) = 26.4 min, tr (major) = 29.5 min); []D20 = +13.1 (c 1.4, CH2Cl2) for 99% ee of 5e. 
1H NMR (300 MHz, CDCl3) δ 7.08 (d, J = 0.8 Hz, 1H), 6.99 (s, 1H), 3.96 (s, 3H), 3.22 (dd, J = 16.6, 
10.3 Hz, 1H), 3.08–2.97 (m, 1H), 2.74 (dd, J = 16.6, 2.6 Hz, 1H), 2.50–2.30 (m, 2H), 2.21–2.06 (m, 1H), 
2.01–1.85 (m, 3H), 1.42 (s, 9H), 0.94 (d, J = 6.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 214.5, 191.2, 169.2, 143.2, 128.9, 127.0, 82.0, 65.8, 41.7, 38.6, 36.2, 32.4, 
29.4, 27.9, 19.4, 16.4. 
IR (film): ν (cm1) 3112, 2970, 2868, 1743, 1715, 1673, 1462, 1405, 1368, 1283, 1246, 1151, 1125, 
1005, 979, 914, 834, 775, 695, 589, 549, 434. 
HRMS (ESI, m/z) calcd for C18H27N2O4 [M+H]+: 335.1965, found: 335.1964. 
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(R)-tert-Butyl 2-((R)-4-(1-methyl-1H-imidazol-2-yl)-4-oxobutan-2-yl)-1-oxo-2,3-dihydro-1H-
indene-2-carboxylate (5f) 
 
Starting from 4a (30.2 mg, 0.2 mmol) and tert-butyl 1-oxo-2,3-dihydro-1H-indene-2-carboxylate (92.9 
mg, 0.4 mmol) according to the general procedure to give 5f (major product) as a colorless oil (catalyzed 
by -IrO: 68.1 mg, yield: 89%, ee: 97%, dr: 10:1; catalyzed by -RhO: 70.4 mg, yield: 92%, ee: 96%, 
dr: 14:1). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 97:3, flow rate 0.5 mL/min, 25 C, tr (major) = 84.2 min, tr (minor) 
= 168.0 min); []D20 = 96.9 (c 0.7, CH2Cl2) for 97% ee of 5f. The dr value was determined by 1H 
NMR as shown below (Figure 82).  
 
Figure 82 1H NMR of the crude product 5f and its diastereomer 5f. Calculated dr = 1:10. 
1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 7.6 Hz, 1H), 7.65–7.56 (m, 1H), 7.50 (d, J = 7.7 Hz, 1H), 
7.45–7.31 (m, 1H), 7.13 (d, J = 0.9 Hz, 1H), 7.03 (s, 1H), 4.01 (s, 3H), 3.69 (d, J = 17.5 Hz, 1H), 3.51–
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3.39 (m, 1H), 3.32–3.18 (m, 2H), 3.09 (dd, J = 16.3, 2.8 Hz, 1H), 1.36 (s, 9H), 0.76 (d, J = 6.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 202.4, 191.2, 169.3, 154.1, 143.3, 136.0, 135.2, 128.9, 127.6, 127.0, 126.3, 
124.6, 82.1, 65.9, 42.4, 36.3, 33.1, 33.0, 27.8, 15.2. 
IR (film): ν (cm1) 2969, 2930, 1705, 1673, 1604, 1464, 1406, 1369, 1332, 1252, 1213, 1146, 1092, 986, 
913, 844, 769, 743, 694, 651, 590, 517, 466. 
HRMS (ESI, m/z) calcd for C22H27N2O4 [M+H]+: 383.1965, found: 383.1962. 
 
2) Procedure for asymmetric cascade reaction.  
 
To a solution of catalyst Δ-RhO (3.2 mg, 2 mol%) in distilled, anhydrous THF (0.2 mL) was added the 
acylimidazole 4a (30.2 mg, 0.20 mmol) in a Schlenk tube. After being stirred at room temperature for 
20 min, malononitrile (15.9 mg, 0.24 mmol) and (E)-dibenzyl diazene-1,2-dicarboxylate (119.3 mg, 
0.40 mmol) were added. The reaction was stirred at room temperature for 16 h under nitrogen 
atmosphere. Afterwards, the mixture was concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica gel (EtOAc/hexane = 1:4 to 1:2) to afford the diastereomeric mixture 
of 6 as a white solid (84.3 mg, yield: 82%, ee of the major diastereoisomer: 92%, dr: 4:1 (after purified 
by flash chromatography)). The ee values were determined by HPLC analysis using a Chiralpak AD-H 
column (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 0.5 mL/min, 25 C. Major 
diastereoisomer tr (minor) = 80.5 min, tr (major) = 117.4 min); []D20 = 30.5 (c 1.0, CH2Cl2, 92% ee). 
 
Dibenzyl 1-((2S,3S)-4,4-dicyano-3-methyl-1-(1-methyl-1H-imidazol-2-yl)-1-oxobutan-2-
yl)hydrazine-1,2-dicarboxylate (6) 
 
1H NMR (300 MHz, CDCl3) δ 7.25–6.72 (m, 12H), 5.22–4.60 (m, 6H), 3.77 (s, 3H), 3.10–2.95 (m, 1H), 
1.29 (s, 3H). (major diastereoisomer) 
13C NMR (75 MHz, CDCl3) δ 155.7, 141.3, 135.4, 135.3, 128.8, 128.6, 128.5, 128.4, 128.2, 128.1, 128.0, 
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127.9, 113.3, 111.7, 69.1, 68.3, 53.5, 36.2, 35.4, 26.9. (major diastereoisomer) 
IR (film): ν (cm1) 3260, 2958, 2925, 2254, 1726, 1677, 1454, 1396, 1241, 1207, 1156, 1079, 1040, 986, 
959, 918, 852, 795, 740, 697, 641, 567, 506, 475, 403. 
HRMS (ESI, m/z) calcd for C27H26N6O5Na [M+Na]+: 537.1856, found: 537.1848. 
 
5.2.3 Investigation of the Stability of Rhodium Catalyst -/-RhO 
1) Catalyst stability investigated by 1H NMR 
The rhodium complex -RhO (5.0 mg) was dissolved in CD2Cl2 and kept in the NMR tube at room 
temperature under reduced light. 1H NMR spectra were recorded after 2, 4, 6 and 8 days (Figure 83). 
 
Figure 83 1H NMR of -RhO recorded in CD2Cl2 over 8 days. 
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2) Catalyst stability investigated by chiral HPLC 
Enantiopure pure rhodium complex -RhO (2.0 mg) was dissolved in CH2Cl2 (1.0 mL, HPLC grade) 
and kept in a brown glass vial at room temperature. The HPLC spectra were collected after 2-8 days. 
HPLC conditions: Daicel Chiralpak IB (250 × 4.6 mm) HPLC column, the column temperature was 
25 °C and UV-absorption was measured at 254 nm. Solvent A = 0.1% TFA, solvent B = MeCN with a 
linear gradient of 30% to 41% B in 60 min at a flow rate = 0.6 mL/min. 
 
Figure 84 HPLC traces of the freshly prepared Λ-RhO in CH2Cl2 (>99% ee) and after 2-8 days in 
CH2Cl2 (>99% ee). 
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5.2.4 Investigation of the Proposed Catalyst-Coordinated Substrate Intermediate 
To a solution of -RhO (10.0 mg, 0.012 mmol) in CD2Cl2 (0.70 mL) at room temperature was added 
substrate 4a (9.5 mg, 0.063 mmol). The mixture was stirred at room temperature for 20 min and then 
analyzed by 1H NMR spectroscopy. The 1H NMR analysis is consistent with a fast bidentate coordination 
of 4a to -RhO under release of the coordinated acetonitrile ligands.  
 
 
Figure 85 1H NMR spectra of substrate 4a, catalyst Δ-RhO, and a mixture of 4a and Δ-RhO. 
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5.2.5 The Acetonitrile Exchange Rates: -RhO vs. -IrO 
To a solution of -RhO (5.0 mg, 0.006 mmol) or -IrO (5.5 mg, 0.006 mmol) in CD2Cl2 (3 mL) at 
room temperature was added bipyridine (1.64 mg, 0.0105 mmol). The 1H NMR spectra were collected 
after the indicated time. The conversion was calculated by area integration ratio of two different tert-
butyl groups, which reveal that the acetonitrile exchange rates are faster in -RhO compared to -IrO.  
 
 
Figure 86 1H NMR spectra of -RhO and the mixture of -RhO and bipyridine in CD2Cl2.  
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Figure 87 1H NMR spectra of the mixture of -IrO and bipyridine in CD2Cl2.  
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5.2.6 Single Crystal X-Ray Diffraction 
Crystals of Δ-(R)-3 and -RhO were obtained by slow diffusion from a solution of the compounds in 
CH2Cl2 layered with Et2O at room temperature for several weeks. Crystals of 5d, racemic 5f and 6 were 
obtained by slow diffusion from a solution of the compounds in CH2Cl2 layered with hexane at 5 °C for 
several days. Single crystals suitable for X-ray diffraction of the substrate coordinated rhodium catalyst 
(here denoted as RhO-I) were obtained by reacting 4b (0.06 mmol) with /-RhO (0.06 mmol) 
overnight at room temperature in CH2Cl2 (2.0 mL). After the slow addition of hexane (5.0 mL), crystals 
were collected after several days (70% yield). 
Crystal data and details of the structure determination are presented in Appendices 6.7. In the packing 
of RhO-I there are holes present that contain diffuse electron density that may belong to heavily 
disordered solvent molecules. This was taken into account using the “squeeze” procedure in the 
PLATON program system. The determination of the absolute configuration of the light atom structure 
5d by means of refining the “Flack parameter” was not possible. The absolute configurations of 
compounds -(R)-3 and -RhO have been determined. 
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5.3 Merger of Visible Light Induced Oxidation and Enantioselective 
Alkylation with Chiral Iridium Catalyst 
5.3.1 Synthesis of Substrates 
1) Synthesis of 2-acyl imidazoles 
2-Acyl imidazoles 7a, 7a and Weinreb amides were synthesized following our recently published 
procedures.12 2-Acyl imidazoles 7a-h were synthesized following the route shown below. 
 
General procedure for the preparation of the 2-acyl imidazoles. All 2-acyl imidazoles were 
synthesized according to reported procedures with some modifications.13 To a solution of N-
phenylimidazole (1.1 eq.) in THF (0.4 M) at 78 C was added n-BuLi (1.1 eq.) dropwise. The reaction 
was stirred at 78 C for 30 min, then stirred at room temperature for 30 min. The corresponding 
Weinreb amides (1.0 eq.) was added to the flask after the reaction was cooled back down to 78 C. The 
reaction was allowed to slowly warm to room temperature and stirred overnight. The reaction was 
quenched with AcOH (6.0 eq.) and extracted with EtOAc. The organic layer was washed with aqueous 
saturated NaHCO3 and brine. The combined organic layers were dried over anhydrous Na2SO4, and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:3) to provide the 2-acyl imidazoles 7a-h. 
 
2-Phenyl-1-(1-phenyl-1H-imidazol-2-yl)ethanone (7a) 
 
Following the general procedure, N-methoxy-N-methyl-2-phenylacetamide (1.797 g, 10.0 mmol) was 
converted to 2-acyl imidazole 7a (1.709 g, 6.5 mmol, yield: 65%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.46–7.37 (m, 3H), 7.34–7.20 (m, 8H), 7.19 (d, J = 1.0 Hz, 1H), 4.45 (s, 
2H). 
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All spectroscopic data are in agreement with the literature.13 
 
1-(1-Phenyl-1H-imidazol-2-yl)-2-meta-tolylethanone (7b) 
 
Following the general procedure, N-methoxy-N-methyl-2-(m-tolyl)acetamide (1.544 g, 8.0 mmol) was 
converted to 2-acyl imidazole 7b (1.186 g, 4.3 mmol, yield: 54%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.45–7.38 (m, 3H), 7.33 (d, J = 1.0 Hz, 1H), 7.25–7.20 (m, 2H), 7.20–
7.09 (m, 4H), 7.07–7.01 (m, 1H), 4.42 (s, 2H), 2.32 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 188.5, 142.8, 138.3, 138.0, 134.2, 130.7, 129.6, 128.9, 128.6, 128.3, 127.5, 
127.3, 126.9, 125.8, 45.5, 21.3. 
IR (film): ν (cm1) 3125, 3109, 1681, 1597, 1500, 1448, 1393, 1245, 1209, 1176, 1160, 1094, 963, 913, 
894, 880, 842, 798, 767, 652, 543. 
HRMS (ESI, m/z) calcd for C18H17N2O [M+H]+: 277.1333, found: 277.1335. 
 
1-(1-Phenyl-1H-imidazol-2-yl)-2-ortho-tolylethanone (7c) 
 
Following the general procedure, N-methoxy-N-methyl-2-(o-tolyl)acetamide (1.544 g, 8.0 mmol) was 
converted to 2-acyl imidazole 7c (1.450 g, 5.3 mmol, yield: 66%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.44–7.38 (m, 3H), 7.33 (d, J = 1.0 Hz, 1H), 7.29–7.22 (m, 2H), 7.22–
7.19 (m, 2H), 7.17–7.10 (m, 3H), 4.53 (s, 2H), 2.29 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 188.4, 142.9, 138.2, 137.1, 133.1, 130.8, 130.2, 129.5, 128.9, 128.7, 127.3, 
127.1, 125.87, 125.85, 43.5, 19.8. 
IR (film): ν (cm1) 3104, 2936, 2911, 1691, 1594, 1490, 1407, 1393, 1340, 1326, 1208, 1189, 1142, 
1076, 964, 942, 868, 806, 773, 738, 706, 693, 607, 556. 
HRMS (ESI, m/z) calcd for C18H17N2O [M+H]+: 277.1335, found: 277.1333. 
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2-(4-Methoxyphenyl)-1-(1-phenyl-1H-imidazol-2-yl)ethanone (7d) 
 
Following the general procedure, N-methoxy-2-(4-methoxyphenyl)-N-methylacetamide (1.674 g, 8.0 
mmol) was converted to 2-acyl imidazole 7d (1.682 g, 5.8 mmol, yield: 72%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.48–7.41 (m, 3H), 7.35 (d, J = 1.0 Hz, 1H), 7.31–7.23 (m, 4H), 7.22 (d, 
J = 1.0 Hz, 1H), 6.92–6.87 (m, 1H), 6.87–6.84 (m, 1H), 4.43 (s, 2H), 3.80 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 188.7, 158.5, 142.7, 138.3, 130.9, 129.6, 128.9, 128.6, 127.3, 126.4, 125.8, 
113.9, 55.2, 44.7. 
IR (film): ν (cm1) 3129, 2949, 2828, 1668, 1602, 1505, 1450, 1393, 1345, 1302, 1244, 1170, 1141, 
1032, 967, 910, 853, 823, 791, 763, 689, 610, 584, 520. 
HRMS (ESI, m/z) calcd for C18H17N2O2 [M+H]+: 293.1285, found: 293.1283. 
 
2-(4-Chlorophenyl)-1-(1-phenyl-1H-imidazol-2-yl)ethanone (7e) 
 
Following the general procedure, 2-(4-chlorophenyl)-N-methoxy-N-methylacetamide (1.764 g, 8.3 
mmol) was converted to 2-acyl imidazole 7e (1.536 g, 5.2 mmol, yield: 63%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.47–7.40 (m, 3H), 7.33 (d, J = 1.0 Hz, 1H), 7.28–7.18 (m, 7H), 4.43 (s, 
2H). 
13C NMR (75 MHz, CDCl3) δ 187.9, 142.5, 138.2, 132.8, 132.7, 131.3, 129.8, 129.0, 128.8, 128.5, 127.6, 
125.8, 44.8. 
IR (film): ν (cm1) 3012, 1682, 1594, 1492, 1446, 1397, 1307, 1148, 1092, 1041, 965, 862, 805, 764, 
689, 659, 578, 547.  
HRMS (ESI, m/z) calcd for C17H14ClN2O [M+H]+: 297.0789, found: 297.0788. 
 
 
 
 
Chapter 5: Experimental Part 
109 
 
1-(1-Phenyl-1H-imidazol-2-yl)-2-(thiophen-3-yl)ethanone (7f) 
 
Following the general procedure, N-methoxy-N-methyl-2-(thiophen-3-yl)acetamide (1.482 g, 8.0 mmol) 
was converted to 2-acyl imidazole 7f (1.256 g, 4.7 mmol, yield: 59%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.46–7.40 (m, 3H), 7.32 (d, J = 1.0 Hz, 1H), 7.28–7.22 (m, 3H), 7.21–
7.16 (m, 2H), 7.06 (dd, J = 4.9, 1.3 Hz, 1H), 4.50 (s, 2H). 
13C NMR (75 MHz, CDCl3) δ 187.8, 142.6, 138.2, 133.9, 129.7, 129.0, 128.9, 128.7, 127.4, 125.8, 125.3, 
123.2, 40.1. 
IR (film): ν (cm1) 3122, 3094, 1698, 1593, 1490, 1407, 1387, 1317, 1295, 1149, 1038, 969, 880, 823, 
805, 763, 696, 669, 610, 589. 
HRMS (ESI, m/z) calcd for C15H13N2OS [M+H]+: 269.0743, found: 269.0743. 
 
1-(1-Phenyl-1H-imidazol-2-yl)propan-1-one (7g) 
 
Following the general procedure, N-methoxy-N-methylpropionamide (874 mg, 7.5 mmol) was 
converted to 2-acyl imidazole 7g (1.071 g, 5.3 mmol, yield: 71%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.48–7.41 (m, 3H), 7.31–7.23 (m, 3H), 7.16 (d, J = 1.0 Hz, 1H), 3.17 (q, 
J = 7.3 Hz, 2H), 1.13 (t, J = 7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 192.0, 142.9, 138.5, 129.3, 128.9, 128.7, 126.8, 125.9, 32.4, 7.8. 
IR (film): ν (cm1) 3123, 2972, 1686, 1593, 1491, 1450, 1407, 1346, 1215, 1149, 1034, 976, 936, 879, 
801, 769, 693, 608, 565. 
HRMS (ESI, m/z) calcd for C12H13N2O [M+H]+: 201.1022, found: 201.1023. 
 
1-(1-Phenyl-1H-imidazol-2-yl)butan-1-one (7h) 
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Following the general procedure, N-methoxy-N-methylbutyramide (1.495 g, 11.4 mmol) was converted 
to 2-acyl imidazole 7h (1.305 g, 6.1 mmol, yield: 54%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.51–7.43 (m, 3H), 7.32–7.25 (m, 3H), 7.18 (d, J = 1.0 Hz, 1H), 3.14 (t, 
J = 7.2 Hz, 2H), 1.82–1.60 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 191.5, 143.1, 138.5, 129.3, 128.9, 128.7, 126.9, 125.9, 41.1, 17.4, 13.7. 
IR (film): ν (cm1) 3095, 2966, 2930, 2877, 1683, 1594, 1449, 1339, 1328, 1265, 1112, 1072, 961, 914, 
891, 814, 796, 691, 542. 
HRMS (ESI, m/z) calcd for C13H15N2O [M+H]+: 215.1179, found: 215.1180. 
 
2) Synthesis of α-silylamines 
All α-silylamines were synthesized according to reported procedures with some modifications.14 To a 
solution of amines (1.0 eq.) in THF (0.4 M) under nitrogen atmosphere at 0 C was added n-BuLi (1.0 
eq.) dropwise. The reaction was stirred at 0 C for 30 min, then stirred at room temperature for further 
1 h. (Iodomethyl)trimethylsilane (1.5 eq.) was added slowly to the flask after the reaction was cooled 
back down to 0 C, and the resulting solution was stirred at room temperature (9a-b) or 60 C (9c-e) 
overnight. Afterwards, the reaction was quenched with water and extracted with n-hexane. The 
combined organic layers were dried (Na2SO4) and concentrated under reduced pressure.  The residue 
was purified by flash chromatography on silica gel (100% n-hexane) to produce 9a-e. The new 
synthesized α-silylamines were stored at 20 C under nitrogen atmosphere. 
 
N-Phenyl-N-((trimethylsilyl)methyl)aniline (9a) 
 
Following the general procedure, diphenylamine (1.690 g, 10.0 mmol) was converted to α-silylamine 
9a (1.788 g, 7.0 mmol, yield: 70%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.33–7.23 (m, 4H), 7.06–7.00 (m, 4H), 6.98–6.92 (m, 2H), 3.34 (s, 2H), 
–0.01 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ 149.6, 129.1, 121.1, 120.9, 43.7, –1.3. 
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All spectroscopic data are in agreement with the literature.14 
 
4-Methyl-N-p-tolyl-N-((trimethylsilyl)methyl)aniline (9b) 
 
Following the general procedure, di-p-tolylamine (1.479g, 7.5 mmol) was converted to α-silylamine 9b 
(1.381 g, 4.9 mmol, yield: 65%) as a pale yellow oil. 
1H NMR (300 MHz, CDCl3) δ 7.04 (d, J = 8.3 Hz, 4H), 6.86 (d, J = 8.4 Hz, 4H), 3.23 (s, 2H), 2.29 (s, 
6H), –0.05 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ 147.4, 130.6, 129.6, 121.1, 44.2, 20.6, –1.3. 
All spectroscopic data were in agreement with the literature.14 
 
4-Methoxy-N-phenyl-N-((trimethylsilyl)methyl)aniline (9c) 
 
Following the general procedure, 4-methoxy-N-phenylaniline (1.374 g, 6.9 mmol) was converted to α-
silylamine 9c (0.925 g, 3.2 mmol, yield: 47%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.26–7.05 (m, 4H), 6.98–6.68 (m, 5H), 3.87 (s, 3H), 3.27 (s, 2H), 0.00 
(s, 9H). 
13C NMR (75 MHz, CDCl3) δ 156.5, 150.9, 142.1, 128.7, 127.6, 117.5, 115.7, 114.7, 55.5, 43.9, –1.38. 
IR (film): ν (cm1) 3036, 2950, 2833, 1595, 1574, 1494, 1463, 1341, 1296, 1237, 1179, 1130, 1088, 868, 
832, 790, 692, 555, 516. 
HRMS (ESI, m/z) calcd for C17H24NOSi [M+H]+: 286.1622, found: 286.1624. 
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4-Chloro-N-phenyl-N-((trimethylsilyl)methyl)aniline (9d) 
 
Following the general procedure, 4-chloro-N-phenylaniline (0.713 g, 3.5 mmol) was converted to α-
silylamine 9d (0.639 g, 2.2 mmol, yield: 63%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.36–7.27 (m, 2H), 7.23–7.17 (m, 2H), 7.09–6.98 (m, 3H), 6.93–6.85 (m, 
2H), 3.31 (s, 2H), 0.00 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ 149.1, 148.3, 129.3, 128.9, 124.9, 122.4, 122.2, 120.8, 43.9, 1.3. 
IR (film): ν (cm1) 2952, 1585, 1487, 1429, 1354, 1248, 1188, 1095, 901, 839, 815, 746, 697, 627, 510. 
HRMS (ESI, m/z) calcd for C16H21ClN2Si [M+H]+: 290.1126, found: 290.1129. 
 
N-Phenyl-N-((trimethylsilyl)methyl)naphthalen-2-amine (9e) 
 
Following the general procedure, N-phenylnaphthalen-2-amine (2.192 g, 10.0 mmol) was converted to 
α-silylamine 9e (1.832 g, 6.0 mmol, yield: 60%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.75–7.61 (m, 3H), 7.44–7.36 (m, 1H), 7.33–7.24 (m, 4H), 7.17 (dd, J = 
8.9, 2.4 Hz, 1H), 7.10–7.05 (m, 2H), 7.03–6.95 (m, 1H), 3.44 (s, 2H), 0.00 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ 149.6, 147.0, 134.7, 129.2, 128.9, 128.4, 127.5, 126.6, 126.2, 123.4, 122.1, 
121.8, 114.9, 44.2, 1.2. 
All spectroscopic data are in agreement with the literature.14 
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5.3.2 Iridium-Catalyzed Photoredox Reactions 
1) Reaction of 2-acyl imidazoles with N,N-diaryl-N-(trimethylsilyl)methylamines 
 
General catalysis procedure. To a solution of catalyst Λ- or Δ-IrO (2 mol% or 4 mol%) in distilled, 
anhydrous CH2Cl2 (0.50 mL, 0.4 M) in a 10 mL test tube, was added the 2-acyl imidazole (0.20 mmol). 
After being stirred at room temperature for 20 min, the α-silylamine (0.60 mmol) was added. The tube 
was positioned approximately 2 cm away from a 12 W white light energy saving lamp. The reaction 
was stirred at room temperature for the indicated time (monitored by TLC) under an atmosphere of air 
(air balloon). Afterwards, the solvent was concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica gel (EtOAc/n-hexane = 1:20) to afford the non-racemic product. The 
enantiomeric excess was determined by chiral HPLC analysis. The absolute configuration of the product 
(R)-10e was determined by X-ray crystallography and used to assign the configuration of all other 
compounds. Racemic samples were obtained by carrying out the analogous reactions with the racemic 
catalyst rac-IrO. 
 
(S)-3-(Diphenylamino)-1-(1-methyl-1H-imidazol-2-yl)-2-phenylpropan-1-one (10a'') 
 
Using Λ-IrO (2 mol%) as catalyst, starting from 2-acyl imidazole 7a'' (40.0 mg, 0.20 mmol) and α-
silylamine 9a (153.2 mg, 0.60 mmol) according to the general procedure to give 10a'' as a pale yellow 
oil (25.9 mg, 0.068 mmol, yield: 34%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 91% (HPLC: AD-H, 254 nm, hexane/isopropanol = 85:15, flow rate 0.5 
mL/min, 25 C, tr (minor) = 13.2 min, tr (major) = 13.9 min).  
1H NMR (300 MHz, CD2Cl2) δ 7.45–7.38 (m, 2H), 7.34–7.25 (m, 3H), 7.24–7.20 (m, 3H), 7.19–7.16 
(m, 1H), 7.05 (d, J = 0.9 Hz, 1H), 7.00–6.97 (m, 1H), 6.97–6.90 (m, 2H), 6.90–6.84 (m, 4H), 5.66 (dd, 
J = 8.8, 4.9 Hz, 1H), 4.73–4.62 (dd, J = 14.5, 8.7 Hz, 1H), 4.02 (dd, J = 14.5, 4.9 Hz, 1H), 3.80 (s, 3H). 
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13C NMR (75 MHz, CD2Cl2) δ 191.4, 148.5, 143.5, 138.3, 129.6, 129.5, 129.1, 129.0, 127.9, 127.6, 
121.9, 121.8, 55.8, 51.8, 36.3. 
IR (film): ν (cm1) 3059, 2923, 2853, 1668, 1587, 1491, 1453, 1364, 1288, 1207, 1185, 1154, 1029, 990, 
950, 909, 862, 772, 745, 693, 630, 506.  
HRMS (ESI, m/z) calcd for C25H24N3O [M+H]+: 382.1914, found: 382.1916. 
 
(S)-3-(Diphenylamino)-1-(1-isopropyl-1H-imidazol-2-yl)-2-phenylpropan-1-one (10a') 
 
Using Λ-IrO (2 mol%) as catalyst, starting from 2-acyl imidazole 7a' (45.7 mg, 0.20 mmol) and α-
silylamine 9a (153.2 mg, 0.60 mmol) according to the general procedure to give 10a' as a pale yellow 
oil (39.3 mg, 0.096 mmol, yield: 48%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 90% (HPLC: AD-H, 254 nm, hexane/isopropanol = 85:15, flow rate 0.5 
mL/min, 25 C, tr (major) = 10.0 min, tr (minor) = 10.8 min).  
1H NMR (300 MHz, CD2Cl2) δ 7.45–7.38 (m, 3H), 7.33–7.26 (m, 3H), 7.24–7.17 (m, 5H), 7.09 (d, J = 
0.8 Hz, 1H), 6.97–6.86 (m, 5H), 5.72 (dd, J = 8.8, 4.9 Hz, 1H), 5.36–5.26 (m, 1H), 4.68 (dd, J = 14.5, 
8.8 Hz, 1H), 4.00 (dd, J = 14.5, 4.9 Hz, 1H), 1.34 (d, J = 6.7 Hz, 3H), 1.30 (d, J = 6.7 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 191.4, 161.9, 148.5, 138.5, 130.0, 129.5, 129.1, 129.0, 127.5, 127.3, 
127.2, 126.7, 125.5, 122.1, 121.9, 121.8, 55.9, 52.3, 49.7, 23.6, 23.5. 
IR (film): ν (cm1) 3060, 3030, 2979, 2931, 2870, 1687, 1670, 1589, 1492, 1392, 1298, 1254, 1194, 
1029, 990, 947, 910, 862, 846, 745, 720, 695, 647, 577, 543. 
HRMS (ESI, m/z) calcd for C27H27N3ONa [M+Na]+: 432.2046, found: 432.2052. 
 
(R)-3-(Diphenylamino)-2-phenyl-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (10a) 
 
Using -IrO (2 mol%) as catalyst, starting from 2-acyl imidazole 7a (52.4 mg, 0.20 mmol) and α-
silylamine 9a (153.2 mg, 0.60 mmol) according to the general procedure to give 10a as a pale yellow 
oil (79.7 mg, 0.184 mmol, yield: 92%). Enantiomeric excess established by HPLC analysis using a 
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Chiralpak AD-H column, ee = 97% (HPLC: AD-H, 254 nm, hexane/isopropanol = 97:3, flow rate 0.5 
mL/min, 25 C, tr (major) = 20.8 min, tr (minor) = 24.4 min). []D20 = +76.4 (c 0.6, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.47–7.36 (m, 5H), 7.34–7.27 (m, 3H), 7.26–7.19 (m, 5H), 7.14 (d, J = 
0.9 Hz, 1H), 7.10–7.03 (m, 2H), 7.00–6.93 (m, 2H), 6.93–6.86 (m, 4H), 5.68 (dd, J = 8.7, 5.0 Hz, 1H), 
4.62 (dd, J = 14.6, 8.7 Hz, 1H), 3.97 (dd, J = 14.6, 5.0 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 189.7, 161.6, 147.9, 142.7, 138.2, 137.4, 129.8, 129.6, 129.1, 128.7, 128.6, 
128.5, 127.2, 127.0, 126.8, 126.0, 125.7, 125.0, 121.5, 121.4, 55.3, 51.7. 
IR (film): ν (cm1) 3059, 2924, 2854, 1681, 1588, 1490, 1452, 1398, 1339, 1304, 1266, 1247, 1150, 
1095, 990, 970, 908, 862, 744, 665, 621. 
HRMS (ESI, m/z) calcd for C30H25N3ONa [M+Na]+: 466.1890, found: 466.1893. 
 
(R)-3-(Diphenylamino)-1-(1-phenyl-1H-imidazol-2-yl)-2-m-tolylpropan-1-one (10b) 
 
Using -IrO (2 mol%) as catalyst, starting from 2-acyl imidazole 7b (55.3 mg, 0.20 mmol) and α-
silylamine 9a (153.2 mg, 0.60 mmol) according to the general procedure to give 10b as a pale yellow 
oil (75.0 mg, 0.164 mmol, yield: 82%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak OD-H column, ee = 96% (HPLC: OD-H, 254 nm, hexane/isopropanol = 99:1, flow rate 0.5 
mL/min, 25 C, tr (major) = 23.5 min, tr (minor) = 25.9 min). []D20 = +82.7 (c 0.6, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.47–7.39 (m, 4H), 7.34–7.30 (m, 1H), 7.29–7.23 (m, 3H), 7.22–7.18 
(m, 5H), 7.14 (d, J = 1.0 Hz, 1H), 7.10–7.05 (m, 2H), 7.01–6.94 (m, 2H), 6.94–6.90 (m, 3H), 5.66 (dd, 
J = 8.9, 4.8 Hz, 1H), 4.62 (dd, J = 14.5, 8.9 Hz, 1H), 3.97 (dd, J = 14.5, 4.9 Hz, 1H), 2.32 (s, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 190.0, 161.9, 148.5, 143.4, 138.9, 137.8, 130.1, 130.0, 129.8, 129.5, 
129.1, 128.9, 128.8, 128.4, 127.9, 127.3, 127.2, 126.7, 126.2, 125.5, 121.9, 121.8, 55.7, 52.0, 21.5. 
IR (film): ν (cm1) 3035, 2920, 1682, 1590, 1491, 1448, 1399, 1305, 1261, 1147, 1067, 1031, 943, 905, 
865, 750, 693, 578, 547. 
HRMS (ESI, m/z) calcd for C31H27N3ONa [M+Na]+: 480.2046, found: 480.2049. 
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(R)-3-(Diphenylamino)-1-(1-phenyl-1H-imidazol-2-yl)-2-o-tolylpropan-1-one (10c) 
 
Using -IrO (2 mol%) as catalyst, starting from 2-acyl imidazole 7c (55.3 mg, 0.20 mmol) and α-
silylamine 9a (153.2 mg, 0.60 mmol) according to the general procedure to give 10c as a pale yellow 
oil (70.5 mg, 0.154 mmol, yield: 77%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 96% (HPLC: AD-H, 254 nm, hexane/isopropanol = 98:2, flow rate 0.5 
mL/min, 25 C, tr (minor) = 16.7 min, tr (major) = 17.3 min). []D20 = +144.9 (c 0.8, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.45–7.36 (m, 3H), 7.33–7.28 (m, 1H), 7.25–7.15 (m, 6H), 7.14–7.08 (m, 
2H), 7.08–7.03 (m, 3H), 6.98–6.93 (m, 2H), 6.92–6.86 (m, 4H), 5.94 (dd, J = 7.9, 5.6 Hz, 1H), 4.66 (dd, 
J = 14.6, 7.9 Hz, 1H), 3.93 (dd, J = 14.6, 5.6 Hz, 1H), 2.52 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 190.4, 148.1, 143.2, 138.3, 137.8, 135.9, 130.7, 129.8, 129.1, 128.8, 128.5, 
127.6, 127.13, 127.10, 126.0, 125.7, 121.5, 121.4, 55.6, 47.5, 20.0. 
IR (film): ν (cm1) 3059, 2924, 1679, 1587, 1490, 1399, 1308, 1271, 1218, 1149, 1072, 991, 908, 869, 
731, 658, 648. 
HRMS (ESI, m/z) calcd for C31H27N3ONa [M+Na]+: 480.2046, found: 480.2052. 
 
(R)-3-(Diphenylamino)-2-(4-methoxyphenyl)-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (10d) 
 
Using -IrO (4 mol%) as catalyst, starting from 2-acyl imidazole 7d (58.5 mg, 0.20 mmol) and α-
silylamine 9a (153.2 mg, 0.60 mmol) according to the general procedure to give 10d as a pale yellow 
oil (57.8 mg, 0.122 mmol, yield: 61%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 90% (HPLC: AD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 0.5 
mL/min, 25 C, tr (major) = 24.4 min, tr (minor) = 28.7 min). []D20 = +88.2 (c 0.6, CH2Cl2). 
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1H NMR (300 MHz, CD2Cl2) δ 7.45–7.37 (m, 3H), 7.31–7.23 (m, 4H), 7.23–7.18 (m, 4H), 7.13 (d, J = 
1.0 Hz, 1H), 7.08–7.03 (m, 2H), 6.99–6.93 (m, 2H), 6.92–6.87 (m, 3H), 6.86–6.82 (m, 2H), 5.60 (dd, J 
= 8.7, 5.1 Hz, 1H), 4.56 (dd, J = 14.5, 8.7 Hz, 1H), 3.93 (dd, J = 14.5, 5.1 Hz, 1H), 3.76 (s, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 190.2, 159.4, 148.5, 143.3, 138.8, 130.2, 130.1, 130.0, 129.8, 129.6, 
129.5, 129.4, 129.1, 128.9, 127.8, 126.2, 122.0, 121.9, 121.8, 114.4, 55.62, 55.60, 51.1. 
IR (film): ν (cm1) 3062, 2931, 2835, 1679, 1587, 1443, 1398, 1244, 1094, 973, 908, 864, 829, 747, 728, 
689, 531. 
HRMS (ESI, m/z) calcd for C31H27N3O2Na [M+Na]+: 496.1995, found: 496.2000. 
 
(R)-2-(4-Chlorophenyl)-3-(diphenylamino)-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (10e) 
 
Using -IrO (2 mol%) as catalyst, starting from 2-acyl imidazole 7e (59.3 mg, 0.20 mmol) and α-
silylamine 9a (153.2 mg, 0.60 mmol) according to the general procedure to give 10e as a white solid 
(66.9 mg, 0.140 mmol, yield: 70%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 98% (HPLC: AD-H, 254 nm, hexane/isopropanol = 97:3, flow rate 0.5 
mL/min, 25 C, tr (major) = 21.7 min, tr (minor) = 27.3 min). []D20 = +118.0 (c 0.8, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.32–7.18 (m, 5H), 7.14–7.04 (m, 7H), 6.97 (d, J = 0.8 Hz, 1H), 6.94–
6.87 (m, 2H), 6.86–6.81 (m, 2H), 6.80–6.74 (m, 4H), 5.59 (dd, J = 8.1, 5.7 Hz, 1H), 4.49 (dd, J = 14.6, 
8.1 Hz, 1H), 3.88 (dd, J = 14.6, 5.6 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 189.3, 147.8, 142.5, 138.1, 135.9, 133.2, 130.2, 129.9, 129.1, 128.8, 128.7, 
128.6, 127.4, 125.7, 121.6, 121.4, 55.2, 51.1. 
IR (film): ν (cm1) 3034, 2910, 1673, 1587, 1455, 1396, 1269, 1185, 1105, 1034, 992, 938, 859, 830, 
746, 731, 690, 645, 617, 589, 558, 526. 
HRMS (ESI, m/z) calcd for C30H24ClN3ONa [M+Na]+: 500.1500, found: 500.1506. 
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(R)-3-(Diphenylamino)-1-(1-phenyl-1H-imidazol-2-yl)-2-(thiophen-3-yl)propan-1-one (10f) 
 
Using -IrO (2 mol%) as catalyst, starting from 2-acyl imidazole 7f (53.7 mg, 0.20 mmol) and α-
silylamine 9a (153.2 mg, 0.60 mmol) according to the general procedure to give 10f as a pale yellow oil 
(55.7 mg, 0.124 mmol, yield: 62%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 94% (HPLC: AD-H, 254 nm, hexane/isopropanol = 97:3, flow rate 0.5 
mL/min, 25 C, tr (major) = 25.9 min, tr (minor) = 38.1 min). []D20 = +54.5 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.46–7.39 (m, 3H), 7.29–7.25 (m, 2H), 7.25–7.19 (m, 5H), 7.17 (d, J = 
1.0 Hz, 1H), 7.13–7.06 (m, 3H), 7.01–6.95 (m, 2H), 6.94–6.89 (m, 4H), 5.87 (dd, J = 8.7, 5.3 Hz, 1H), 
4.58 (dd, J = 14.5, 8.7 Hz, 1H), 3.99 (dd, J = 14.5, 5.3 Hz, 1H). 
13C NMR (75 MHz, CD2Cl2) δ 189.7, 148.4, 143.2, 138.7, 138.0, 130.2, 129.5, 129.1, 128.9, 128.1, 
128.0, 126.2, 126.0, 123.2, 122.0, 121.7, 55.6, 47.5. 
IR (film): ν (cm1) 3059, 2922, 1681, 1587, 1490, 1445, 1364, 1341, 1244, 1188, 1148, 1095, 907, 859, 
841, 747, 690, 654, 575, 547. 
HRMS (ESI, m/z) calcd for C28H23N3OSNa [M+Na]+: 472.1454, found: 472.1457. 
 
(R)-3-(Di-p-tolylamino)-2-methyl-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (10g) 
 
Using -IrO (4 mol%) as catalyst, starting from 2-acyl imidazole 7g (40.0 mg, 0.20 mmol) and α-
silylamine 9b (170.0 mg, 0.60 mmol) according to the general procedure to give 10g as a pale yellow 
oil (76.2 mg, 0.186 mmol, yield: 93%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 96% (HPLC: AD-H, 254 nm, hexane/isopropanol = 97:3, flow rate 0.5 
mL/min, 25 C, tr (major) = 21.7 min, tr (minor) = 29.3 min). []D20 = –108.2 (c 0.8, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.45–7.40 (m, 2H), 7.25–7.16 (m, 3H), 7.14–7.08 (m, 2H), 7.07–7.00 
(m, 4H), 6.89–6.81 (m, 4H), 4.53–4.31 (m, 1H), 4.15 (dd, J = 14.4, 8.0 Hz, 1H), 3.66 (dd, J = 14.4, 6.0 
Hz, 1H), 2.30 (s, 6H), 1.20 (d, J = 7.0 Hz, 3H). 
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13C NMR (75 MHz, CD2Cl2) δ 194.3, 161.9, 146.6, 143.3, 139.0, 131.1, 130.5, 130.0, 129.9, 129.1, 
128.8, 127.7, 126.4, 126.3, 125.3, 121.6, 56.2, 41.2, 20.7, 15.7. 
IR (film): ν (cm1) 3052, 2922, 1679, 1606, 1596, 1505, 1492, 1444, 1366, 1263, 1225, 1074, 949, 910, 
810, 758, 727, 691, 664, 578, 539. 
HRMS (ESI, m/z) calcd for C27H27N3ONa [M+Na]+: 432.2046, found: 432.2049. 
 
(R)-2-((Di-p-tolylamino)methyl)-1-(1-phenyl-1H-imidazol-2-yl)butan-1-one (10h) 
 
Using -IrO (4 mol%) as catalyst, starting from 2-acyl imidazole 7h (42.9 mg, 0.20 mmol) and α-
silylamine 9b (170.0 mg, 0.60 mmol) according to the general procedure to give 10h as a pale yellow 
oil (55.0 mg, 0.130 mmol, yield: 65%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 96% (HPLC: AD-H, 254 nm, hexane/isopropanol = 97:3, flow rate 0.5 
mL/min, 25 C, tr (major) = 18.5 min, tr (minor) = 22.9 min). []D20 = –84.4 (c 0.7, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.45–7.38 (m, 2H), 7.24–7.15 (m, 3H), 7.10–7.00 (m, 6H), 6.85–6.76 
(m, 4H), 4.45–4.29 (m, 1H), 4.11 (dd, J = 14.4, 8.8 Hz, 1H), 3.73 (dd, J = 14.4, 5.1 Hz, 1H), 2.30 (s, 
6H), 1.86–1.56 (m, 2H), 0.91 (t, J = 7.5 Hz, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 194.4, 161.9, 146.6, 144.1, 139.0, 131.0, 130.5, 130.0, 129.9, 129.0, 
128.7, 127.6, 126.4, 126.3, 125.3, 121.6, 55.3, 47.9, 24.3, 20.7, 11.9. 
IR (film): ν (cm1) 3027, 2962, 2920, 2860, 1676, 1607, 1569, 1506, 1456, 1367, 1277, 1187, 1074, 952, 
812, 760, 726, 708, 692, 665, 556. 
HRMS (ESI, m/z) calcd for C28H29N3ONa [M+Na]+: 446.2203, found: 446.2208. 
 
(R)-3-((4-Methoxyphenyl)(phenyl)amino)-2-phenyl-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one 
(10i) 
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Using -IrO (2 mol%) as catalyst, starting from 2-acyl imidazole 7a (52.4 mg, 0.20 mmol) and α-
silylamine 9c (171.3 mg, 0.60 mmol) according to the general procedure to give 10i as a pale yellow oil 
(85.2 mg, 0.180 mmol, yield: 90%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 95% (HPLC: AD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 0.5 
mL/min, 25 C, tr (major) = 22.6 min, tr (minor) = 25.4 min). []D20 = +31.3 (c 0.6, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.48–7.38 (m, 5H), 7.35–7.26 (m, 3H), 7.22 (d, J = 1.0 Hz, 1H), 7.21–
7.13 (m, 3H), 7.11–7.06 (m, 2H), 6.95–6.88 (m, 2H), 6.87–6.80 (m, 2H), 6.79–6.71 (m, 3H), 5.68 (dd, 
J = 8.8, 4.8 Hz, 1H), 4.57 (dd, J = 14.4, 8.8 Hz, 1H), 3.92 (dd, J = 14.4, 4.8 Hz, 1H), 3.81 (s, 3H). 
13C NMR (75 MHz, CD2Cl2) δ 190.0, 157.1, 149.5, 143.4, 140.9, 138.9, 138.1, 130.1, 129.3, 129.2, 
129.1, 129.0, 128.9, 127.94, 127.91, 127.7, 126.2, 118.9, 116.7, 115.0, 55.9, 55.8, 52.2. 
IR (film): ν (cm1) 3059, 3031, 2931, 2835, 1734, 1681, 1595, 1506, 1492, 1453, 1398, 1371, 1340, 
1307, 1273, 1180, 1072, 990, 965, 869, 760, 692. 
HRMS (ESI, m/z) calcd for C31H27N3O2Na [M+Na]+: 496.1995, found: 496.1999. 
 
(R)-3-((4-Chlorophenyl)(phenyl)amino)-2-phenyl-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one 
(10j) 
 
Using -IrO (2 mol%) as catalyst, starting from 2-acyl imidazole 7a (52.4 mg, 0.20 mmol) and α-
silylamine 9d (174.0 mg, 0.60 mmol) according to the general procedure to give 10j as a pale yellow oil 
(62.1 mg, 0.130 mmol, yield: 65%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 95% (HPLC: AD-H, 254 nm, hexane/isopropanol = 97:3, flow rate 0.5 
mL/min, 25 C, tr (major) = 17.6 min, tr (minor) = 19.5 min). []D20 = +54.3 (c 0.8, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.46–7.38 (m, 5H), 7.33–7.24 (m, 5H), 7.22–7.17 (m, 2H), 7.16–7.14 (m, 
2H), 7.10–7.05 (m, 2H), 7.05–6.98 (m, 1H), 6.96–6.90 (m, 2H), 6.87–6.80 (m, 2H), 5.69 (dd, J = 8.6, 
5.1 Hz, 1H), 4.61 (dd, J = 14.6, 8.7 Hz, 1H), 3.96 (dd, J = 14.6, 5.1 Hz, 1H). 
13C NMR (75 MHz, CD2Cl2) δ 189.8, 148.0, 147.3, 143.2, 138.8, 137.8, 130.2, 129.7, 129.4, 129.2, 
129.14, 129.12, 129.0, 128.0, 127.8, 127.7, 126.2, 122.8, 122.6, 122.3, 55.7, 52.0. 
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IR (film): ν (cm1) 3065, 2929, 1682, 1587, 1488, 1454, 1399, 1218, 1181, 1133, 1030, 938, 909, 865, 
830, 759, 692, 541. 
HRMS (ESI, m/z) calcd for C30H24ClN3ONa [M+Na]+: 500.1500, found: 500.1504. 
 
(R)-3-(Di-p-tolylamino)-2-phenyl-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (10k) 
 
Using -IrO (2 mol%) as catalyst, starting from 2-acyl imidazole 7a (52.4 mg, 0.20 mmol) and α-
silylamine 9b (170.0 mg, 0.60 mmol) according to the general procedure to give 10k as a pale yellow 
oil (84.0 mg, 0.178 mmol, yield: 89%). Enantiomeric excess established by HPLC analysis using a 
Chiralpak AD-H column, ee = 91% (HPLC: AD-H, 254 nm, hexane/isopropanol = 97:3, flow rate 0.5 
mL/min, 25 C, tr (major) = 22.6 min, tr (minor) = 25.3 min). []D20 = +54.5 (c 0.8, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.46–7.36 (m, 5H), 7.35–7.24 (m, 3H), 7.23–7.17 (m, 2H), 7.13 (d, J = 
1.0 Hz, 1H), 7.08–7.04 (m, 3H), 7.03–7.00 (m, 2H), 6.81–6.74 (m, 4H), 5.65 (dd, J = 8.9, 4.7 Hz, 1H), 
4.56 (dd, J = 14.4, 8.9 Hz, 1H), 3.90 (dd, J = 14.4, 4.7 Hz, 1H), 2.30 (s, 6H). 
13C NMR (75 MHz, CD2Cl2) δ 190.0, 161.9, 146.3, 143.3, 138.8, 138.1, 131.3, 130.5, 130.1, 130.03, 
130.00, 129.10, 129.09, 129.00, 128.9, 127.9, 127.6, 126.4, 126.2, 125.3, 121.6, 55.9, 52.0, 20.7. 
IR (film): ν (cm1) 3027, 2919, 2858, 1681, 1598, 1507, 1445, 1399, 1263, 1247, 1148, 1073, 938, 909, 
869, 848, 759, 735, 693, 610, 547. 
HRMS (ESI, m/z) calcd for C32H29N3ONa [M+Na]+: 494.2203, found: 494.2206. 
 
(R)-3-(Naphthalen-2-yl(phenyl)amino)-2-phenyl-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one 
(10l) 
 
Using -IrO (2 mol%) as catalyst, starting from 2-acyl imidazole 7a (52.4 mg, 0.20 mmol) and α-
silylamine 9e (183.3 mg, 0.60 mmol) according to the general procedure to give 10l as a white solid 
(62.2 mg, 0.126 mmol, yield: 63%). Enantiomeric excess established by HPLC analysis using a 
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Chiralpak AD-H column, ee = 97% (HPLC: AD-H, 254 nm, hexane/isopropanol = 97:3, flow rate 0.5 
mL/min, 25 C, tr (minor) = 34.8 min, tr (major) = 37.3 min). []D20 = +29.2 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CD2Cl2) δ 7.77 (d, J = 7.9 Hz, 1H), 7.62 (t, J = 8.9 Hz, 2H), 7.48–7.40 (m, 4H), 
7.40–7.30 (m, 7H), 7.28–7.22 (m, 2H), 7.19 (d, J = 0.9 Hz, 1H), 7.10 (td, J = 5.1, 2.4 Hz, 2H), 7.05–
6.90 (m, 5H), 5.80 (dd, J = 8.6, 4.9 Hz, 1H), 4.77 (dd, J = 14.6, 8.6 Hz, 1H), 4.09 (dd, J = 14.6, 4.9 Hz, 
1H). 
13C NMR (75 MHz, CD2Cl2) δ 189.8, 148.4, 145.8, 143.2, 138.7, 138.1, 135.0, 130.1, 129.9, 129.6, 
129.2, 129.10, 129.07, 129.00, 128.8, 128.0, 127.8, 127.7, 127.2, 126.6, 126.1, 124.4, 123.3, 122.2, 
122.0, 117.1, 55.9, 51.8. 
IR (film): ν (cm1) 3056, 2924, 2853, 1734, 1681, 1627, 1592, 1491, 1469, 1397, 1371, 1303, 1263, 
1182, 1147, 1044, 938, 902, 846, 814, 742, 691, 663, 521, 503. 
HRMS (ESI, m/z) calcd for C34H27N3ONa [M+Na]+: 516.2046, found: 516.2050. 
 
5.3.3 Substrate-Coordinated Iridium Complex (Proposed Intermediate A) 
1) Synthesis of complex A 
 
The racemic complex A was obtained by reacting substrate 7a (13.0 mg, 0.049 mmol) with racemic /-
IrO (40.0 mg, 0.043 mmol) at room temperature overnight in CH2Cl2 (1.0 mL). After the slow addition 
of hexane (5.0 mL), crystals were collected after several days (32.2 mg, yield: 68%).  
1H NMR (300 MHz, CD2Cl2) δ 7.90–7.80 (m, 2H), 7.78–7.71 (m, 3H), 7.70–7.68 (m, 1H), 7.67–7.47 
(m, 4H), 7.28 (t, J = 1.8 Hz, 2H), 7.22–7.07 (m, 3H), 7.05–6.96 (m, 3H), 6.95–6.93 (m, 1H), 6.69 (t, J 
= 7.8 Hz, 2H), 6.62 (d, J = 7.7 Hz, 2H), 6.12–6.07 (m, 2H), 6.06–6.04 (m, 1H), 4.15 (d, J = 14.7 Hz, 
1H), 3.98 (d, J = 14.7 Hz, 1H), 1.36 (s, 9H), 1.13 (s, 9H). 
13C NMR (75 MHz, CD2Cl2) δ 197.0, 178.9, 176.8, 151.3, 151.2, 148.9, 148.8, 147.3, 145.8, 137.6, 
137.5, 135.9, 134.8, 134.4, 133.7, 133.3, 133.1, 133.0, 132.9, 132.8, 132.5, 131.2, 130.6, 130.2, 129.3, 
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129.1, 128.5, 128.3, 126.9, 126.5, 124.8, 124.6, 124.0, 123.6, 112.4, 112.3, 111.5, 111.0, 45.4, 35.5, 
35.4, 31.8, 31.7. 
 
2) Absorption and emission spectra of complex A 
UV/Vis-absorbance and photoluminescence (ex = 390 nm) spectra of complex A were performed in 
CH2Cl2 at a concentration of 0.1 mM using a Spectra Max M5 microplate reader with a 10 mm quartz 
cuvette. 
 
3) Stern-volmer-plot with complex A 
Performed in CH2Cl2 at a concentration of 0.1 mM of complex A (volume of 1.0 mL) and different 
concentrations of amine 9a. Emission intensities were recorded with a Spectra Max M5 microplate 
reader in a 10 mm quartz cuvette with a cap upon excitation at 390 nm. A concentrated stock solution 
(100 mM in CH2Cl2) of amine 9a was titrated in 5.0 L steps. After the additions, the solutions were 
shaken once in a while over a period of 5 min and thereafter the emission quenching measured.  
 
4) Cyclovoltammetry with complex A 
Cyclic voltammetry was carried out on a BAS C3 Cell Strand and a BAS 100 series Electrochemical 
Analyzer using a platinum disk working electrode (2.0 mm diameter) and a platinum wire counter 
electrode (0.5 mm diameter) at room temperature in THF containing Bu4NBF4 (0.1 M). Potentials were 
referred to a saturated Ag/AgCl reference electrode. Before each experiment, the surface of the working 
electrode was polished followed by thorough rinsing with distilled water. The solution was purged with 
nitrogen before each measurement.  
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5.3.4 Synthesis of the Proposed Intermediate Iridium Enolate Complex B 
 
To a solution of racemic catalyst /-IrO (40.0 mg, 0.043 mmol) in CH2Cl2 (1.5 mL) was added 2-acyl 
imidazole 7a (33.8 mg, 0.129 mmol). The reaction mixture was concentrated after around 16 h. The 
residue was purified by flash chromatography on silica gel (CH2Cl2/EtOAc = 50:1) to afford the enolate 
complex B as a red solid (34.9 mg, 0.036 mmol, yield: 85%). 
1H NMR (300 MHz, CD2Cl2) δ 7.86 (d, J = 1.5 Hz, 1H), 7.78–7.69 (m, 2H), 7.61 (dt, J = 4.5, 2.2 Hz, 
1H), 7.56–7.49 (m, 4H), 7.48–7.38 (m, 4H), 7.37–7.32 (m, 2H), 7.05–6.97 (m, 4H), 6.94 (dd, J = 7.5, 
1.1 Hz, 1H), 6.88 (dd, J = 7.5, 1.5 Hz, 1H), 6.85–6.73 (m, 3H), 6.71–6.65 (m, 3H), 4.75 (s, 1H), 1.26 (s, 
9H), 0.95 (s, 9H). 
13C NMR (75 MHz, CD2Cl2) δ 179.1, 178.1, 155.5, 155.4, 153.3, 150.8, 150.0, 149.0, 148.8, 148.1, 
139.9, 139.0, 138.9, 138.4, 134.7, 134.1, 131.7, 131.6, 131.02, 131.01, 129.9, 127.9, 127.5, 127.4, 126.8, 
126.1, 126.0, 124.8, 123.5, 123.1, 122.6, 121.3, 120.9, 115.6, 112.7, 111.3, 110.3, 103.9, 35.5, 35.2, 
32.0, 31.4. 
 
5.3.5 Control Reactions 
1) Evaluating the catalytic activities of complexes A and B 
Using complex A (2 mol%) as catalyst, starting from 2-acyl imidazole 7a (52.4 mg, 0.20 mmol) and α-
silylamine 9a (153.2 mg, 0.60 mmol) according to the general procedure of synthesizing 10a-l to give 
10a (92% yield, 7.5 h). When use complex B (2 mol%) as catalyst instead, the product 10a could not be 
observed. 
 
2) Trapping experiment with dibenzyl diazodicarboxylate 
To a solution of catalyst -IrO (2 mol%) in anhydrous CH2Cl2 (0.50 mL, 0.4 M) was added the 2-acyl 
imidazole 7a (52.4 mg, 0.2 mmol) in a 10 mL test tube. After being stirred at room temperature for 20 
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min, dibenzyl diazodicarboxylate (298.3 mg, 1.0 mmol) was added. The reaction was stirred at room 
temperature for 7 h under air atmosphere. Afterwards, the solvent was concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexane = 1:2) to afford 
the product 13 (97.5 mg, 0.174 mmol, yield: 87%) as a white oil. Enantiomeric excess established by 
HPLC analysis using a Chiralpak AD-H column, ee = 89% (HPLC: AD-H, 254 nm, hexane/isopropanol 
= 60:40, flow rate 1.0 mL/min, 40 C, tr (minor) = 9.0 min, tr (major) = 15.8 min). 
1H NMR (300 MHz, CD2Cl2) δ 7.55–7.45 (m, 3H), 7.43–7.36 (m, 2H), 7.35–7.24 (m, 12H), 7.23–7.18 
(m, 3H), 7.13–6.97 (m, 3H), 5.28–4.30 (m, 5H). 
13C NMR (75 MHz, CD2Cl2) δ 171.2, 138.4, 136.4, 133.2, 130.9, 130.8, 130.6, 129.4, 129.2, 129.0, 
128.8, 128.7, 128.4, 128.04, 128.02, 127.9, 126.2, 120.4, 68.6, 67.3, 60.6. 
IR (film): ν (cm1) 3300, 3029, 2953, 1691, 1594, 1492, 1448, 1397, 1338, 1213, 1117, 1051, 969, 912, 
844, 740, 693, 647, 591, 547. 
HRMS (ESI, m/z) calcd for C33H28N4O5Na [M+Na]+: 583.1952, found: 583.1946. 
 
3) Dark reaction with the oxidant tBuOOH 
To a solution of catalyst -IrO (5 mol%) in anhydrous CH2Cl2 (0.50 mL, 0.4 M) was added the 2-acyl 
imidazole 7a (52.4 mg, 0.2 mmol) in a 10 mL test tube. After being stirred at room temperature for 20 
min, 9a (153.2 mg, 0.60 mmol) and tert-butyl hydroperoxide (36.0 mg, 0.40 mmol) were added. The 
reaction was stirred at room temperature for 24 h in the dark under air atmosphere. Afterwards, the 
resulting reaction mixture was purified to afford the product 10a (54.0 mg, 0.121 mmol, yield: 61%, ee: 
97%). 
 
5.3.6 Single-Crystal X-Ray Diffraction Studies  
Single crystals of the intermediate iridium enolate complex B suitable for X-ray diffraction were 
obtained after several days from a solution of the compound in CH2Cl2 layered with n-hexane. Crystals 
of 10e were obtained from a solution of the compound in methanol at 5 °C after several days. Crystal 
data and details of the structure determination are presented in Appendices 6.7. The absolute 
configurature was determined   
Chapter 5: Experimental Part 
126 
 
5.4 Asymmetric Radical-Radical Cross-Coupling through Visible Light 
Activated Iridium Catalysis 
5.4.1 Synthesis of Substrates 
1) Synthesis of 2-acyl imidazoles  
2-Acyl imidazoles 14a, 14b'-d' were synthesized according to a reported procedure with some 
modifications.15 To a solution of the corresponding 1-substituted-1H-imidazole (1.0 eq.) in toluene (0.1 
M) at 20 C was added trifluoroacetic anhydride (1.2 eq.) dropwise. After that, triethylamine (1.2 eq.) 
was added dropwise to the flask. The reaction was allowed to slowly warm to room temperature and 
stirred overnight. Removal of the solvent in vacuo and the residue was purified by flash chromatography 
on silica gel (EtOAc/hexane = 1:3) to provide the 2-acyl imidazole 14a, 14b'-d'.  
 
2,2,2-Trifluoro-1-(1-phenyl-1H-imidazol-2-yl)ethanone (14a) 
 
Following the general procedure, 1-phenyl-1H-imidazole (1.440 g, 10.0 mmol) was converted to 2-acyl 
imidazole 14a (1.801 g, 7.5 mmol, yield: 75%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.56–7.47 (m, 4H), 7.39–7.35 (m, 1H), 7.34–7.28 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 169.8 (q, J = 36.7 Hz), 137.9, 137.0, 132.3, 129.6, 129.3, 129.2, 125.7, 
116.3 (q, J = 288.5 Hz). 
19F NMR (282 MHz, CDCl3) δ –73.40 (s, 3F). 
IR (film): ν (cm1) 3255, 3095, 2918, 2357, 1769, 1704, 1595, 1498, 1408, 1312, 1269, 1188, 1135, 
1063, 1006, 906, 819, 757, 691, 649, 528. 
 
2,2,2-Trifluoro-1-(1-methyl-1H-imidazol-2-yl)ethanone (14b') 
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Following the general procedure, 1-methyl-1H-imidazole (0.821 g, 10.0 mmol) was converted to 2-acyl 
imidazole 14b' (1.478, 8.3 mmol, yield: 83%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.37 (d, J = 0.9 Hz, 1H), 7.23 (d, J = 0.9 Hz, 1H), 4.07 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 170.2 (q, J = 35.3 Hz), 137.8, 131.7, 129.5, 116.2 (q, J = 288.7 Hz), 
36.3.  
All spectroscopic data were in agreement with the literature.15 
 
2,2,2-Trifluoro-1-(1-(4-fluorophenyl)-1H-imidazol-2-yl)ethanone (14c') 
 
Following the general procedure, 1-(4-fluorophenyl)-1H-imidazole (1.622 g, 10.0 mmol) was converted 
to 2-acyl imidazole 14c' (2.065 g, 8.0 mmol, yield: 80%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.53 (d, J = 0.9 Hz, 1H), 7.37 (d, J = 0.9 Hz, 1H), 7.35–7.27 (m, 2H), 
7.26–7.17 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 169.6 (q, J = 36.5 Hz), 164.5, 161.2, 137.8, 132.9, 132.8, 132.2, 129.3, 
127.6, 127.5, 116.4, 116.2 (q, J = 288.5 Hz), 116.1. 
19F NMR (282 MHz, CDCl3) δ –73.45 (s, 3F), –111.49 (s, 1F).
  
IR (film): ν (cm1) 3102, 1711, 1604, 1509, 1458, 1408, 1350, 1194, 1140, 898, 815, 740, 682, 633, 528. 
 
2,2,2-Trifluoro-1-(1-(4-methoxyphenyl)-1H-imidazol-2-yl)ethanone (14d') 
 
Following the general procedure, 1-(4-methoxyphenyl)-1H-imidazole (1.742 g, 10.0 mmol) was 
converted to 2-acyl imidazole 14d' (0.811 g, 3.0 mmol, yield: 30%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.47 (d, J = 0.9 Hz, 1H), 7.33 (d, J = 0.9 Hz, 1H), 7.25–7.18 (m, 2H), 
7.01–6.94 (m, 2H), 3.87 (s, 3H). 
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13C NMR (75 MHz, CDCl3) δ 169.6 (q, J = 36.0 Hz), 160.2, 137.8, 132.0, 129.6, 129.5, 126.8, 118.2 (q, 
J = 288.8 Hz), 114.9, 55.5. 
19F NMR (282 MHz, CDCl3) δ –73.37 (s, 3F). 
IR (film): ν (cm1) 3208, 3154, 2942, 2841, 1699, 1605, 1510, 1456, 1355, 1252, 1134, 1073, 933, 828, 
777, 633, 538. 
 
2) Synthesis of tertiary amines 
2-Aryl-1,2,3,4-tetrahydroisoquinolines 17a-e were synthesized according to a reported procedure 
without any further change.16 All N-methyldiarylamines were synthesized according to a reported 
procedure with some modifications.17 To a solution of the corresponding diarylamines (1.0 eq.) in THF 
(0.4 M) under nitrogen atmosphere at 0 C was added n-BuLi (1.1 eq.) dropwise. The reaction was 
stirred at 0 C for 30 min, then stirred at room temperature for an additional 1 h. Methyl iodide (1.5 eq.) 
was added slowly to the flask after the reaction was cooled back down to 0 C, and the resulting solution 
was stirred at room temperature overnight. Afterwards, the reaction was quenched with water and 
extracted with CH2Cl2. The combined organic layers were dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel 
(EtOAc/hexane = 1:100) to produce 15a-h.  
 
N,4-Dimethyl-N-(p-tolyl)aniline (15a) 
 
Following the general procedure, di(p-tolyl)amine (3.946 g, 20.0 mmol) was converted to amine 15a 
(3.676 g, 17.4 mmol, yield: 87%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.14–7.06 (m, 4H), 6.98–6.86 (m, 4H), 3.29 (s, 3H), 2.33 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ 147.1, 130.4, 129.7, 120.4, 40.4, 20.6. 
All spectroscopic data were in agreement with the literature.18 
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N-Methyl-N-phenylaniline (15b) 
 
Following the general procedure, diphenylamine (1.692 g, 10.0 mmol) was converted to amine 15b 
(1.557 g, 8.5 mmol, yield: 85%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.37–7.26 (m, 4H), 7.11–7.04 (m, 4H), 7.00 (ddt, J = 8.4, 7.5, 1.1 Hz, 
2H), 3.37 (s, 3H). 
 13C NMR (75 MHz, CDCl3) δ 149.1, 129.2, 121.3, 120.5, 40.2. 
All spectroscopic data were in agreement with the literature.17 
 
N,4-Dimethyl-N-phenylaniline (15c) 
 
Following the general procedure, 4-methyl-N-phenylaniline (1.410 g, 7.7 mmol) was converted to amine 
15c (1.184 g, 6.0 mmol, yield: 78%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 7.32–7.25 (m, 2H), 7.20–7.14 (m, 2H), 7.08–7.04 (m, 2H), 7.01–6.95 (m, 
2H), 6.94–6.87 (m, 1H), 3.34 (s, 3H), 2.38 (s, 3H) 
13C NMR (75 MHz, CDCl3) δ 149.4, 146.6, 132.0, 129.9, 129.0, 122.5, 119.8, 118.3, 40.3, 20.7. 
All spectroscopic data were in agreement with the literature.18 
 
4-Chloro-N-methyl-N-(p-tolyl)aniline (15d) 
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Following the general procedure, 4-chloro-N-(p-tolyl)aniline (0.860 g, 3.9 mmol) was converted to 
amine 15d (0.730 g, 3.1 mmol, yield: 80%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.20–7.08 (m, 4H), 7.00 (d, J = 8.4 Hz, 2H), 6.81 (d, J = 9.0 Hz, 2H), 
3.26 (s, 3H), 2.34 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 148.0, 146.2, 132.9, 130.1, 128.8, 124.2, 123.2, 118.6, 40.4, 20.8. 
IR (film): ν (cm1) 3026, 2917, 2814, 1706, 1589, 1507, 1498, 1411, 1333, 1251, 1068, 937, 868, 748, 
716, 641, 607, 546. 
HRMS (FD, m/z) calcd for C14H14ClN: 231.08148, found: 231.08143. 
 
4-Methoxy-N-methyl-N-(p-tolyl)aniline (15e) 
 
Following the general procedure, 4-methoxy-N-(p-tolyl)aniline (1.826 g, 8.5 mmol) was converted to 
amine 15e (1.642 g, 7.2 mmol, yield: 85%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.08–6.97 (m, 4H), 6.91–6.84 (m, 2H), 6.81–6.75 (m, 2H), 3.81 (s, 3H), 
3.25 (s, 3H), 2.29 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 155.5, 147.6, 142.9, 129.5, 128.6, 124.5, 117.5, 114.7, 55.5, 40.7, 20.4. 
IR (film): ν (cm1) 2906, 2824, 1606, 1501, 1331, 1236, 1179, 1113, 1029, 870, 816, 763, 716, 650, 552. 
HRMS (FD, m/z) calcd for C15H17NO: 227.13101, found: 227.13108. 
 
4-(tert-Butyl)-N-(4-(tert-butyl)phenyl)-N-methylaniline (15f) 
 
Following the general procedure, bis(4-(tert-butyl)phenyl)amine (2.814 g, 10.0 mmol) was converted to 
amine 15f (2.393 g, 8.1 mmol, yield: 81%) as a white solid. 
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1H NMR (300 MHz, CDCl3) δ 7.35–7.22 (m, 4H), 7.02–6.90 (m, 4H), 3.30 (s, 3H), 1.33 (s, 18H). 
13C NMR (75 MHz, CDCl3) δ 146.6, 143.8, 125.9, 119.8, 40.2, 34.1, 31.5. 
IR (film): ν (cm1) 3032, 2952, 2868, 1604, 1565, 1340, 1252, 1194, 1073, 874, 820, 766, 556. 
HRMS (FD, m/z) calcd for C21H29N: 295.23000, found: 295.23011. 
 
4-Chloro-N-(4-chlorophenyl)-N-methylaniline (15g) 
 
Following the general procedure, bis(4-chlorophenyl)amine (1.520 g, 6.4 mmol) was converted to amine 
15g (1.290 g, 5.1 mmol, yield: 80%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.33–7.17 (m, 4H), 7.00–6.86 (m, 4H), 3.29 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 147.3, 129.2, 126.6, 121.7, 40.4. 
IR (film): ν (cm1) 3082, 2894, 1580, 1481, 1328, 1246, 1176, 999, 815, 757, 673, 579. 
HRMS (ESI, m/z) calcd for C13H12Cl2N [M+H]+: 252.0341, found: 252.0341. 
 
N-Methyl-N-(p-tolyl)naphthalen-2-amine (15h) 
 
Following the general procedure, N-(p-tolyl)naphthalen-2-amine (1.353 g, 5.8 mmol) was converted to 
amine 15h (1.112 g, 4.5 mmol, yield: 77%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.65–7.57 (m, 2H), 7.56–7.51 (m, 1H), 7.34–7.26 (m, 1H), 7.20–7.15 (m, 
1H), 7.14–7.11 (m, 1H), 7.08–7.01 (m, 3H), 7.00–6.94 (m, 2H), 3.31 (s, 3H), 2.26 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 147.0, 146.7, 134.8, 132.5, 130.0, 128.5, 128.3, 127.5, 126.5, 126.2, 123.2, 
123.1, 120.7, 112.1, 40.7, 20.8. 
IR (film): ν (cm1) 3020, 2907, 1607, 1496, 1369, 1275, 1121, 946, 820, 776, 646, 555. 
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HRMS (FD, m/z) calcd for C18H17N: 247.13610, found: 247.13579. 
 
5.4.2 Iridium-Catalyzed Photoredox Reactions 
1) Reactions of 2-acyl imidazoles with N-methyldiarylamines 
 
General catalysis procedure. A dried 10 mL Schlenk tube was charged with the catalyst Λ-IrS12 (3 
mol%), 2-acyl imidazoles 14a, 14b'-d' (0.20 mmol, 1.0 eq.) and the corresponding amine 15a-h (0.60 
mmol, 3.0 eq.). The tube was purged with nitrogen and CHCl3 (0.4 mL) was added via syringe. The 
reaction mixture was degassed via freeze-pump-thaw for three cycles. After the mixture was thoroughly 
degassed, the vial was sealed and positioned approximately 5 cm from a 23 W CFL or approximately 8 
cm from a 24 W blue LEDs. The reaction was stirred at room temperature for the indicated time 
(monitored by TLC) under nitrogen atmosphere. Afterwards, the mixture was diluted with CH2Cl2 (4 
mL). The combined organic layers were concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica gel (EtOAc/hexane = 1:20 to 1:10) to afford the products 16a-h. 
Racemic samples were obtained by carrying out the reactions with rac-IrS. The enantiomeric excess 
was determined by chiral HPLC analysis. 
 
(S)-3-(Di-p-tolylamino)-1,1,1-trifluoro-2-(1-phenyl-1H-imidazol-2-yl)propan-2-ol (16a) 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and amine 15a (126.8 mg, 0.60 mmol) 
according to the general procedure to give 16a as a colorless oil (74.0 mg, 0.164 mmol, yield: 82%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 99% (HPLC: 
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AD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 0.5 mL/min, 25 C, tr (minor) = 14.7 min, tr (major) 
= 20.0 min). []D20 = –63.9 (c 0.7, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.41–7.27 (m, 3H), 7.07 (d, J = 1.2 Hz, 1H), 7.05–6.98 (m, 4H), 6.94–
6.86 (m, 2H), 6.78 (d, J = 1.3 Hz, 1H), 6.75–6.66 (m, 4H), 4.86 (d, J = 15.1 Hz, 1H), 4.27 (d, J = 15.1 
Hz, 1H), 4.14 (s, 1H), 2.28 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ 146.2, 142.7, 139.0, 132.4, 129.8, 128.5, 128.3, 127.4, 126.9, 124.7, 122.0, 
74.8 (q, J = 28.5 Hz), 58.1, 20.5. 
19F NMR (282 MHz, CDCl3) δ –78.00 (s, 3F). 
IR (film): ν (cm1) 3336, 3029, 2922, 2864, 1684, 1607, 1505, 1360, 1161, 1052, 983, 811, 761, 738, 
693, 643, 570, 530.  
 
(S)-3-(Di-p-tolylamino)-1,1,1-trifluoro-2-(1-methyl-1H-imidazol-2-yl)propan-2-ol (16b') 
 
Starting from 2-acyl imidazole 14b' (35.6 mg, 0.20 mmol) and amine 15a (126.8 mg, 0.60 mmol) 
according to the general procedure to give 16b' as a white solid (30.8 mg, 0.079 mmol, yield: 40%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 98% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 0.5 mL/min, 25 C, tr (minor) = 18.9 min, tr (major) 
= 23.9 min). []D20 = –145.0 (c 0.3, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.04–6.98 (m, 4H), 6.94 (d, J = 1.1 Hz, 1H), 6.79–6.73 (m, 4H), 6.71 (d, 
J = 1.1 Hz, 1H), 5.10 (s, 1H), 4.81 (d, J = 15.5 Hz, 1H), 4.50 (d, J = 15.5 Hz, 1H), 3.56 (s, 3H), 2.28 (s, 
6H). 
13C NMR (75 MHz, CDCl3) δ 146.6, 141.9, 132.4, 129.9, 126.9, 126.3, 124.3, 122.0, 74.4 (q, J = 29.2 
Hz), 57.1, 34.9, 20.6. 
19F NMR (282 MHz, CDCl3) δ –78.86 (s, 3F). 
IR (film): ν (cm1) 3359, 3112, 2933, 2851, 1654, 1581, 1453, 1336, 1208, 1154, 1029, 950, 910, 862, 
745, 693, 663, 586.  
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(S)-3-(Di-p-tolylamino)-1,1,1-trifluoro-2-(1-(4-fluorophenyl)-1H-imidazol-2-yl)propan-2-ol (16c') 
 
Starting from 2-acyl imidazole 14c' (51.6 mg, 0.20 mmol) and amine 15a (126.8 mg, 0.60 mmol) 
according to the general procedure to give 16c' as a colorless oil (62.1 mg, 0.132 mmol, yield: 66%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 90% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 0.5 mL/min, 25 C, tr (minor) = 12.9 min, tr 
(major) = 17.0 min). []D20 = –51.4 (c 0.6, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.08 (d, J = 1.2 Hz, 1H), 7.05–6.99 (m, 4H), 6.99–6.93 (m, 2H), 6.88–
6.81 (m, 2H), 6.76 (d, J = 1.2 Hz, 1H), 6.75–6.69 (m, 4H), 4.88 (d, J = 15.1 Hz, 1H), 4.25 (d, J = 15.1 
Hz, 1H), 4.19 (s, 1H), 2.28 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ 163.9, 160.6, 146.2, 142.9, 135.0, 132.6, 129.8, 128.6, 128.5, 127.7, 126.3, 
125.9, 125.3, 124.7, 122.5, 122.0, 115.8, 115.5, 115.3, 115.0, 74.6 (q, J = 28.5 Hz), 58.1, 20.6. 
19F NMR (282 MHz, CDCl3) δ –73.05 (s, 1F), –79.01 (s, 3F). 
IR (film): ν (cm1) 3305, 3121, 3025, 2923, 1612, 1504, 1445, 1356, 1213, 1152, 959, 823, 769, 707, 
628, 523.  
 
(S)-3-(Di-p-tolylamino)-1,1,1-trifluoro-2-(1-(4-methoxyphenyl)-1H-imidazol-2-yl)propan-2-ol 
(16d') 
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Starting from 2-acyl imidazole 14d' (54.0 mg, 0.20 mmol) and amine 15a (126.8 mg, 0.60 mmol) 
according to the general procedure to give 16d' as a white solid (64.5 mg, 0.134 mmol, yield: 67%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 92% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 0.5 mL/min, 25 C, tr (minor) = 11.7 min, tr 
(major) = 18.1 min). []D20 = –73.2 (c 0.6, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.00–6.87 (m, 5H), 6.77–6.52 (m, 9H), 4.70 (d, J = 15.1 Hz, 1H), 4.28–
4.12 (m, 2H), 3.72 (s, 3H), 2.19 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ 159.5, 146.3, 142.9, 132.3, 131.6, 129.8, 128.0, 127.2, 125.1, 122.0, 113.4, 
74.9 (q, J = 28.5 Hz), 57.9, 55.4, 20.6. 
19F NMR (282 MHz, CDCl3) δ –78.85 (s, 3F). 
IR (film): ν (cm1) 3344, 3020, 2925, 1610, 1508, 1455, 1365, 1247, 1164, 1114, 1038, 980, 887, 813, 
743, 628, 568, 515.  
 
(S)-3-(Diphenylamino)-1,1,1-trifluoro-2-(1-phenyl-1H-imidazol-2-yl)propan-2-ol (16b) 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and amine 15b (109.9 mg, 0.60 mmol) 
according to the general procedure to give 16b as a pale yellow oil (50.8 mg, 0.12 mmol, yield: 60%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 98% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 98:2, flow rate 0.5 mL/min, 25 C, tr (major) = 20.4 min, tr (minor) 
= 33.0 min). []D20 = –67.6 (c 0.3, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.47–7.40 (m, 1H), 7.37–7.27 (m, 2H), 7.26–7.22 (m, 1H), 7.21–7.16 
(m, 3H), 7.04 (d, J = 1.2 Hz, 1H), 6.98 (ddt, J = 8.5, 6.9, 1.2 Hz, 2H), 6.89–6.79 (m, 6H), 6.74 (d, J = 
1.2 Hz, 1H), 4.89 (d, J = 15.2 Hz, 1H), 4.31 (d, J = 15.2 Hz, 1H), 4.06 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ 148.3, 142.5, 138.9, 129.3, 128.9, 128.64, 128.57, 128.4, 127.4, 126.9, 
125.8, 125.2, 124.9, 124.3 (q, J = 284.2 Hz), 123.0, 122.1, 75.1 (q, J = 28.5 Hz), 57.7. 
19F NMR (282 MHz, CDCl3) δ –78.50 (s, 3F). 
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IR (film): ν (cm1) 3335, 3059, 2923, 1592, 1493, 1452, 1365, 1307, 1258, 1162, 970, 917, 835, 752, 
688, 589, 500.  
HRMS (ESI, m/z) calcd for C24H20F3N3ONa [M+Na]+: 446.1462, found: 446.1453. 
 
(S)-1,1,1-Trifluoro-3-(phenyl(p-tolyl)amino)-2-(1-phenyl-1H-imidazol-2-yl)propan-2-ol (16c) 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and amine 15c (118.4 mg, 0.60 mmol) 
according to the general procedure to give 16c as a colorless oil (52.5 mg, 0.12 mmol, yield: 60%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 96% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 98:2, flow rate 0.5 mL/min, 25 C, tr (major) = 23.5 min, tr (minor) 
= 27.6 min). []D20 = –78.3 (c 0.3, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.42–7.25 (m, 3H), 7.23–7.14 (m, 2H), 7.10–7.01 (m, 3H), 6.98–6.85 (m, 
3H), 6.83–6.70 (m, 5H), 4.87 (d, J = 15.1 Hz, 1H), 4.31 (d, J = 15.1 Hz, 1H), 4.12 (s, 1H), 2.30 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 149.0, 145.6, 142.6, 139.0, 133.5, 130.0, 129.1, 128.6, 128.4, 127.4, 126.9, 
124.9, 124.3 (q, J = 284.2 Hz), 123.7, 121.9, 120.4, 75.0 (q, J = 28.5 Hz), 57.9, 20.7. 
19F NMR (282 MHz, CDCl3) δ –78.58 (s, 3F). 
IR (film): ν (cm1) 3330, 3034, 2924, 1594, 1498, 1454, 1364, 1258, 1166, 1117, 1050, 980, 884, 821, 
754, 690, 591. 
HRMS (ESI, m/z) calcd for C25H22F3N3ONa [M+Na]+: 460.1618, found: 460.1609. 
 
(S)-3-((4-Chlorophenyl)(p-tolyl)amino)-1,1,1-trifluoro-2-(1-phenyl-1H-imidazol-2-yl)propan-2-ol 
(16d) 
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Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and amine 15d (139.0 mg, 0.60 mmol) 
according to the general procedure to give 16d as a pale yellow oil (75.5 mg, 0.16 mmol, yield: 80%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 94% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 0.5 mL/min, 25 C, tr (minor) = 15.0 min, tr (major) 
= 16.7 min). []D20 = –95.4 (c 0.7, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.43–7.28 (m, 3H), 7.15–7.11 (m, 1H), 7.10–7.06 (m, 4H), 6.92–6.85 (m, 
2H), 6.81 (d, J = 1.2 Hz, 1H), 6.79–6.73 (m, 2H), 6.72–6.65 (m, 2H), 4.71 (d, J = 15.2 Hz, 1H), 4.28 (d, 
J = 15.2 Hz, 1H), 4.22 (s, 1H), 2.32 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 147.9, 145.1, 142.4, 138.6, 134.4, 130.2, 128.9, 128.8, 128.5, 127.3, 126.9, 
126.3, 125.2, 124.6, 124.2 (q, J = 284.2 Hz), 120.5, 75.3 (q, J = 28.5 Hz), 57.5, 20.7. 
19F NMR (282 MHz, CDCl3) δ –78.26 (s, 3F). 
IR (film): ν (cm1) 3300, 3050, 2928, 1686, 1594, 1491, 1366, 1257, 1166, 1122, 921, 809, 758, 697, 
625, 530.  
HRMS (ESI, m/z) calcd for C25H21ClF3N3ONa [M+Na]+: 494.1228, found: 494.1221. 
 
(S)-1,1,1-Trifluoro-3-((4-methoxyphenyl)(p-tolyl)amino)-2-(1-phenyl-1H-imidazol-2-yl)propan-2-
ol (16e) 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and amine 15e (136.4 mg, 0.60 mmol) 
according to the general procedure to give 16e as a pale yellow oil (66.4 mg, 0.142 mmol, yield: 71%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 97% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 0.5 mL/min, 25 C, tr (minor) = 14.1 min, tr 
(major) = 15.5 min). []D20 = –55.0 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.42–7.27 (m, 3H), 7.08 (d, J = 1.2 Hz, 1H), 7.02–6.90 (m, 4H), 6.87–
6.76 (m, 5H), 6.68–6.60 (m, 2H), 4.83 (d, J = 15.0 Hz, 1H), 4.44 (br s, 1H), 4.24 (d, J = 15.0 Hz, 1H), 
3.78 (s, 3H), 2.25 (s, 3H). 
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13C NMR (75 MHz, CDCl3) δ 156.5, 147.3, 142.7, 141.1, 138.9, 131.0, 129.6, 128.6, 128.4, 127.3, 126.9, 
125.9, 124.8, 124.3 (q, J = 284.2 Hz), 119.4, 114.7, 74.8 (q, J = 28.5 Hz), 58.3, 55.5, 20.4. 
19F NMR (282 MHz, CDCl3) δ –78.63 (s, 3F). 
IR (film): ν (cm1) 3313, 3117, 2928, 2842, 1676, 1605, 1503, 1454, 1359, 1241, 1165, 1035, 886, 814, 
757, 693, 643, 576.  
HRMS (ESI, m/z) calcd for C26H24F3N3O2Na [M+Na]+: 490.1724, found: 490.1715. 
 
(S)-3-(Bis(4-(tert-butyl)phenyl)amino)-1,1,1-trifluoro-2-(1-phenyl-1H-imidazol-2-yl)propan-2-ol 
(16f) 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and amine 15f (177.3 mg, 0.60 mmol) 
according to the general procedure to give 16f as a white solid (80.3 mg, 0.15 mmol, yield: 75%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak IC column, ee = 95% (HPLC: IC, 
254 nm, hexane/isopropanol = 98:2, flow rate 0.5 mL/min, 25 C, tr (minor) = 8.7 min, tr (major) = 9.4 
min). []D20 = –69.4 (c 0.8, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.40–7.18 (m, 7H), 7.05 (d, J = 1.2 Hz, 1H), 6.86–6.78 (m, 6H), 6.73 (d, 
J = 1.2 Hz, 1H), 4.91 (d, J = 15.0 Hz, 1H), 4.29 (d, J = 15.0 Hz, 1H), 4.12 (s, 1H), 1.31 (s, 18H). 
13C NMR (75 MHz, CDCl3) δ 145.8, 145.6, 142.7, 139.0, 128.5, 128.3, 127.5, 126.8, 126.1, 124.6, 124.3 
(q, J = 283.5 Hz), 121.6, 74.9 (q, J = 28.5 Hz), 58.0, 34.2, 31.4. 
19F NMR (282 MHz, CDCl3) δ –78.65 (s, 3F). 
IR (film): ν (cm1) 3304, 3043, 2956, 1601, 1503, 1366, 1168, 1117, 979, 827, 755, 696, 629, 555.  
HRMS (ESI, m/z) calcd for C32H37F3N3O [M+H]+: 536.2894, found: 536.2892. 
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(S)-3-(Bis(4-chlorophenyl)amino)-1,1,1-trifluoro-2-(1-phenyl-1H-imidazol-2-yl)propan-2-ol (16g) 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and amine 15g (151.3 mg, 0.60 mmol) 
according to the general procedure to give 16g as a white solid (62.0 mg, 0.126 mmol, yield: 63%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 91% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 99:1, flow rate 0.5 mL/min, 25 C, tr (major) = 33.6 min, tr (minor) 
= 36.2 min). []D20 = –105.0 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.49–7.43 (m, 1H), 7.42–7.38 (m, 1H), 7.36–7.31 (m, 1H), 7.22–7.18 (m, 
2H), 7.17–7.13 (m, 2H), 7.07 (d, J = 1.3 Hz, 1H), 6.95–6.90 (m, 2H), 6.83 (d, J = 1.2 Hz, 1H), 6.78–
6.72 (m, 4H), 4.68 (d, J = 15.3 Hz, 1H), 4.27 (d, J = 15.3 Hz, 1H), 4.09 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ 146.7, 142.1, 138.3, 129.4, 129.0, 128.9, 128.7, 128.6, 128.4, 127.3, 126.9, 
126.8, 125.8, 125.5, 125.2, 124.1 (q, J = 285.0 Hz), 123.3, 75.6 (q, J = 28.5 Hz), 57.2. 
19F NMR (282 MHz, CDCl3) δ –78.10 (s, 3F). 
IR (film): ν (cm1) 3312, 3049, 2921, 1684, 1592, 1488, 1359, 1317, 1252, 1120, 1048, 937, 896, 754, 
684, 618, 533.  
HRMS (ESI, m/z) calcd for C24H19Cl2F3N3O [M+H]+: 492.0852, 494.0822, found: 492.0855, 494.0824. 
 
(S)-1,1,1-Trifluoro-3-(naphthalen-2-yl(p-tolyl)amino)-2-(1-phenyl-1H-imidazol-2-yl)propan-2-ol 
(16h) 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and amine 15h (148.4 mg, 0.60 mmol) 
according to the general procedure to give 16h as a white solid (59.5 mg, 0.122 mmol, yield: 61%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 95% (HPLC: 
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AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 0.5 mL/min, 25 C, tr (minor) = 15.3 min, tr 
(major) = 23.2 min). []D20 = –67.0 (c 0.3, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.62 (d, J = 7.9 Hz, 1H), 7.55 (d, J = 8.9 Hz, 1H), 7.48 (d, J = 8.1 Hz, 
1H), 7.39–7.29 (m, 1H), 7.28–7.21 (m, 2H), 7.20–7.13 (m, 2H), 7.03–6.90 (m, 5H), 6.79–6.68 (m, 4H), 
6.65–6.62 (m, 1H), 4.94 (d, J = 15.1 Hz, 1H), 4.28 (d, J = 15.1 Hz, 1H), 4.00 (s, 1H), 2.23 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 145.9, 145.8, 142.8, 138.9, 134.2, 133.7, 130.1, 129.4, 128.8, 128.6, 128.5, 
128.3, 127.5, 127.4, 127.1, 126.8, 126.4, 124.9, 124.4, 124.3 (q, J = 284.3 Hz), 123.7, 121.6, 116.3, 74.9 
(q, J = 29.2 Hz), 57.9, 20.7. 
19F NMR (282 MHz, CDCl3) δ –78.86 (s, 3F). 
IR (film): ν (cm1) 3342, 3051, 2924, 1598, 1502, 1458, 1375, 1262, 1164, 1054, 957, 819, 750, 692, 
534. 
HRMS (ESI, m/z) calcd for C29H25F3N3O [M+H]+: 488.1944, found: 488.1946. 
 
2) Reactions of 2-acyl imidazole 14a with 2-aryl-1,2,3,4-tetrahydroisoquinolines 
 
General catalysis procedure. A dried 10 mL Schlenk tube was charged with the catalyst Λ-IrS (5 
mol%), 2-acyl imidazole 14a (0.20 mmol, 1.0 eq.), and the corresponding 2-aryl-1,2,3,4-
tetrahydroisoquinolines 17a-e (0.60 mmol, 3.0 eq.). The tube was purged with nitrogen and CHCl3 (0.40 
mL) was added via syringe. The reaction mixture was degassed via freeze-pump-thaw for three cycles. 
After the mixture was thoroughly degassed, the vial was sealed and positioned approximately 8 cm from 
24 W blue LEDs (18a) or approximately 5 cm from a 23 W CFL (18b-e). The reaction was stirred at 
room temperature for the indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, 
the mixture was diluted with CH2Cl2 (4 mL). The combined organic layers were concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexane = 1:20 
to 1:10) to afford the products 18a-e. Racemic samples were obtained by carrying out the reactions with 
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rac-IrS. The enantiomeric excess was determined by chiral HPLC analysis and dr values were 
determined by 1H NMR analysis of the crude product. Shown below is an example for the calculation 
of dr value (Figure 88). 
 
(S)-2,2,2-Trifluoro-1-((R)-2-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)-1-(1-phenyl-1H-imidazol-
2-yl)ethanol (18a) 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and 2-aryl-1,2,3,4-tetrahydroisoquinoline 17a 
(125.6 mg, 0.60 mmol) according to the general procedure to give 18a as a white solid (82.7 mg, 0.184 
mmol, yield: 92%, dr: 8:1). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-
H column, ee = 94% (major product) (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 0.5 
mL/min, 25 C, tr (minor) = 10.7 min, tr (major) = 17.1 min). []D20 = +15.3 (c 0.5, CH2Cl2). The dr 
value was determined by crude 1H NMR as shown below.  
 
Figure 88 1H NMR of the crude product 18a and its diastereomer 18a. Calculated dr = 8:1. 
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1H NMR (300 MHz, CDCl3) δ 7.40–7.32 (m, 1H), 7.30–7.22 (m, 1H), 7.19–7.16 (m, 1H), 7.16–7.04 (m, 
6H), 7.03–6.97 (m, 3H), 6.85 (d, J = 1.3 Hz, 1H), 6.83–6.76 (m, 1H), 6.65–6.55 (m, 2H), 5.41 (s, 1H), 
5.25 (br s, 1H), 3.84 (ddd, J = 13.2, 7.9, 5.6 Hz, 1H), 3.30 (dt, J = 12.4, 6.0 Hz, 1H), 2.88–2.55 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 150.4, 144.7, 138.5, 136.5, 131.6, 129.8–129.6 (m), 129.1, 128.7, 128.3, 
128.1, 127.7, 127.5, 126.9, 125.6, 125.5, 124.0 (q, J = 285.8 Hz), 121.0, 118.4, 79.9 (q, J = 27.0 Hz), 
63.8, 46.2, 26.0. 
19F NMR (282 MHz, CDCl3) δ –71.23 (s, 3F). 
IR (film): ν (cm1) 3341, 3018, 2974, 2738, 1688, 1593, 1492, 1454, 1385, 1309, 1250, 1162, 1110, 918, 
823, 754, 690, 593, 549.  
 
(S)-2,2,2-Trifluoro-1-(1-phenyl-1H-imidazol-2-yl)-1-((R)-2-(p-tolyl)-1,2,3,4-
tetrahydroisoquinolin-1-yl)ethanol (18b) 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and 2-aryl-1,2,3,4-tetrahydroisoquinoline 17b 
(134.0 mg, 0.60 mmol) according to the general procedure to give 18b as a colorless oil (52.8 mg, 0.114 
mmol, yield: 57%, dr: 4:1 (determined by the isolated yield of each isomer)). Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 97% (major product) (HPLC: AD-
H, 254 nm, hexane/isopropanol = 90:10, flow rate 0.5 mL/min, 25 C, tr (minor) = 10.5 min, tr (major) 
= 14.9 min). []D20 = +28.7 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.60–7.51 (m, 1H), 7.46–7.38 (m, 1H), 7.35–7.24 (m, 5H), 7.23–7.14 (m, 
3H), 7.07–6.98 (m, 3H), 6.72–6.62 (m, 2H), 5.63 (s, 1H), 5.55 (s, 1H), 3.93 (ddd, J = 13.1, 7.9, 5.5 Hz, 
1H), 3.39 (dt, J = 12.4, 5.9 Hz, 1H), 2.95–2.76 (m, 2H), 2.33 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 148.2, 144.9, 138.7, 136.5, 131.6, 130.9, 129.9–129.7 (m), 129.6, 128.6, 
128.3, 128.1, 127.6, 127.5, 127.0, 125.6, 125.3, 124.1 (q, J = 285.8 Hz), 119.1, 79.4 (q, J = 27.0 Hz), 
64.5, 46.6, 26.0, 20.4. 
19F NMR (282 MHz, CDCl3) δ –70.53 (s, 3F). 
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IR (film): ν (cm1) 3279, 3030, 2921, 2732, 1682, 1604, 1504, 1456, 1302, 1165, 1020, 921, 812, 748, 
690, 515. 
 
(S)-1-((R)-2-(4-Chlorophenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-
imidazol-2-yl)ethanol (18c) 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and 2-aryl-1,2,3,4-tetrahydroisoquinoline 17c 
(146.2 mg, 0.60 mmol) according to the general procedure to give 18c as a white solid (86.7 mg, 0.180 
mmol, yield: 90%, dr: 8:1). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-
H column, ee = 98% (major product) (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 0.5 
mL/min, 25 C, tr (minor) = 11.8 min, tr (major) = 16.3 min). []D20 = +11.4 (c 0.6, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.45–7.35 (m, 2H), 7.33–7.19 (m, 5H), 7.17–7.12 (m, 2H), 7.11–7.07 (m, 
3H), 6.96 (d, J = 1.3 Hz, 1H), 6.69–6.58 (m, 2H), 5.38 (s, 1H), 5.09 (s, 1H), 3.96 (ddd, J = 13.4, 8.0, 5.8 
Hz, 1H), 3.35 (dt, J = 12.5, 6.0 Hz, 1H), 2.95–2.60 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 149.0, 144.2, 138.3, 136.4, 131.1, 129.6–129.5 (m), 128.94, 128.89, 128.5, 
128.3, 127.9, 127.5, 126.9, 125.7, 125.6, 125.5, 123.9 (q, J = 285.8 Hz), 119.2, 80.4 (q, J = 27.0 Hz), 
63.1, 45.9, 25.8. 
19F NMR (282 MHz, CDCl3) δ –70.53 (s, 3F). 
IR (film): ν (cm1) 3298, 3057, 2921, 1673, 1593, 1488, 1393, 1250, 1166, 1005, 918, 818, 749, 691, 
508.  
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(S)-1-((R)-2-(4-Bromophenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-
imidazol-2-yl)ethanol (18d) 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and 2-aryl-1,2,3,4-tetrahydroisoquinoline 17d 
(172.9 mg, 0.60 mmol) according to the general procedure to give 18d as a white solid (102.5 mg, 0.194 
mmol, yield: 97%, dr: 10:1). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-
H column, ee = 98% (major product) (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 0.5 
mL/min, 25 C, tr (minor) = 12.4 min, tr (major) = 17.4 min). []D20 = +9.9 (c 0.6, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.43–7.33 (m, 2H), 7.31–7.23 (m, 4H), 7.22–7.18 (m, 3H), 7.15–7.07 (m, 
3H), 6.96 (d, J = 1.2 Hz, 1H), 6.66–6.48 (m, 2H), 5.38 (s, 1H), 5.02 (s, 1H), 3.96 (ddd, J = 13.4, 8.0, 5.8 
Hz, 1H), 3.36 (dt, J = 12.6, 6.0 Hz, 1H), 2.98–2.65 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 149.4, 144.1, 138.3, 136.4, 131.9, 131.1, 129.6–129.5 (m), 128.9, 128.5, 
128.3, 128.0, 127.5, 126.8, 125.7, 125.6, 123.9 (q, J = 285.8 Hz), 119.5, 112.8, 80.4 (q, J = 27.0 Hz), 
63.0, 45.7, 25.8. 
19F NMR (282 MHz, CDCl3) δ –70.67 (s, 3F). 
IR (film): ν (cm1) 3352, 3062, 2922, 2856, 1671, 1591, 1490, 1396, 1302, 1254, 1167, 918, 814, 751, 
691, 507.  
 
(S)-2,2,2-Trifluoro-1-((R)-2-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)-1-(1-phenyl-1H-
imidazol-2-yl)ethanol (18e) 
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Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol) and 2-aryl-1,2,3,4-tetrahydroisoquinoline 17e 
(136.4 mg, 0.60 mmol) according to the general procedure to give 18e as a white solid (83.0 mg, 0.178 
mmol, yield: 89%, dr: 8:1). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-
H column, ee = 97% (major product) (HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 0.5 
mL/min, 25 C, tr (minor) = 10.7 min, tr (major) = 15.3 min). []D20 = +17.7 (c 0.8, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.40–7.31 (m, 2H), 7.27–7.14 (m, 5H), 7.13–7.06 (m, 3H), 6.93 (d, J = 
1.2 Hz, 1H), 6.89–6.80 (m, 2H), 6.69–6.60 (m, 2H), 5.42 (s, 1H), 5.33 (s, 1H), 3.89 (ddd, J = 12.9, 8.3, 
5.5 Hz, 1H), 3.26 (dt, J = 12.3, 5.8 Hz, 1H), 2.92–2.59 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 159.4, 156.2, 147.03, 147.00, 144.5, 138.3, 136.5, 131.1, 129.6–129.4 
(m), 128.8, 128.4, 128.3, 127.7, 127.4, 126.6, 125.7, 125.5, 123.9 (q, J = 285.8 Hz), 121.0, 120.9, 115.7, 
115.4, 80.9 (q, J = 27.8 Hz), 64.0, 47.2, 25.8. 
19F NMR (282 MHz, CDCl3) δ –73.1 (s, 3F), –123.1 (s, 1F). 
IR (film): ν (cm1) 3340, 3039, 2922, 2710, 1682, 1598, 1501, 1385, 1162, 1108, 921, 823, 749, 692, 
516.  
 
3) Reactions of 2-acyl pyridines with amine 15a 
General catalysis procedure. A dried 10 mL Schlenk tube was charged with the catalyst Λ-IrS (3 or 5 
mol%), 2-acyl pyridines19 19a-c (0.20 mmol, 1.0 eq.) and amine 15a (0.60 mmol, 3.0 eq.). The tube was 
purged with nitrogen and CHCl3 (0.4 mL) was added via syringe. The reaction mixture was degassed 
via freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed 
and positioned approximately 8 cm from a 24 W blue LEDs. The reaction was stirred at room 
temperature for the indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, the 
mixture was diluted with CH2Cl2 (4 mL). The combined organic layers were concentrated under reduced 
pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexane = 1:50) to 
afford the products 20a-c. Racemic samples were obtained by carrying out the reactions with rac-IrS. 
The enantiomeric excess was determined by chiral HPLC analysis. 
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(S)-3-(Di-p-tolylamino)-1,1,1-trifluoro-2-(pyridin-2-yl)propan-2-ol (20a) 
 
Starting from 2-acyl pyridine 19a (35.0 mg, 0.20 mmol) and amine 15a (126.6 mg, 0.60 mmol) 
according to the general procedure to give 20a as a white solid (57.2 mg, 0.148 mmol, yield: 74%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 93% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 98:2, flow rate 0.5 mL/min, 25 C, tr (major) = 16.8 min, tr (minor) 
= 18.9 min). []D20 = –266.0 (c 0.3, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 8.52–8.43 (m, 1H), 7.43–7.29 (m, 1H), 7.23–7.09 (m, 2H), 6.93–6.84 (m, 
4H), 6.72–6.60 (m, 5H), 4.56 (s, 2H), 2.23 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ 152.5, 146.9, 146.8, 136.3, 131.0, 129.5, 125.1 (q, J = 285 Hz), 123.4, 
122.3–122.1 (m), 121.5, 77.4 (q, J = 26.3 Hz), 56.7, 20.5. 
19F NMR (282 MHz, CDCl3) δ –78.69 (s, 3F). 
IR (film): ν (cm1) 3292, 3023, 2925, 2863, 1605, 1508, 1412, 1367, 1258, 1169, 1052, 988, 916, 857, 
815, 769, 708, 661, 572, 520.  
HRMS (ESI, m/z) calcd for C22H22F3N2O [M+H]+: 387.1679, found: 387.1677. 
 
(S)-3-(Di-p-tolylamino)-1,1,1-trifluoro-2-(5-methylpyridin-2-yl)propan-2-ol (20b) 
 
Starting from 2-acyl pyridine 19b (37.8 mg, 0.20 mmol) and amine 15a (126.6 mg, 0.60 mmol) 
according to the general procedure to give 20b as a white solid (52.2 mg, 0.130 mmol, yield: 65%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 90% (HPLC: 
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AD-H, 254 nm, hexane/isopropanol = 98:2, flow rate 0.5 mL/min, 25 C, tr (major) = 15.7 min, tr (minor) 
= 18.0 min).  
1H NMR (300 MHz, CDCl3) δ 8.18 (dd, J = 2.0, 1.1 Hz, 1H), 7.05 (dd, J = 8.2, 2.1 Hz, 1H), 6.98–6.90 
(m, 1H), 6.85–6.77 (d, J = 8.3 Hz, 4H), 6.61–6.54 (m, 4H), 4.44 (s, 2H), 2.20 (s, 3H), 2.15 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ 149.7, 147.0, 146.8, 136.9, 133.3, 130.9, 129.4, 121.7, 121.63, 121.58, 
56.8, 20.5, 17.9. 
 
(S)-3-(Di-p-tolylamino)-1,1,1-trifluoro-2-(pyridin-2-yl)propan-2-ol (20c) 
 
Starting from 2-acyl pyridine 19c (37.8 mg, 0.20 mmol) and amine 15a (126.6 mg, 0.60 mmol) 
according to the general procedure to give 20c as a white solid (49.5 mg, 0.124 mmol, yield: 62%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 90% (HPLC: 
AD-H, 254 nm, hexane/isopropanol = 99:1, flow rate 0.5 mL/min, 25 C, tr (minor) = 12.1 min, tr (major) 
= 18.4 min).  
1H NMR (300 MHz, CDCl3) δ 8.29 (dd, J = 5.1, 0.9 Hz, 1H), 6.98–6.93 (m, 1H), 6.92–6.89 (m, 5H), 
6.71–6.63 (m, 4H), 4.64–4.45 (m, 2H), 2.23 (s, 6H), 2.05 (s, 3H). 
19F NMR (282 MHz, CDCl3) δ –78.90 (s, 3F). 
 
4) Reaction of 2-acyl imidazole 14a with amine 15a on gram scale 
 
A dried 25 mL Schlenk tube was charged with catalyst Λ-IrS (5 mol%), 2-acyl imidazole 14a (0.818 g, 
3.4 mmol), and amine 15a (2.152 g, 10.2 mmol). The tube was purged with nitrogen and CHCl3 (6.8 
mL) was added via syringe. The reaction mixture was degassed via freeze-pump-thaw for three cycles. 
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After the mixture was thoroughly degassed, the vial was sealed and positioned approximately 5 cm away 
from two 23 W CFL. The reaction was stirred at room temperature for 46 h under nitrogen atmosphere. 
Afterwards, the mixture was diluted with CH2Cl2. The combined organic layers were concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexane = 1:15) 
to afford the product 16a (0.915 g, 2.05 mmol, 60% yield with 98% ee) and unreacted starting material 
14a was recollected in a yield of 25%. 
 
Reaction setup: 
 
5.4.3 Mechanistic Investigations 
1) Substrate-coordinated iridium complex IrS-I 
 
The racemic substrate-coordinated iridium complex was obtained by reacting substrate 14a (12.1 mg, 
0.050 mmol) with racemic /-IrS (40.0 mg, 0.042 mmol) at 50 C overnight in CHCl3 (5.0 mL). After 
the slow addition of hexane (5.0 mL), crystals were collected after several days (32.2 mg, yield: 69%).  
1H NMR (300 MHz, CD2Cl2) δ 8.12–8.04 (m, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 8.6 Hz, 1H), 
7.83–7.72 (m, 2H), 7.57 (td, J = 8.7, 1.9 Hz, 2H), 7.44–7.25 (m, 5H), 7.12 (d, J = 1.5 Hz, 1H), 7.08–
6.95 (m, 2H), 6.94–6.77 (m, 3H), 6.58–6.45 (m, 2H), 6.29 (d, J = 7.6 Hz, 1H), 1.26 (s, 9H), 1.11 (s, 9H). 
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13C NMR (75 MHz, CD2Cl2) δ 183.1, 178.1, 151.7, 150.8, 150.2, 149.5, 147.2, 146.2, 143.2, 140.6, 
138.2, 136.5, 134.5, 134.3, 130.2, 129.8, 129.5, 129.1, 128.8, 128.4, 128.2, 127.4, 126.32, 126.29, 125.7, 
125.6, 124.8, 124.4, 123.5, 122.5, 122.2, 121.9, 121.7, 117.4, 115.7, 34.83, 34.79, 31.3, 30.6. 
 
2) Control reactions 
Performed in analogy to entry 8 of Table 7 (chapter 3.3), but in the presence of air. The reaction was 
performed in a 10 mL test tube under an atmosphere of air (air balloon). No product 16a could be 
detected by crude 1H NMR. 
 
3) Trapping experiments with alkenes and a diazodicarboxylate 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol), amine 15a (21.1 mg, 0.20 mmol) and (E)-
dibenzyl diazene-1,2-dicarboxylate (298.3 mg, 1.0 mol) according to the general procedure of 
synthesizing 16a-h to give 21 (88.2 mg, 0.172 mmol, yield: 86%) and product rac-16a was not observed. 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol), amine 15a (21.1 mg, 0.20 mmol), and ethyl 
acrylate (0.054 mL, 0.60 mol) according to the general procedure of synthesizing 16a-h to give 22a 
(30.0 mg, 0.101 mmol, yield: 51%) and rac-16a (24.6 mg, 0.054 mmol, yield: 27%). 
 
Starting from 2-acyl imidazole 14a (48.0 mg, 0.20 mmol), amine 15a (21.1 mg, 0.20 mmol), and 
acrylonitrile (0.066 mL, 1.0 mol) according to the general procedure of synthesizing 16a-h to give 22b 
(23.1 mg, 0.088 mmol, yield: 44%) and rac-16a (yield <10%). 
 
Dibenzyl 1-((di-p-tolylamino)methyl)hydrazine-1,2-dicarboxylate (21) 
 
1H NMR (300 MHz, CDCl3) δ 7.31–7.10 (m, 11H), 6.98–6.85 (m, 4H), 6.83–6.70 (m, 3H), 5.43–4.72 
(m, 6H), 2.17 (s, 6H). 
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13C NMR (75 MHz, CDCl3) δ 155.5, 144.4, 135.6, 131.6, 129.8, 129.3, 128.6, 128.47, 128.45, 128.2, 
128.0, 125.7, 121.0, 67.6, 20.6. 
HRMS (ESI, m/z) calcd for C31H31N3O4Na [M+Na]+: 532.2207, found: 532.2210. 
 
Methyl 6-methyl-1-(p-tolyl)-1,2,3,4-tetrahydroquinoline-4-carboxylate (22a) 
 
1H NMR (300 MHz, CDCl3) δ 7.20–7.08 (m, 4H), 7.00–6.96 (m, 1H), 6.80 (dd, J = 8.4, 2.2 Hz, 1H), 
6.63–6.55 (m, 1H), 3.84 (t, J = 5.2 Hz, 1H), 3.75 (s, 3H), 3.73–3.65 (m, 1H), 3.59–3.50 (m, 1H), 2.39–
2.28 (m, 4H), 2.23 (s, 3H), 2.21–2.07 (m, 1H). 
13C NMR (75 MHz, CDCl3) δ 174.7, 145.8, 142.4, 133.8, 130.2, 130.1, 128.5, 127.1, 125.3, 119.9, 116.1, 
52.1, 48.2, 42.6, 25.3, 20.9, 20.4. 
HRMS (ESI, m/z) calcd for C19H22NO2 [M+H]+: 296.1645, found: 296.1645. 
 
6-Methyl-1-(p-tolyl)-1,2,3,4-tetrahydroquinoline-4-carbonitrile (22b) 
 
1H NMR (300 MHz, CDCl3) δ 7.23–7.16 (m, 2H), 7.14–7.07 (m, 3H), 6.84 (dd, J = 8.5, 2.1 Hz, 1H), 
6.56 (d, J = 8.4 Hz, 1H), 4.03 (t, J = 5.9 Hz, 1H), 3.82–3.70 (m, 1H), 3.67–3.53 (m, 1H), 2.42–2.29 (m, 
5H), 2.25 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 144.9, 142.0, 134.6, 130.3, 129.6, 129.4, 127.9, 125.4, 121.2, 116.2, 116.1, 
48.4, 29.3, 26.4, 20.9, 20.2. 
HRMS (ESI, m/z) calcd for C18H19N2 [M+H]+: 263.1543, found: 263.1543. 
 
4) Trapping experiments with single electron oxidants 
A dried 10 mL Schlenk tube was charged with the catalyst Δ/Λ-IrS (3 mol%), 2-acyl imidazole 14a 
(0.20 mmol, 1.0 eq), amine 15a (0.60 mmol, 3.0 eq), and the corresponding single electron oxidant (5 
mol% or 1.0 eq). The tube was purged with nitrogen and CHCl3 (0.40 mL) was added via syringe. The 
Chapter 5: Experimental Part 
151 
 
reaction mixture was degassed via freeze-pump-thaw for three cycles. After the mixture was thoroughly 
degassed, the vial was sealed and positioned in the dark. The reaction was stirred at room temperature 
for 22 h under nitrogen atmosphere.  
No product 16b could be detected by 1H NMR when Cp2FePF6 or (BrC6H4)3NSbCl6 or Ce(NH4)2(NO3)6 
(5 mol% or 1.0 eq.) was used as single electron oxidant. 
 
5) Quantum yield measurement 
The quantum yield was measured by standard ferrioxalate actinometry.20 A 150 W Xenon lamp (50% 
of light intensity, 420±5 nm bandpass filter high transmittance) was used as the light source. The 
measured method was designed according to published procedures with modifications.21, 22 
The solutions were prepared under the red light (1.1 W red LEDs) and stored in the dark: 
Potassium ferrioxalate solution (0.15 M): 736.9 mg of potassium ferrioxalate hydrate was dissolved 
in 10 mL of 0.05 M H2SO4. 
Buffered solution of phenanthroline: 50 mg of 1,10-phenanthroline and 11.25 g of sodium acetate 
were dissolved in 50 mL of 0.5 M H2SO4. 
 
a) Measurement of light intensity at 420 nm 
1 mL of the ferrioxalate solution was added to a quartz cuvette (l = 10 mm). The actinometry solution 
was irradiated with 150 W Xenon lamp (50% of light intensity, 420 nm ± 5 nm bandpass filter high 
transmittance) for specified time intervals (30s, 60s, 90s, 120s). After irradiation, 175 μL of the 
phenanthroline solution was added to the cuvette. The solution was kept in dark for 30 min to make sure 
the complete coordination. The absorbance of the actinometry solution was monitored at 510 nm. The 
absorbance of a non-irradiated (in dark) sample was also measured at 510 nm. 
t/s 30 60 90 120 
ΔA/a.u. 0.350 0.738 1.108 1.399 
The moles of Fe2+ formed were determined using Beer’s Law (eq 1): 
 
V is the final volume (0.01175 L) after complexation with phenanthroline;  
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 ΔA (510 nm) is the optical difference in absorbance between the irradiated and non-irradiated 
solutions;  
 l is the path length (1 cm);  
 ε(510 nm) is the molar absorptivity of Fe(phen)32+(11100 L·mol-1·cm-1). 
The photon flux (defined as the number of photons per second per unit area) can be calculated (eq 2): 
 
 
 Φ is the quantum yield for the ferrioxalate actinometer (1.05 for a 0.15 M solution at 412 nm; 1.04 
for a 0.15 M solution at 422 nm; 1.03 for a 0.15 M solution at 433 nm);20 
 f is the fraction of light absorbed which was calculated using eq 3, where A is the absorbance of 
above ferrioxalate solution at 420 nm (as shown in Figure 90, A > 3, indicating f is > 0.999≈1). 
 
Figure 89 The moles of Fe2+ are plotted as a function of time. 
 
According to the equation, photon flux can be calculated as follows: 
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Figure 90 Absorbance of the ferrioxalate actinometer solution (0.15 M). 
 
b) Measurement of quantum yield 
Model reaction: 
 
A screw-top cuvette (10.0 mm) was charged with the catalyst rac-IrS (3 mol%), 2-acyl imidazole 14a 
(96.0 mg, 0.40 mmol), amine 15a (253.6 mg, 1.20 mmol), 0.8 mL CHCl3 (0.5 M), and a small magnetic 
stir bar. The cuvette was degassed with a nitrogen stream for 10 min. After thoroughly degassed, the 
reaction mixture was stirred and irradiated with 150 W Xenon lamp (50% of light intensity, 420 nm ± 5 
nm bandpass filter high transmittance) for 50400 s (14 h). After irradiation, the reaction mixture was 
passed through a short silica gel column. The yield of product formed was measured by 1H NMR with 
trimethyl(phenyl)silane as internal standard. The quantum yield calculation is then as following:  
 
 
5.4.4 Single-Crystal X-Ray Diffraction Studies  
Crystals of the (S)-16g and (S,R)-18a were obtained from a solution of the compound in CH2Cl2 layered 
with n-hexane. Crystal data and details of the structure determination are presented in Appendices 6.7. 
The absolute configurature was determined.   
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5.5 Catalytic Asymmetric C(sp3)-H Functionalization under Photoredox 
Conditions by Radical Translocation and Stereocontrolled Alkene Addition 
5.5.1 Synthesis of Substrates 
α,β-Unsaturated 2-acyl pyrazoles 24a-l23, N-alkoxyphthalimides 25i and 25j24 were synthesized 
according to published procedures without any further change, while N-alkoxyphthalimides 25a-h, 25k 
and 25l were synthesized according to the procedure with some modifications.24  
General procedure for the synthesis of N-alkoxyphthalimides. 
 
To a solution of the corresponding alcohol (1.0 eq.), PPh3 (1.2 eq.) and N-hydroxyphthalimide (1.2 eq.) 
in THF (0.2 M) was added diisopropyl azodicarboxylate (2.2 M in toluene, 1.2 eq.) over 5 min at room 
temperature under nitrogen atmosphere. The reaction mixture was stirred overnight at ambient 
temperature. Afterwards, the reaction was quenched with aqueous saturated NaHCO3 and extracted with 
EtOAc. The organic layer was washed with brine. The combined organic layers were dried over 
anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (EtOAc/hexane = 1:10 to 1:5) to produce the N-alkoxyphthalimides 25a-
h, 25k and 25l. 
 
2-(2-Methoxyethoxy)isoindoline-1,3-dione (25a) 
 
Following the general procedure, 2-methoxyethanol (0.761 g, 10.0 mmol) was converted to N-
alkoxyphthalimide 25a (1.858 g, 8.4 mmol, yield: 84%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.83 (dd, J = 5.5, 3.1 Hz, 2H), 7.74 (dd, J = 5.5, 3.1 Hz, 2H), 4.39–4.31 
(m, 2H), 3.80–3.72 (m, 2H), 3.37 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 163.4, 134.4, 129.0, 123.5, 70.4, 59.1. 
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All spectroscopic data were in agreement with the literature.24 
 
2-(2-Isopropoxyethoxy)isoindoline-1,3-dione (25b) 
 
Following the general procedure, 2-isopropoxyethanol (0.520 g, 5.0 mmol) was converted to N-
alkoxyphthalimide 25b (1.122 g, 4.5 mmol, yield: 90%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.83 (dd, J = 5.5, 3.1 Hz, 2H), 7.73 (dd, J = 5.5, 3.1 Hz, 2H), 4.40–4.32 
(m, 2H), 3.83–3.70 (m, 2H), 3.59 (p, J = 6.1 Hz, 1H), 1.05 (d, J = 6.1 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ 163.5, 134.3, 129.1, 123.4, 72.1, 66.4, 21.8. 
IR (film): ν (cm1) 2969, 2875, 1787, 1726, 1611, 1464, 1417, 1373, 1329, 1283, 1230, 1184, 1127, 
1091, 979, 876, 787, 695, 624, 569, 516. 
HRMS (ESI, m/z) calcd for C13H15NO4Na [M+Na]+: 272.0893, found: 272.0894. 
 
2-(2-(Cyclopentyloxy)ethoxy)isoindoline-1,3-dione (25c) 
 
Following the general procedure, 2-(cyclopentyloxy)ethanol (0.978 g, 5.0 mmol) was converted to N-
alkoxyphthalimide 25c (1.211 g, 4.4 mmol, yield: 88%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.83 (dd, J = 5.5, 3.1 Hz, 2H), 7.73 (dd, J = 5.5, 3.1 Hz, 2H), 4.42–4.29 
(m, 2H), 3.95–3.82 (m, 1H), 3.80–3.69 (m, 2H), 1.73–1.31 (m, 8H). 
13C NMR (75 MHz, CDCl3) δ 163.5, 134.3, 129.1, 123.4, 82.1, 67.2, 32.0, 23.5. 
IR (film): ν (cm1) 2951, 2868, 1788, 1727, 1611, 1462, 1369, 1290, 1235, 1183, 1116, 1026, 876, 786, 
700, 518. 
HRMS (ESI, m/z) calcd for C15H17NO4Na [M+Na]+: 298.1050, found: 298.1050. 
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2-(2-((2,3-Dihydro-1H-inden-2-yl)oxy)ethoxy)isoindoline-1,3-dione (25d) 
 
Following the general procedure, 2-((1-tosylazetidin-3-yl)oxy)ethanol (0.660 g, 3.7 mmol) was 
converted to N-alkoxyphthalimide 25d (1.135 g, 3.5 mmol, yield: 95%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.90–7.62 (m, 4H), 7.19–7.05 (d, J = 1.5 Hz, 4H), 4.49–4.29 (m, 3H), 
3.96–3.77 (m, 2H), 3.09 (dd, J = 16.2, 6.6 Hz, 2H), 2.87 (dd, J = 16.2, 4.6 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 163.4, 140.7, 134.3, 128.9, 126.4, 124.6, 123.4, 81.0, 67.5, 39.0. 
All spectroscopic data were in agreement with the literature.24 
 
2-(2-(Cyclohexyloxy)ethoxy)isoindoline-1,3-dione (25e) 
 
Following the general procedure, 2-(cyclohexyloxy)ethanol (0.596 g, 4.1 mmol) was converted to N-
alkoxyphthalimide 25e (0.664 g, 2.3 mmol, yield: 56%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.82 (dd, J = 5.5, 3.1 Hz, 2H), 7.73 (dd, J = 5.5, 3.1 Hz, 2H), 4.42–4.28 
(m, 2H), 3.88–3.65 (m, 2H), 3.35–3.15 (m, 1H), 1.77 (dq, J = 13.1, 8.4, 6.3 Hz, 2H), 1.68–1.57 (m, 2H), 
1.52–1.36 (m, 1H), 1.30–1.01 (m, 5H). 
13C NMR (75 MHz, CDCl3) δ 163.4, 134.3, 129.1, 123.4, 77.9, 66.1, 31.8, 25.7, 23.9.  
IR (film): ν (cm1) 2928, 2853, 1784, 1720, 1609, 1453, 1369, 1241, 1181, 1119, 1027, 983, 951, 851, 
790, 698, 693, 609, 513.  
HRMS (ESI, m/z) calcd for C16H19NO4Na [M+Na]+: 312.1206, found: 312.1206. 
 
2-(2-(Cycloheptyloxy)ethoxy)isoindoline-1,3-dione (25f) 
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Following the general procedure, 2-(cycloheptyloxy)ethanol (0.316 g, 2.0 mmol) was converted to N-
alkoxyphthalimide 25f (0.371 g, 1.2 mmol, yield: 61%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.86–7.78 (m, 2H), 7.75–7.68 (m, 2H), 4.40–4.29 (m, 2H), 3.79–3.70 (m, 
2H), 3.50–3.35 (m, 1H), 1.88–1.71 (m, 2H), 1.60–1.38 (m, 8H), 1.34–1.18 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 163.4, 134.3, 129.1, 123.3, 80.6, 77.3, 66.6, 33.5, 28.3, 22.8. 
IR (film): ν (cm1) 2920, 2876, 1723, 1609, 1441, 1360, 1228, 1177, 1110, 1025，1000, 987, 851, 789, 
690, 610, 513. 
HRMS (ESI, m/z) calcd for C17H21NO4Na [M+Na]+: 326.1363, found: 326.1363. 
 
2-(2-((1-Tosylpiperidin-4-yl)oxy)ethoxy)isoindoline-1,3-dione (25g) 
 
Following the general procedure, 2-((1-tosylpiperidin-4-yl)oxy)ethanol (0.596 g, 4.0 mmol) was 
converted to N-alkoxyphthalimide 25g (1.422 g, 3.2 mmol, yield: 80%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.83–7.71 (m, 4H), 7.61 (d, J = 8.2 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 
4.31–4.26 (m, 2H), 3.79–3.67 (m, 2H), 3.46–3.34 (m, 1H), 3.26–3.10 (m, 2H), 2.90–2.74 (m, 2H), 2.42 
(s, 3H), 1.92–1.74 (m, 2H), 1.68–1.54 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 163.3, 143.4, 134.4, 133.5, 129.6, 128.9, 127.6, 123.4, 77.2, 73.5, 66.4, 
43.1, 30.1, 21.5. 
IR (film): ν (cm1) 2953, 2860, 1833, 1786, 1726, 1599, 1460, 1374, 1332, 1249, 1149, 1112, 1031, 938, 
878, 800, 698, 647, 543. 
HRMS (ESI, m/z) calcd for C22H24N2O6SNa [M+Na]+: 467.1247, found: 467.1244. 
 
2-(2-((1-Tosylazetidin-3-yl)oxy)ethoxy)isoindoline-1,3-dione (25h) 
 
Following the general procedure, 2-((1-tosylazetidin-3-yl)oxy)ethanol (0.600 g, 2.2 mmol) was 
converted to N-alkoxyphthalimide 25h (0.559 g, 1.3 mmol, yield: 61%) as a white solid. 
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1H NMR (300 MHz, CDCl3) δ 7.89–7.77 (m, 4H), 7.74 (d, J = 8.3 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 
4.32–4.19 (m, 3H), 4.03–3.92 (m, 2H), 3.72–3.67 (m, 2H), 3.66–3.58 (m, 2H), 2.48 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 163.3, 144.0, 134.6, 131.7, 129.7, 128.8, 128.4, 123.6, 67.4, 67.3, 57.9, 
21.6. 
IR (film): ν (cm1) 3046, 2998, 2951, 2873, 1791, 1721, 1600, 1463, 1367, 1336, 1296, 1155, 1125, 
1090, 1004, 956, 923, 872, 809, 748, 700, 665, 601, 745, 513. 
HRMS (ESI, m/z) calcd for C20H20N2O6SNa [M+Na]+: 439.0931, found: 439.0934. 
 
2-(2-(Methylthio)ethoxy)isoindoline-1,3-dione (25k) 
 
Following the general procedure, 2-(methylthio)ethanol (0.461 g, 5.0 mmol) was converted to N-
alkoxyphthalimide 25k (1.103 g, 4.65 mmol, yield: 93%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.85–7.60 (m, 4H), 4.27 (t, J = 7.2 Hz, 2H), 2.80 (t, J = 7.2 Hz, 2H), 2.10 
(s, 3H). 
13C NMR (75 MHz, CDCl3) δ 163.2, 134.3, 128.6, 123.3, 76.9, 31.3, 15.7. 
IR (film): ν (cm1) 2922, 1780, 1721, 1611, 1458, 1362, 1293, 1181, 1118, 1075, 1021, 980, 872, 793, 
759, 699, 597, 553, 515.  
HRMS (ESI, m/z) calcd for C11H11NO3SNa [M+Na]+: 260.0352, found: 260.0352. 
 
2-(2-(Isopropylthio)ethoxy)isoindoline-1,3-dione (25l) 
 
Following the general procedure, 2-(isopropylthio)ethanol (0.601 g, 5.0 mmol) was converted to N-
alkoxyphthalimide 25l (1.035 g, 3.9 mmol, yield: 78%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.92–7.80 (m, 2H), 7.78–7.70 (m, 2H), 4.32 (t, J = 7.5 Hz, 2H), 3.10–
2.85 (m, 3H), 1.28 (d, J = 6.7 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ 163.5, 134.5, 128.9, 123.6, 77.6, 35.4, 28.1, 23.5. 
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IR (film): ν (cm1) 2960, 2920, 2864, 1781, 1717, 1610, 1459, 1366, 1288, 1231, 1181, 1124, 1077, 
1014, 976, 872, 784, 696, 606, 550, 515. 
HRMS (ESI, m/z) calcd for C13H15NO3SNa [M+Na]+: 288.0665, found: 288.0665. 
 
5.5.2 Rhodium-Catalyzed Photoredox Reactions 
 
General catalysis procedure. A dried 10 mL Schlenk tube was charged with the catalyst fac-[Ir(ppy)3] 
(1 mol%), Δ-RhS (8 mol%), Hantzsch ester (0.30 mmol, 1.5 eq.), 2-acyl pyrazoles 24a-j (0.40 mmol, 
2.0 eq.), and the corresponding N-alkoxyphthalimides 25a-l (0.20 mmol, 1.0 eq.). The tube was purged 
with nitrogen and THF (1.0 mL) was added via syringe. The reaction mixture was degassed via freeze-
pump-thaw for three cycles. After the mixture was thoroughly degassed, the tube was sealed and 
positioned approximately 5 cm from a 23 W compact fluorescent lamp (CFL). The reaction was stirred 
at room temperature for the indicated time (monitored by TLC) under nitrogen atmosphere. Afterwards, 
the mixture was diluted with DCM (2 mL). The combined organic layers were concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (EtOAc/hexane = 1:10 
to 1:5) to afford the products 26a-j, 26m-y. Racemic samples were obtained by carrying out the reactions 
with rac-RhS. The enantiomeric excess was determined by chiral HPLC analysis. 
Exemplary reaction setup: 
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(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-(2-hydroxyethoxy)-3-methylbutan-1-one (26a) 
 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25a (44.2 mg, 0.20 
mmol) according to the general procedure to give 26a as a pale yellow oil (33.6 mg, 0.140 mmol, yield: 
70%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 92% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 8.1 min, 
tr (minor) = 8.7 min). []D25 = +14.5 (c 0.4, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 5.94 (s, 1H), 3.68–3.60 (m, 2H), 3.56–3.46 (m, 2H), 3.44–3.32 (m, 2H), 
3.24 (dd, J = 15.9, 6.8 Hz, 1H), 2.90 (dd, J = 15.9, 6.8 Hz, 1H), 2.56–2.46 (m, 4H), 2.44–2.37 (m, 1H), 
2.22 (s, 3H), 1.02 (d, J = 6.8 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.5, 151.8, 144.0, 111.0, 75.8, 72.1, 61.7, 39.5, 30.6, 17.2, 14.6, 13.7. 
IR (film): ν (cm1) 3477, 2993, 2923, 2861, 1724, 1582, 1479, 1445, 1384, 1345, 1251, 1212, 1117, 
1064, 1028, 995, 968, 893, 845, 738, 695, 614, 589, 554, 507. 
HRMS (ESI, m/z) calcd for C12H20N2O3Na [M+Na]+: 263.1366, found: 263.1367. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-((2-hydroxyethoxy)methyl)pentan-1-one (26b) 
 
Starting from 2-acyl pyrazole 24b (71.3 mg, 0.40 mmol) and N-alkoxyphthalimide 25a (44.2 mg, 0.20 
mmol) according to the general procedure to give 26b as a pale yellow oil (34.1 mg, 0.134 mmol, yield: 
67%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 93% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 7.1 min, 
tr (minor) = 7.7 min). []D25 = +14.0 (c 0.3, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 5.95 (s, 1H), 3.65–3.56 (m, 2H), 3.54–3.35 (m, 4H), 3.22 (dd, J = 15.9, 
8.0 Hz, 1H), 2.99 (dd, J = 15.9, 5.4 Hz, 1H), 2.53 (s, 3H), 2.41–2.26 (m, 2H), 2.22 (s, 3H), 1.55–1.35 
(m, 2H), 0.95 (t, J = 7.5 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.9, 151.8, 144.0, 111.1, 73.7, 72.1, 61.7, 37.5, 37.3, 24.5, 14.6, 13.7, 
11.4. 
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IR (film): ν (cm1) 3404, 2925, 2867, 1721, 1581, 1457, 1378, 1337, 1257, 1119, 1063, 999, 964, 890, 
804, 744, 652, 588.  
HRMS (ESI, m/z) calcd for C13H22N2O3Na [M+Na]+: 277.1523, found: 277.1523. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-((2-hydroxyethoxy)methyl)hexan-1-one (26c) 
 
Starting from 2-acyl pyrazole 24c (76.9 mg, 0.40 mmol) and N-alkoxyphthalimide 25a (44.2 mg, 0.20 
mmol) according to the general procedure to give 26c as a pale yellow oil (35.0 mg, 0.130 mmol, yield: 
65%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 92% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 6.5 min, 
tr (minor) = 6.8 min). []D25 = +27.5 (c 0.2, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 5.95 (s, 1H), 3.64–3.51 (m, 2H), 3.53–3.44 (m, 3H), 3.43–3.35 (m, 4H), 
3.21 (dd, J = 15.8, 8.1 Hz, 1H), 2.99 (dd, J = 15.8, 5.2 Hz, 1H), 2.53 (s, 3H), 2.48–2.28 (m, 2H), 2.22 
(s, 3H), 1.43–1.32 (m, 4H), 0.96–0.87 (m, 3H). 
13C NMR (75 MHz, CDCl3) 174.0, 151.8, 144.0, 111.1, 74.2, 72.1, 61.7, 37.9, 35.5, 34.0, 20.1, 14.6, 
14.2, 13.7. 
IR (film): ν (cm1) 3433, 2955, 2926, 2866, 1721, 1581, 1458, 1409, 1378, 1333, 1257, 1174, 1119, 
1061, 992, 963, 890, 802, 742, 649, 589, 530. 
HRMS (ESI, m/z) calcd for C14H24N2O3Na [M+Na]+: 291.1679, found: 291.1680. 
 
(S)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-((2-hydroxyethoxy)methyl)-4-methylpentan-1-one (26d) 
 
Starting from 2-acyl pyrazole 24d (78.9 mg, 0.40 mmol) and N-alkoxyphthalimide 25a (44.2 mg, 0.20 
mmol) according to the general procedure to give 26d as a pale yellow oil (33.3 mg, 0.124 mmol, yield: 
62%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 94% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 6.8 min, 
tr (minor) = 7.5 min). []D25 = –8.4 (c 0.3, CH2Cl2). 
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1H NMR (300 MHz, CDCl3) δ 5.94 (s, 1H), 3.61–3.38 (m, 6H), 3.20 (dd, J = 15.7, 8.8 Hz, 1H), 2.98 
(dd, J = 15.7, 4.4 Hz, 1H), 2.52 (s, 3H), 2.45–2.26 (m, 2H), 2.22 (s, 3H), 1.91–1.73 (m, 1H), 0.95 (d, J 
= 6.9 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ 174.4, 151.8, 144.0, 111.1, 72.6, 72.1, 61.6, 41.5, 35.2, 29.1, 19.8, 19.6, 
14.6, 13.7. 
IR (film): ν (cm1) 3435, 2950, 2923, 2876, 1725, 1578, 1467, 1411, 1389, 1333, 1257, 1170, 1119, 
1065, 998, 956, 891, 802, 743, 649, 530. 
HRMS (ESI, m/z) calcd for C14H24N2O3Na: [M+Na]+: 291.1679, found: 291.1680. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-((2-hydroxyethoxy)methyl)-5-methylhexan-1-one (26e) 
 
Starting from 2-acyl pyrazole 24e (82.5 mg, 0.40 mmol) and N-alkoxyphthalimide 25a (44.2 mg, 0.20 
mmol) according to the general procedure to give 26e as a pale yellow solid (35.0 mg, 0.124 mmol, 
yield: 62%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 
91% (HPLC: OD-H, 254 nm, hexane/isopropanol = 98:2, flow rate 0.5 mL/min, 25 C, tr (major) = 18.9 
min, tr (minor) = 19.6 min). []D25 = +8.0 (c 0.4, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 5.95 (s, 1H), 3.66–3.55 (m, 2H), 3.53–3.41 (m, 3H), 3.40–3.31 (m, 1H), 
3.17 (dd, J = 15.5, 8.5 Hz, 1H), 2.99 (dd, J = 15.5, 4.7 Hz, 1H), 2.58–2.32 (m, 5H), 2.22 (s, 3H), 1.77–
1.58 (m, J = 6.7 Hz, 1H), 1.24 (t, J = 7.1 Hz, 2H), 0.92 (d, J = 6.6 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ 174.1, 151.8, 144.0, 111.1, 74.5, 72.2, 61.7, 41.2, 38.4, 33.8, 25.4, 22.8, 
22.6, 14.6, 13.7. 
IR (film): ν (cm1) 3435, 2953, 2927, 2868, 1722, 1622, 1580, 1464, 1410, 1377, 1333, 1258, 1170, 
1119, 1058, 1000, 962, 888, 803, 746, 648, 588, 550. 
HRMS (ESI, m/z) calcd for C15H26N2O3Na [M+Na]+: 305.1836, found: 305.1837. 
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(S)-3-Cyclohexyl-1-(3,5-dimethyl-1H-pyrazol-1-yl)-4-(2-hydroxyethoxy)butan-1-one (26f) 
 
Starting from 2-acyl pyrazole 24f (92.9 mg, 0.40 mmol) and N-alkoxyphthalimide 25a (44.2 mg, 0.20 
mmol) according to the general procedure to give 26f as a white solid (45.6 mg, 0.148 mmol, yield: 
74%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 91% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 6.1 min, 
tr (minor) = 6.8 min). []D25 = –4.3 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 5.94 (s, 1H), 3.62–3.49 (m, 3H), 3.48–3.42 (m, 2H), 3.22 (dd, J = 15.8, 
8.7 Hz, 1H), 3.00 (dd, J = 15.8, 4.5 Hz, 1H), 2.52 (s, 3H), 2.46–2.27 (m, 2H), 2.22 (s, 3H), 1.81–1.59 
(m, 5H), 1.54–1.38 (m, 1H), 1.34–0.98 (m, 6H). 
13C NMR (75 MHz, CDCl3) δ 174.5, 151.8, 144.0, 111.0, 72.5, 72.1, 61.6, 40.9, 39.5, 35.6, 30.3, 30.2, 
26.63, 26.61, 26.5, 14.6, 13.7. 
IR (film): ν (cm1) 3424, 2922, 2853, 1723, 1581, 1446, 1410, 1378, 1333, 1237, 1172, 1118, 1057, 963, 
889, 801, 748, 649, 588. 
HRMS (ESI, m/z) calcd for C17H28N2O3Na [M+Na]+: 331.1992, found: 331.1994. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-ethoxy-4-(2-hydroxyethoxy)butan-1-one (26g) 
 
Starting from 2-acyl pyrazole 24g (77.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25a (44.2 mg, 0.20 
mmol) according to the general procedure to give 26g as a pale yellow oil (43.2 mg, 0.160 mmol, yield: 
80%). Enantiomeric excess established by HPLC analysis using a Chiralpak IC column, ee = 97% 
(HPLC: IC, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 30.0 min, tr 
(minor) = 32.3 min). []D25 = –11.0 (c 0.5, CH2Cl2). 
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1H NMR (300 MHz, CDCl3) δ 5.94 (s, 1H), 4.21–4.05 (m, 1H), 3.72–3.66 (m, 2H), 3.64–3.55 (m, 5H), 
3.41 (dd, J = 16.0, 6.5 Hz, 1H), 3.29 (dd, J = 16.1, 6.1 Hz, 1H), 3.15 (q, J = 7.3, 6.3 Hz, 1H), 2.52 (s, 
3H), 2.31–2.11 (m, 4H), 1.16 (t, J = 7.0 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 171.8, 152.0, 144.0, 111.2, 74.9, 72.8, 72.7, 65.5, 61.7, 38.2, 15.4, 14.4, 
13.7. 
IR (film): ν (cm1) 3414, 2971, 2925, 2873, 1721, 1582, 1440, 1380, 1335, 1249, 1121, 1063, 995, 963, 
846, 747, 662, 592, 588. 
HRMS (ESI, m/z) calcd for C13H22N2O4Na [M+Na]+: 293.1472, found: 293.1473. 
 
(R)-3-(Benzyloxy)-1-(3,5-dimethyl-1H-pyrazol-1-yl)-4-(2-hydroxyethoxy)butan-1-one (26h) 
 
Starting from 2-acyl pyrazole 24h (102.5 mg, 0.40 mmol) and N-alkoxyphthalimide 25a (44.2 mg, 0.20 
mmol) according to the general procedure to give 26h as a white solid (52.0 mg, 0.156 mmol, yield: 
78%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 97% 
(HPLC: AD-H, 254 nm, hexane/isopropanol = 94:6, flow rate 1.0 mL/min, 25 C, tr (minor) = 20.0 min, 
tr (major) = 22.0 min). []D25 = –6.1 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.41–7.20 (m, 5H), 5.99 (s, 1H), 4.78–4.64 (m, 2H), 4.36–4.25 (m, 1H), 
3.75–3.65 (m, 4H), 3.64–3.58 (m, 2H), 3.53 (dd, J = 15.9, 6.7 Hz, 1H), 3.39 (dd, J = 15.9, 6.0 Hz, 1H), 
2.74–2.62 (m, 1H), 2.56 (s, 3H), 2.25 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 171.6, 152.1, 144.0, 138.3, 128.3, 127.8, 127.6, 111.2, 74.8, 72.8, 72.6, 
72.2, 61.7, 38.3, 14.5, 13.7. 
IR (film): ν (cm1) 3477, 2993, 2923, 2861, 1724, 1582, 1479, 1445, 1384, 1345, 1251, 1212, 1117, 
1064, 1028, 995, 968, 893, 845, 738, 695, 614, 589, 554, 507. 
HRMS (ESI, m/z) calcd for C18H24N2O4Na [M+Na]+: 355.1628, found: 355.1625. 
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(S)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(2,4-dimethylphenyl)-4-(2-hydroxyethoxy)butan-1-one 
(26i) 
 
Starting from 2-acyl pyrazole 24i (101.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25a (44.2 mg, 0.20 
mmol) according to the general procedure to give 26i as a white solid (33.7 mg, 0.102 mmol, yield: 
51%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 91% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (minor) = 8.9 min, 
tr (major) = 12.1 min). []D25 = –24.6 (c 0.3, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.14 (d, J = 7.7 Hz, 1H), 7.05–6.91 (m, 2H), 5.95 (s, 1H), 4.05–3.87 (m, 
1H), 3.69–3.42 (m, 7H), 3.37 (dd, J = 15.9, 6.3 Hz, 1H), 2.50 (s, 3H), 2.42 (s, 3H), 2.33–2.21 (d, J = 
10.3 Hz, 7H). 
13C NMR (75 MHz, CDCl3) δ 173.1, 151.9, 144.0, 136.7, 136.1, 136.0, 131.3, 126.8, 126.1, 111.0, 75.0, 
72.2, 61.6, 39.1, 37.0, 20.9, 19.6, 14.5, 13.7. 
IR (film): ν (cm1) 3429, 2923, 2863, 1722, 1616, 1580, 1501, 1445, 1409, 1377, 1339, 1256, 1169, 
1118, 1056, 1000, 961, 884, 813, 739, 702, 654, 579. 
HRMS (ESI, m/z) calcd for C19H26N2O3Na [M+Na]+: 353.1836, found: 353.1832. 
 
(S)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-(2-hydroxyethoxy)-3-(4-methoxyphenyl)butan-1-one 
(26j) 
 
Starting from 2-acyl pyrazole 2j (102.5 mg, 0.40 mmol) and N-alkoxyphthalimide 25a (44.2 mg, 0.20 
mmol) according to the general procedure to give 26j as a white solid (37.9 mg, 0.114 mmol, yield: 
57%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 82% 
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(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 17.3 min, 
tr (minor) = 20.2 min). []D25 = –8.0 (c 0.4, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.22 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 5.93 (s, 1H), 3.77 (s, 
3H), 3.69–3.58 (m, 6H), 3.54–3.47 (m, 2H), 3.44–3.30 (m, 1H), 2.48 (s, 3H), 2.38–2.28 (m, 1H), 2.24 
(s, 3H). 
13C NMR (75 MHz, CDCl3) δ 172.8, 158.4, 151.9, 144.1, 133.7, 128.7, 113.9, 111.1, 75.3, 72.1, 61.6, 
55.2, 41.1, 38.8, 14.5, 13.8. 
IR (film): ν (cm1) 3450, 2924, 2880, 1726, 1610, 1582, 1501, 1453, 1375, 1324, 1242, 1175, 1112, 
1032, 960, 891, 823, 745, 634, 561, 527.  
HRMS (ESI, m/z) calcd for C18H24N2O4Na [M+Na]+: 355.1625, found: 355.1624. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-(2-hydroxyethoxy)-3,4-dimethylpentan-1-one (26m) 
 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25b (49.9 mg, 0.20 
mmol) according to the general procedure to give 26m as a white solid (45.1 mg, 0.168 mmol, yield: 
84%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 91% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 6.3 min, 
tr (minor) = 6.7 min). []D25 = +25.2 (c 0.5, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 5.93 (s, 1H), 3.63–3.53 (m, 2H), 3.50–3.36 (m, 3H), 2.70 (dd, J = 15.5, 
8.4 Hz, 1H), 2.52 (s, 3H), 2.49–2.35 (m, 2H), 2.22 (s, 3H), 1.16 (d, J = 14.2 Hz, 6H), 0.98 (d, J = 6.9 
Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 174.4, 151.7, 144.0, 111.0, 77.2, 62.2, 62.1, 38.7, 37.6, 23.7, 20.6, 15.9, 
14.6, 13.7. 
IR (film): ν (cm1) 3425, 2974, 2873, 1721, 1581, 1514, 1461, 1376, 1326, 1246, 1153, 1049, 992, 960, 
927, 888, 801, 757, 707, 657, 561, 524.  
HRMS (ESI, m/z) calcd for C14H24N2O3Na [M+Na]+: 291.1679, found: 291.1680. 
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(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(1-(2-hydroxyethoxy)cyclopentyl)butan-1-one (26n) 
 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25c (55.1 mg, 0.20 
mmol) according to the general procedure to give 26n as a pale yellow oil (43.0 mg, 0.146 mmol, yield: 
73%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 93% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 6.7 min, 
tr (minor) = 7.7 min). []D25 = +24.5 (c 0.2, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 5.94 (s, 1H), 3.71–3.63 (m, 2H), 3.55–3.47 (m, 1H), 3.46–3.35 (m, 2H), 
2.81 (dd, J = 15.6, 9.7 Hz, 1H), 2.68–2.57 (m, 1H), 2.53 (s, 3H), 2.45–2.28 (m, 1H), 2.22 (s, 3H), 1.83–
1.52 (m, 8H), 0.99 (d, J = 6.8 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 174.2, 151.8, 144.0, 111.0, 89.6, 62.43, 62.36, 38.3, 34.6, 32.8, 32.5, 24.7, 
24.6, 15.7, 14.6, 13.7. 
IR (film): ν (cm1) 3422, 2957, 2870, 1721, 1581, 1456, 1409, 1377, 1326, 1243, 1180, 1139, 1055, 965, 
893, 803, 755, 658, 613, 553.  
HRMS (ESI, m/z) calcd for C16H26N2O3Na [M+Na]+: 317.1836, found: 317.1838. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(2-(2-hydroxyethoxy)-2,3-dihydro-1H-inden-2-yl)butan-
1-one (26o) 
 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25d (64.7 mg, 0.20 
mmol) according to the general procedure to give 26o as a pale yellow oil (52.0 mg, 0.152 mmol, yield: 
76%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 94% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 13.7 min, 
tr (minor) = 15.8 min). []D25 = +4.8 (c 0.6, CH2Cl2). 
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1H NMR (300 MHz, CDCl3) δ 7.24–7.09 (m, 4H), 5.96 (s, 1H), 3.56–3.41 (m, 3H), 3.36–3.20 (m, 2H), 
3.19–3.04 (m, 4H), 2.96 (dd, J = 15.7, 8.6 Hz, 1H), 2.75–2.60 (m, 1H), 2.55 (s, 3H), 2.42–2.30 (m, 1H), 
2.24 (s, 3H), 1.06 (d, J = 6.8 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 174.0, 151.8, 144.0, 141.5, 141.3, 126.59, 126.55, 124.04, 124.01, 111.1, 
88.7, 63.9, 62.2, 41.3, 40.4, 38.3, 38.2, 16.0, 14.6, 13.8. 
IR (film): ν (cm1) 3426, 2928, 2871, 1721, 1581, 1514, 1460, 1410, 1377, 1326, 1289, 1217, 1092, 
1044, 964, 888, 802, 740, 655, 582, 551.  
HRMS (ESI, m/z) calcd for C20H26N2O3Na [M+Na]+: 365.1836, found: 365.1835. 
 
(S)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(2-(2-hydroxyethoxy)-2,3-dihydro-1H-inden-2-yl)-4-
methylpentan-1-one (26p) 
 
Starting from 2-acyl pyrazole 24d (78.9 mg, 0.40 mmol) and N-alkoxyphthalimide 25d (64.7 mg, 0.20 
mmol) according to the general procedure to give 26p as a pale yellow oil (58.1 mg, 0.170 mmol, yield: 
85%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 97% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 9.3 min, 
tr (minor) = 10.8 min). []D25 = –9.1 (c 0.6, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.21–7.09 (m, 4H), 5.98 (s, 1H), 3.60–3.39 (m, 3H), 3.22–3.09 (m, 5H), 
3.05–2.93 (m, 2H), 2.65–2.58 (m, 1H), 2.56 (s, 3H), 2.48–2.39 (m, 1H), 2.26 (s, 3H), 2.20–2.09 (m, 1H), 
1.00 (d, J = 6.9 Hz, 6H). 
13C NMR (75 MHz, CDCl3) δ 175.3, 152.0, 144.1, 141.6, 141.4, 126.6, 126.5, 123.83, 123.79, 111.2, 
89.5, 64.0, 62.2, 49.0, 42.6, 41.5, 31.5, 28.4, 23.6, 18.7, 14.7, 13.8. 
IR (film): ν (cm1) 3445, 2929, 2871, 1722, 1581, 1461, 1411, 1379, 1314, 1279, 1234, 1173, 1094, 
1053, 989, 961, 803, 737, 674, 583, 540.  
HRMS (ESI, m/z) calcd for C22H30N2O3Na [M+Na]+: 393.2149, found: 393.2149. 
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(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(1-(2-hydroxyethoxy)cyclohexyl)butan-1-one (26q) 
 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25e (57.9 mg, 0.20 
mmol) according to the general procedure to give 26q as a pale yellow oil (50.0 mg, 0.162 mmol, yield: 
81%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 94% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 99:1, flow rate 1.0 mL/min, 25 C, tr (major) = 14.2 min, 
tr (minor) = 15.5 min). []D25 = +8.5 (c 0.6, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 5.93 (s, 1H), 3.80–3.68 (m, 2H), 3.56–3.46 (m, 1H), 3.44–3.30 (m, 2H), 
2.80 (dd, J = 15.8, 10.8 Hz, 1H), 2.58–2.36 (m, 5H), 2.21 (s, 3H), 1.72–1.33 (m, 9H), 1.22–1.07 (m, 
1H), 0.94 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 174.4, 151.7, 144.0, 111.0, 77.1, 62.6, 60.3, 37.0, 34.6, 30.1, 29.9, 25.8, 
21.6, 21.4, 15.0, 14.6, 13.7. 
IR (film): ν (cm1) 3424, 2930, 2860, 1722, 1581, 1449, 1410, 1377, 1327, 1218, 1146, 1055, 965, 899, 
804, 755, 705, 659, 600, 548.  
HRMS (ESI, m/z) calcd for C17H28N2O3Na [M+Na]+: 331.1992, found: 331.1993. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(1-(2-hydroxyethoxy)cycloheptyl)butan-1-one (26r) 
 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25f (60.7 mg, 0.20 
mmol) according to the general procedure to give 26r as a pale yellow oil (40.0 mg, 0.124 mmol, yield: 
62%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 95% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 5.7 min, 
tr (minor) = 6.3 min). []D25 = +21.1 (c 0.4, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 5.93 (s, 1H), 3.71 (t, J = 4.7 Hz, 2H), 3.57–3.48 (m, 1H), 3.45–3.37 (m, 
1H), 3.32 (dd, J = 15.8, 2.6 Hz, 1H), 2.85 (dd, J = 15.8, 10.7 Hz, 1H), 2.57–2.39 (m, 5H), 2.21 (s, 3H), 
1.82–1.40 (m, 12H), 0.95 (d, J = 6.8 Hz, 3H). 
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13C NMR (75 MHz, CDCl3) δ 174.3, 151.7, 144.0, 111.0, 80.7, 62.5, 61.0, 37.2, 36.7, 34.8, 34.5, 29.4, 
29.3, 22.6, 22.5, 15.1, 14.6, 13.7. 
IR (film): ν (cm1) 3430, 2925, 2860, 1723, 1581, 1460, 1410, 1379, 1331, 1218, 1171, 1048, 963, 892, 
805, 751, 664, 593, 555.  
HRMS (ESI, m/z) calcd for C18H30N2O3Na [M+Na]+: 345.2149, found: 345.2149.  
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(4-(2-hydroxyethoxy)-1-tosylpiperidin-4-yl)butan-1-one 
(26s) 
 
Starting from 2-acyl 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25g (88.9 mg, 0.20 mmol) 
according to the general procedure to give 26s as a white solid (67.0 mg, 0.144 mmol, yield: 72%). 
Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 93% (HPLC: 
OD-H, 254 nm, hexane/isopropanol = 80:20, flow rate 1.0 mL/min, 25 C, tr (major) = 10.6 min, tr 
(minor) = 13.1 min). []D25 = +25.6 (c 0.8, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.63 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 7.9 Hz, 2H), 5.93 (s, 1H), 3.70–3.49 
(m, 4H), 3.47–3.38 (m, 1H), 3.35–3.17 (m, 2H), 2.74 (dd, J = 15.7, 10.6 Hz, 1H), 2.62 (td, J = 11.9, 3.0 
Hz, 1H), 2.56–2.36 (d, J = 25.5 Hz, 8H), 2.18 (s, 3H), 2.12–1.98 (m, 1H), 1.90–1.61 (m, 4H), 0.90 (d, J 
= 6.8 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.5, 151.9, 144.0, 143.4, 133.4, 129.5, 127.6, 111.1, 74.8, 62.1, 60.7, 
41.8, 41.7, 36.6, 33.7, 29.2, 28.8, 21.4, 14.8, 14.5, 13.6. 
IR (film): ν (cm1) 3411, 2930, 2866, 1720, 1586, 1459, 1408, 1378, 1327, 1248, 1216, 1159, 1088, 
1050, 968, 893, 846, 815, 762, 651, 545.  
HRMS (ESI, m/z) calcd for C23H33N3O5SNa [M+Na]+: 486.2033, found: 486.2034. 
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(S)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(2,4-dimethylphenyl)-3-(4-(2-hydroxyethoxy)-1-
tosylpiperidin-4-yl)propan-1-oneone (26t) 
 
Starting from 2-acyl pyrazole 24i (101.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25g (88.9 mg, 0.20 
mmol) according to the general procedure to give 26t as a white solid (60.0 mg, 0.108 mmol, yield: 
54%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 92% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 85:15, flow rate 1.0 mL/min, 25 C, tr (major) = 12.6 
min, tr (minor) = 18.9 min). []D25 = –19.7 (c 0.4, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.59 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 7.9 Hz, 
1H), 7.00–6.89 (m, 2H), 5.87 (s, 1H), 4.11 (dd, J = 9.2, 5.2 Hz, 1H), 3.78–3.51 (m, 5H), 3.50–3.41 (m, 
1H), 3.40–3.31 (m, 1H), 2.65 (td, J = 12.1, 3.1 Hz, 1H), 2.50–2.36 (m, 4H), 2.35–2.24 (m, 9H), 2.23–
2.10 (m, 4H), 2.02 (td, J = 12.7, 4.7 Hz, 1H), 1.95–1.81 (m, 2H), 1.44–1.22 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 172.7, 151.8, 144.0, 143.9, 137.1, 136.3, 134.2, 133.3, 131.5, 129.5, 128.0, 
127.6, 126.8, 110.9, 76.4, 62.2, 61.2, 41.9, 41.7, 39.7, 35.8, 30.7, 28.2, 21.5, 20.9, 20.4, 14.3, 13.7. 
IR (film): ν (cm1) 3560, 2928, 2865, 1721, 1585, 1458, 1410, 1378, 1321, 1248, 1161, 1087, 1049, 992, 
959, 811, 768, 726, 653, 585, 545.  
HRMS (ESI, m/z) calcd for C30H39N3O5SNa [M+Na]+: 576.2503, found: 576.2507. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-3-(3-(2-hydroxyethoxy)-1-tosylazetidin-3-yl)butan-1-one 
(26u) 
 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25h (83.2 mg, 0.20 
mmol) according to the general procedure to give 26u as a white solid (50.0 mg, 0.114 mmol, yield: 
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57%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 86% 
(HPLC: AD-H, 254 nm, hexane/isopropanol = 90:10, flow rate 1.0 mL/min, 25 C, tr (minor) = 27.8 
min, tr (major) = 30.8 min). []D25 = +15.8 (c 0.4, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 7.8 Hz, 2H), 5.94 (s, 1H), 3.86–3.68 
(m, 4H), 3.52 (t, J = 4.7 Hz, 2H), 3.39 (ddd, J = 9.0, 5.1, 3.7 Hz, 1H), 3.34–3.25 (m, 1H), 3.11 (dd, J = 
15.6, 4.8 Hz, 1H), 2.80 (dd, J = 15.5, 8.3 Hz, 1H), 2.49 (s, 3H), 2.46–2.34 (m, 4H), 2.25–2.08 (m, 4H), 
0.95 (d, J = 6.8 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 172.9, 152.1, 144.3, 144.0, 131.6, 129.7, 128.3, 111.3, 64.4, 61.6, 57.8, 
57.1, 56.7, 36.6, 35.3, 21.5, 14.5, 14.1, 13.7. 
IR (film): ν (cm1) 3533, 2930, 2877, 1722, 1634, 1590, 1451, 1381, 1336, 1157, 1089, 966, 842, 756, 
705, 667, 607, 548.  
HRMS (ESI, m/z) calcd for C21H29N3O5SNa [M+Na]+: 458.1720, found: 458.1719. 
 
(3R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-(2-hydroxyethoxy)-3-methyl-4-(naphthalen-2-yl)butan-
1-one (26v) 
 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25i (69.3 mg, 0.20 
mmol) according to the general procedure to give 26v as a pale yellow oil (52.0 mg, 0.142 mmol, yield: 
71%, dr = 3:1). Enantiomeric excess established by HPLC analysis using a Chiralpak OJ-H column, ee 
= 97% (major product) (HPLC: OJ-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 
C, tr (minor) = 16.7 min, tr (major) = 27.3 min). The dr value was determined by 1H NMR of 26v (after 
purified by flash chromatography). 
1H NMR (300 MHz, CDCl3) δ 7.84–7.78 (m, 3H), 7.74 (s, 1H), 7.48–7.42 (m, 3H), 5.90 (s, 1H), 4.48 
(d, J = 5.6 Hz, 1H), 3.74–3.66 (m, 2H), 3.61–3.51 (m, 1H), 3.45–3.33 (m, 2H), 2.91 (dd, J = 16.2, 6.8 
Hz, 1H), 2.78–2.66 (m, 1H), 2.64–2.58 (m, 1H), 2.47 (s, 3H), 2.23 (s, 3H), 1.07 (d, J = 6.8 Hz, 3H) 
(major product). 
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13C NMR (75 MHz, CDCl3) δ 173.3, 151.8, 143.9, 137.7, 133.04, 133.02, 128.0, 127.8, 127.6, 126.4, 
126.0, 125.8, 125.0, 111.1, 85.2, 70.6, 62.0, 38.7, 36.7, 15.5, 14.5, 13.7 (major product). 
IR (film): ν (cm1) 3431, 2963, 2927, 2868, 1720, 1582, 1460, 1410, 1377, 1328, 1270, 1168, 1105, 
1058, 963, 898, 818, 740, 658, 588, 554.  
HRMS (ESI, m/z) calcd for C22H26N2O3Na [M+Na]+: 389.1836, found: 389.1841. 
 
(3R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-(2-hydroxyethoxy)-4-mesityl-3-methylbutan-1-one 
(26w) 
 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25j (68.1 mg, 0.20 
mmol) according to the general procedure to give 26w as a pale yellow oil (45.1 mg, 0.126 mmol, yield: 
63%, dr = 3:1). Enantiomeric excess established by HPLC analysis using a Chiralpak IC column, ee = 
97% (major product) (HPLC: IC, 254 nm, hexane/isopropanol = 94:6, flow rate 0.7 mL/min, 25 C, tr 
(major) = 12.2 min, tr (minor) = 16.0 min). The dr value was determined by 1H NMR of 26w (after 
purified by flash chromatography). 
1H NMR (300 MHz, CDCl3) δ 6.78 (s, 1H), 6.66 (s, 1H), 5.86 (s, 1H), 4.54 (d, J = 8.6 Hz, 1H), 3.67 (t, 
J = 4.6 Hz, 2H), 3.41–3.25 (m, 2H), 3.02–2.86 (m, 2H), 2.81–2.70 (m, 1H), 2.51–2.37 (m, 7H), 2.27–
2.14 (m, 9H), 1.21 (d, J = 6.3 Hz, 3H) (major product). 
13C NMR (75 MHz, CDCl3) δ 172.8, 151.4, 143.8, 136.7, 132.3, 131.4, 131.2, 128.9, 128.8, 110.8, 83.1, 
70.0, 62.2, 39.1, 34.7, 21.2, 20.7, 20.4, 17.9, 14.3, 13.7 (major product). 
IR (film): ν (cm1) 3433, 2923, 1723, 1610, 1581, 1455, 1411, 1376, 1324, 1210,1104, 1055, 964, 894, 
854, 802, 746, 655, 586, 536.  
HRMS (ESI, m/z) calcd for C21H30N2O3Na [M+Na]+: 381.2149, found: 381.2145. 
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(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-((2-hydroxyethyl)thio)-3-methylbutan-1-one (26x) 
 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25k (47.5 mg, 0.20 
mmol) according to the general procedure to give 26x as a pale yellow oil (25.1 mg, 0.098 mmol, yield: 
49%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 86% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) =11.2 min, 
tr (minor) = 12.5 min). []D25 = +54.6 (c 0.2, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 5.94 (s, 1H), 3.72 (t, J = 5.9 Hz, 2H), 3.32 (dd, J = 16.6, 6.2 Hz, 1H), 
2.97 (dd, J = 16.6, 7.2 Hz, 1H), 2.73 (t, J = 5.9 Hz, 2H), 2.66–2.45 (m, 6H), 2.38 (dt, J = 13.4, 6.7 Hz, 
1H), 2.22 (s, 3H), 1.10 (d, J = 6.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.0, 151.9, 144.0, 111.1, 60.4, 41.1, 38.7, 35.7, 30.1, 19.7, 14.5, 13.7. 
IR (film): ν (cm1) 3421, 2960, 2925, 2874, 1721, 1582, 1463, 1410, 1377, 1328, 1247, 1165, 1048, 998, 
963, 903, 804, 747, 639, 586, 557.  
HRMS (ESI, m/z) calcd for C12H20N2O2SNa [M+Na]+: 279.1138, found: 279.1139. 
 
(R)-1-(3,5-Dimethyl-1H-pyrazol-1-yl)-4-((2-hydroxyethyl)thio)-3,4-dimethylpentan-1-one (26y) 
 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25l (53.1 mg, 0.20 
mmol) according to the general procedure to give 26y as a pale yellow oil (41.0 mg, 0.144 mmol, yield: 
72%). Enantiomeric excess established by HPLC analysis using a Chiralpak OD-H column, ee = 93% 
(HPLC: OD-H, 254 nm, hexane/isopropanol = 95:5, flow rate 1.0 mL/min, 25 C, tr (major) = 9.3 min, 
tr (minor) = 14.3 min). []D25 = +55.6 (c 0.4, CH2Cl2). 
1H NMR (300 MHz, CDCl3) δ 5.94 (s, 1H), 3.73 (t, J = 6.1 Hz, 2H), 3.58 (dd, J = 16.4, 3.1 Hz, 1H), 
2.98 (dd, J = 16.4, 10.1 Hz, 1H), 2.79 (td, J = 6.0, 2.2 Hz, 2H), 2.53 (s, 3H), 2.49–2.33 (m, 1H), 2.31–
2.15 (s, 4H), 1.38 (s, 3H), 1.28 (s, 3H), 1.04 (d, J = 6.8 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 173.9, 151.8, 144.0, 111.1, 61.4, 49.1, 38.7, 38.2, 31.4, 27.5, 24.9, 15.4, 
14.6, 13.8. 
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IR (film): ν (cm1) 3403, 2928, 2876, 1721, 1582, 1458, 1410, 1377, 1324, 1289, 1240, 1170, 1136, 
1107, 1042, 994, 963, 935, 805, 769, 736, 661, 627, 587.  
HRMS (ESI, m/z) calcd for C14H24N2O2SNa [M+Na]+: 307.1451, found: 307.1452. 
 
5.5.3 Synthetic Transformations 
 
To a solution of 26s (46.4 mg, 0.10 mmol) in THF (0.5 mL) was added p-toluidine (107.2 mg, 1.0 
mmol). The reaction mixture was heated to 80 ºC for 65 h. After cooled to room temperature, the reaction 
residue was purified by flash silica gel column chromatography to afford 27 as a colorless oil (43.0 mg, 
91%). Enantiomeric excess established by HPLC analysis using a Chiralpak AD-H column, ee = 93% 
(HPLC: AD-H, 254 nm, hexane/isopropanol = 80:20, flow rate 1.0 mL/min, 25 C, tr (minor) = 25.4 
min, tr (major) = 28.0 min). []D25 = +8.7 (c 0.4, CH2Cl2). 
 
(R)-3-(4-(2-Hydroxyethoxy)-1-tosylpiperidin-4-yl)-N-(p-tolyl)butanamide (27) 
 
1H NMR (300 MHz, CDCl3) δ 8.04 (s, 1H), 7.63 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 7.32 (d, 
J = 8.0 Hz, 2H), 7.07 (d, J = 8.1 Hz, 2H), 3.67–3.50 (m, 4H), 3.46–3.33 (m, 1H), 3.26–3.15 (m, 1H), 
2.63 (ddd, J = 24.5, 12.9, 2.6 Hz, 2H), 2.52–2.40 (m, 4H), 2.39–2.20 (m, 5H), 1.90–1.77 (m, 1H), 1.76–
1.56 (m, 3H), 1.44 (dd, J = 13.8, 2.7 Hz, 1H), 0.93 (d, J = 6.8 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 171.3, 143.6, 135.7, 133.7, 133.5, 129.6, 129.3, 127.6, 119.7, 74.8, 62.2, 
60.8, 41.9, 41.7, 38.8, 35.0, 29.1, 28.9, 21.5, 20.8, 15.0. 
IR (film): ν (cm1) 3502, 2928, 2870, 1664, 1601, 1526, 1457, 1405, 1325, 1246, 1160, 1086, 977, 930, 
816, 725, 651, 551.  
HRMS (ESI, m/z) calcd for C25H34N2O5SNa [M+Na]+: 497.2080, found: 497.2083. 
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To a solution of 26s (46.4 mg, 0.10 mmol) in THF/H2O (v/v = 4:1, 1.0 mL) at 0 ºC was added NaBH4 
(37.3 mg, 1.0 mmol). The reaction mixture was stirred at room temperature overnight. The reaction was 
quenched with aqueous 2 N HCl and extracted with DCM. The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography on 
silica gel (100% EtOAc) to afford 28 (35.3 mg, yield: 95%) as a colorless oil. Enantiomeric excess 
established by HPLC analysis using a Chiralpak AD-H column, ee = 93% (HPLC: AD-H, 254 nm, 
hexane/isopropanol = 60:40, flow rate 1.0 mL/min, 25 C, tr (minor) = 5.4 min, tr (major) = 6.0 min). 
[]D25 = +25.5 (c 0.4, CH2Cl2). 
 
(R)-3-(4-(2-Hydroxyethoxy)-1-tosylpiperidin-4-yl)butan-1-ol (28) 
 
1H NMR (300 MHz, CDCl3) δ 7.58 (d, J = 8.3 Hz, 2H), 7.25 (d, J = 8.0 Hz, 2H), 3.67 (td, J = 6.2, 3.1 
Hz, 1H), 3.59–3.42 (m, 5H), 3.29 (dt, J = 9.9, 5.0 Hz, 1H), 3.11 (dt, J = 9.5, 4.0 Hz, 1H), 2.68–2.27 (m, 
5H), 1.98–1.82 (m, 3H), 1.80–1.41 (m, 5H), 1.15–0.91 (m, 1H), 0.78 (d, J = 6.8 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 143.4, 133.5, 129.6, 127.6, 75.0, 62.2, 60.9, 60.4, 41.9, 41.8, 33.3, 33.1, 
29.1, 29.0, 21.5, 14.1. 
IR (film): ν (cm1) 3382, 2936, 2873, 1461, 1330, 1244, 1160, 1086, 1054, 977, 929, 894, 815, 725, 
651, 573, 550.  
HRMS (ESI, m/z) calcd for C18H29NO5SNa [M+Na]+: 394.1659, found: 394.1659. 
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5.5.4 Mechanistic Investigations 
1) Substrate-Coordinated Rhodium Complex RhS-I 
 
The racemic substrate-coordinated rhodium complex RhS-I was obtained by reacting substrate 24a 
(11.5 mg, 0.070 mmol) with racemic /-RhS (50.0 mg, 0.058 mmol) overnight in DCM (1.5 mL) at 
room temperature. After the slow addition of hexane (5.0 mL), crystals were collected after several days 
(39.4 mg, yield: 72%).  
1H NMR (300 MHz, CD2Cl2) δ 7.95 (d, J = 8.8 Hz, 2H), 7.84–7.69 (m, 3H), 7.64–7.55 (m, 3H), 7.12 
(tdd, J = 7.5, 2.4, 1.0 Hz, 2H), 6.98–6.86 (m, 3H), 6.73 (dq, J = 14.9, 1.6 Hz, 1H), 6.44–6.37 (m, 2H), 
6.26 (d, J = 7.8 Hz, 1H), 2.66 (s, 3H), 2.10 (dd, J = 7.1, 1.6 Hz, 3H), 1.76 (s, 3H), 1.27 (s, 9H), 1.16 (s, 
9H). 
13C NMR (75 MHz, CD2Cl2) δ 168.5, 161.3, 160.6, 160.2, 159.9, 159.6, 152.5, 152.4, 149.6, 149.4, 
145.7, 140.4, 139.8, 133.89, 133.80, 131.24, 131.22, 131.10, 131.08, 128.94, 128.93, 128.86, 128.84, 
126.6, 126.2, 124.9, 124.5, 124.2, 122.81, 122.78, 118.5, 117.3, 115.1, 114.5, 35.0, 34.8, 31.2, 31.1, 
19.5, 15.6, 13.1. 
 
2) Isolation of byproducts 
Performed the reaction under the conditions of entry 5 in Table 8 (chapter 3.4), the expected byproducts 
isoindoline-1,3-dione 29 and diethyl 2,6-dimethylpyridine-3,5-dicarboxylate 30 were isolated. 
 
Diethyl 2,6-dimethylpyridine-3,5-dicarboxylate (29) 
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1H NMR (300 MHz, CDCl3) δ 8.66 (s, 1H), 4.39 (q, J = 7.1 Hz, 4H), 2.84 (s, 6H), 1.41 (t, J = 7.1 Hz, 
6H). 
All spectroscopic data were in agreement with the literature.25 
 
Isoindoline-1,3-dione (30) 
 
1H NMR (300 MHz, DMSO-d6) δ 11.31 (br s, 1H), 7.81 (s, 4H). 
All spectroscopic data were in agreement with the literature.26 
 
3) Isolation of a side product 
Starting from 2-acyl pyrazole 24a (65.7 mg, 0.40 mmol) and N-alkoxyphthalimide 25h (83.2 mg, 0.20 
mmol) according to the general procedure by using rac-RhS to give 26t as a white solid (51.0 mg, 0.117 
mmol, yield: 59%) and a side product 2-((1-tosylazetidin-3-yl)oxy)ethanol 31 (8.3 mg, 0.030 mmol, 
yield:15%). 
 
2-((1-Tosylazetidin-3-yl)oxy)ethanol (31) 
 
1H NMR (300 MHz, CDCl3) δ 7.73 (d, J = 8.2 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 4.23–4.05 (m, 1H), 
4.03–3.89 (m, 2H), 3.67–3.56 (m, 4H), 3.38 (dd, J = 5.2, 3.9 Hz, 2H), 2.45 (s, 3H), 1.75 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ 144.2, 131.7, 129.7, 128.4, 70.0, 67.0, 61.5, 57.9, 21.6. 
 
4) Trapping Experiments 
a) Trapping experiment with ((2-phenylallyl)sulfonyl)benzene  
Using Δ-RhS (8 mol%) and fac-[Ir(ppy)3] (1 mol%) as dual catalysts, 2-acyl pyrazole 24a (65.7 mg, 
0.40 mmol), N-alkoxyphthalimide 25a (44.2 mg, 0.20 mmol), Hantzsh ester (76.0 mg, 0.30 mmol) and 
((2-phenylallyl)sulfonyl)benzene 32 (103.4 mg, 0.40 mmol)27 according to the general procedure of 
synthesizing 26a-y to give 26a in 64% yield and 92% ee and 33 in 18% yield.  
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2-((3-Phenylbut-3-en-1-yl)oxy)ethanol (33) 
 
1H NMR (300 MHz, CDCl3) δ 7.46–7.39 (m, 2H), 7.38–7.24 (m, 3H), 5.36 (d, J = 1.4 Hz, 1H), 5.14 (d, 
J = 1.3 Hz, 1H), 3.68 (q, J = 4.5 Hz, 2H), 3.61 (t, J = 7.0 Hz, 2H), 3.52 (dd, J = 5.3, 3.8 Hz, 2H), 2.83 
(td, J = 6.9, 1.2 Hz, 2H), 2.06–1.95 (m, 1H). 
13C NMR (75 MHz, CD2Cl2) δ 145.4, 140.9, 128.3, 127.5, 126.0, 113.9, 71.8, 70.0, 61.8, 35.6. 
IR (film): ν (cm1) 3434, 2927, 2872, 1720, 1682, 1597, 1488, 1447, 1364, 1282, 1218, 1114, 1054, 892, 
756, 698, 658, 576, 542.  
 
b) Trapping experiment with N-methyl-N-phenylmethacrylamide  
A dried 10 mL Schlenk tube was charged with the catalyst fac-[Ir(ppy)3] (1 mol%), Δ/Λ-RhS (8 mol%), 
Hantzsch ester (0.30 mmol, 1.5 eq.), 2-acyl pyrazole 24a (0.40 mmol, 2.0 eq.), N-alkoxyphthalimide 
25a (0.20 mmol, 1.0 eq.) and N-methyl-N-phenylmethacrylamide 34 (140.2 mg, 2.0 eq.)28. The tube was 
purged with nitrogen and THF (1.0 mL) was added via syringe. The reaction mixture was degassed via 
freeze-pump-thaw for three cycles. After the mixture was thoroughly degassed, the vial was sealed and 
positioned approximately 8 cm from 24 W blue LEDs. Afterwards, the mixture was diluted with DCM 
(2 mL). The combined organic layers were concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel (EtOAc/hexane = 1:10) to afford the rac-26a in 85% 
yield and 35 in 18% yield.  
 
3-(2-(2-Hydroxyethoxy)ethyl)-1,3-dimethylindolin-2-one (35) 
 
1H NMR (300 MHz, CDCl3) δ 7.32–7.24 (m, 1H), 7.20–7.15 (m, 1H), 7.07 (td, J = 7.5, 1.0 Hz, 1H), 
6.87–6.84 (m, 1H), 3.51 (t, J = 4.4 Hz, 2H), 3.36–3.27 (m, 1H), 3.26–3.10 (m, 6H), 2.50–2.34 (m, 1H), 
2.26–2.10 (m, 1H), 1.96 (dt, J = 14.1, 4.8 Hz, 1H), 1.38 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 181.0, 143.4, 133.5, 127.9, 122.6, 122.4, 108.0, 72.0, 67.5, 61.8, 46.8, 
37.7, 26.2, 24.7. 
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IR (film): ν (cm1) 3434, 2926, 2870, 1692, 1610, 1466, 1425, 1377, 1349, 1308, 1247, 1163, 1121, 
1064, 889, 753, 697, 640, 544.  
HRMS (ESI, m/z) calcd for C14H19NO3Na [M+Na]+: 272.1257, found: 272.1258. 
 
5) The cross-over experiment 
The reaction designed below is to explore the C(sp3)-H activation occurs through intramolecular or 
intermolecular 1,5-HAT. When the N-alkoxyphthalimide 25l and alcohol were both subjected to the 
reaction conditions, the adduct 26y was isolated with no loss any of yield or enantioselectivty, whereas 
the product 26m was not formed in the reaction (Figure 91). It provides a good evidence that the C(sp3)-
H activation occurs through intramolecular 1,5-HAT.  
 
 
Figure 91 1H NMR spectra of 26m, 26y and crude mixture. 
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6) Luminescence quenching experiments  
The luminescence quenching experiments with the photoredox catalyst were investigated both in the 
absence and presence of intermediate RhS-I. Emission intensities were recorded on a Spectra Max M5 
microplate reader in a 10.0 mm quartz cuvette. All fac-[Ir(ppy)3] solutions were excited at 370 nm and 
the emission was measured at 515 nm. The concentration of the photoredox catalyst solution (fac-
[Ir(ppy)3] and intermediate RhS-I) was 0.2 mM in THF. The concentration of the quencher (N-
alkoxyphthalimide 25a and Michael acceptor 24a) stock solution was 10 mM in THF. For each 
quenching experiment, 5 μL of this stock solution were titrated to a solution (1 mL) of iridium complex 
in a screw-top 10.0 mm quartz cuvette. The addition of 5 μL stock solution refers to an increase of the 
quencher concentration of 0.05 mM. After degassing with an argon stream for 5 minutes, the emission 
intensity was collected. 
 
7) Light source screening 
Different light sources contain CFL and blue LEDs were tested in the following reaction. It is not 
obvious that light intensity or wavelength effect the enantioselectivity of the product 26a. For example, 
the enantioselectivities obtained were almost the same when using 12 W or 2 × 20 W CFL as light source 
compared to 23 W CFL. However, it dropped to 86% and 76% ee when using 6 W and 24 W blue LEDs, 
respectively. The output wavelength of the used 6 W blue LEDs is shown in Figure 92. 
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Figure 92 The output wavelength of the used 6 W blue LEDs (420 nm  10 nm). 
 
8) Quantum yield measurement  
The quantum yield was measured by standard ferrioxalate actinometry.20 A 150 W xenon lamp (50% of 
light intensity, 420 5nm bandpass filter) was used as the light source. The measured method was 
designed according to a published procedure with slight modifications.21,22 All the light sensitive 
operations were processed in the darkroom under red light. 
The solutions were prepared and stored in the dark:  
Potassium ferrioxalate solution (0.15 M): 736.9 mg of potassium ferrioxalate hydrate was dissolved 
in 10 mL of 0.05 M H2SO4. 
Buffered solution of phenanthroline: 50 mg of 1,10-phenanthroline and 11.25 g of sodium acetate 
were dissolved in 50 mL of 0.5 M H2SO4. 
 
a) Measurement of light intensity at 420 nm 
1000 μL of the ferrioxalate solution was added to a quartz cuvette (l = 10 mm). The actinometry solution 
was irradiated with 150 W Xennon Lamp (50% of light intensity, 420 nm  5 nm) for specified time 
intervals (30, 60, 90, 120 seconds). After irradiation, 175 μL of the phenanthroline solution was added 
to the cuvette. The solution was kept in dark for 30 min to make sure the complete coordination. The 
absorbance of the actinometry solution was monitored at 510 nm. The absorbance of a non-irradiated 
(in dark) sample was also measured at 510 nm. 
The moles of Fe2+ formed was determined using Beer’s Law: 
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Where V1 (1 mL) is the irradiated volume, V2 (1mL) is the aliquot of the irradiated solution taken for the 
determination of the ferrous ions. V3 (1.175 mL) is the final volume after complexation with 
phenanthroline (all in mL), l is the path length (1 cm), and ΔA(510 nm) is the optical difference in 
absorbance between the irradiated and non-irradiated solutions, ɛ(510 nm) is the molar absorptivity of 
Fe(phen)32+ (11100 L mol-1cm-1). 
The moles of Fe2+ formed for each sample (30, 60, 90, 120 seconds) are shown below: 
Irradiation time 30 s 60 s 90 s 120 s 
ΔA 0.252 0.457 0.658 0.834 
Fe2+ (10-8 mol) 2.668 4.838 6.965 8.828 
The moles of Fe2+ formed are plotted as a function of time (t). The slope is shown as:  
d(moles Fe2+)/dt = 7.619×10-10 
 
The photon flux can be calculated as: 
 
Where Φ is the quantum yield for the ferrioxalate actinometer (1.05 for a 0.15 solution at 412 nm; 1.04 
for a 0.15 solution at 422 nm; 1.03 for a 0.15 solution at 433 nm)21, t is the irradiated time, and f is the 
fraction of light absorbed at λ = 420 nm (f = 110-A).The measurement of the fraction of the light at 420 
nm for the ferrioxalate solution was shown in Figure 93. The absorbance of the ferrioxalate solution at 
420 nm is >3 indicating f (f = 110-A) is >0.999. 
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Figure 93 Absorbance of the ferrioxalate actinometer solution (0.15 M). 
 
b) Measurement of quantum yield: 
Model reaction: 
 
A screw-top cuvette (10.0 mm) was charged with the catalyst rac-RhS (8 mol%), photosensitizer fac-
[Ir(ppy)3] (1 mol%), 24a (0.4 mmol, 2.0 eq.), 25a (0.2 mmol, 1 eq.), Hantzsch ester (0.3 mmol, 1.5 eq.), 
1.0 mL THF and a small magnetic stir bar. The cuvette was degassed with an argon stream for 10 min. 
After the mixture was thoroughly degassed, the vial was sealed and fixed at the same position as the 
measurement of photon flux. The reaction mixture was stirred and irradiated with 150 W Xenon lamp 
(50% of light intensity, 420 nm ± 5 nm bandpass filter high transmittance) for 10800 s (3 h). After 
irradiation, the reaction mixture was passed through a short silica gel column. The moles of product 
formed was measured by GC analysis (FID detector, column: HP-5) using dodecane as internal standard. 
The quantum yield calculation is then as following: 
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Figure 94 Absorbance of the reaction solution (fac-[Ir(ppy)3] = 2 mM, RhS = 16 mM). Absorbance at 
420 nm (>3) demonstrating that the fraction of light absorbed is >0.999 (f = 110-A(420 nm)). 
 
5.5.5 Single-Crystal X-Ray Diffraction Studies  
Single crystals of the rhodium intermediate complex RhS-I suitable for X-ray diffraction were obtained 
after one night from a solution of the compound in CH2Cl2 layered with n-hexane. Crystals of the (R)-
26t were obtained by slow diffusion from a solution in CH2Cl2 layered with n-hexane. X-ray data of 
RhS-I and (R)-26t were collected with a Bruker 3 circuit D8 Quest diffractometer with MoKα radiation 
(microfocus tube with multilayer optics) and Photon 100 CMOS detector at 100 K. Crystal data and 
details of the structure determination of RhS-I and (R)-26t are presented in Appendices 6.7 The absolute 
configuration has been determined.
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Chapter 6: Appendices 
6.1 List of Abbreviations 
1H NMR proton nuclear magnetic resonance spectroscopy 
13C NMR carbon nuclear magnetic resonance spectroscopy 
9F NMR fluorine nuclear magnetic resonance spectroscopy 
δ chemical shift 
J coupling constant 
br broad 
s singlet 
d doublet 
t triplet 
q quartet 
m multiplet 
ppm parts per million 
AcOH acetic acid 
aq aqueous 
Ar argon 
bpy 2,2´-bipyridine 
CD circular dichroism 
CH2Cl2/ DCM dichloromethane 
CD2Cl2 dideuteromethylenechloride 
CHCl3 chloroform 
CDCl3 deuterochloroform 
CH3CN/ MeCN acetonitrile 
conc concentrated 
DMAP 4-dimethylaminopyridine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
dr diastereomeric ratio 
EDA electron donor-acceptor 
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
ee enantiomeric excesses 
e.g. exempli gratia (lat.: for example) 
et al. et alii (lat.: and others) 
ESI electrospray ionization 
EtOH ethanol 
Et2O diethyl ether 
Et3N triethyl amine 
EtOAc ethyl acetate 
EWG electron withdrawing group 
HAT hydrogen atom transfer 
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h hour(s) 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
Hz Hertz 
IR spectra infrared spectra 
Ir iridium 
L liter(s) 
M mol/liter 
m meta- 
min minute(s) 
mL milliliter(s) 
mmol millimole 
MS mass spectroscopy 
N2 nitrogen 
Nu nucleophile 
PCET proton-coupled electron transfer 
Ph phenyl 
PPh3 triphenylphosphine 
ppm parts per million 
ppy 2-phenylpyridine 
PC photoredox catalyst 
rac racemate 
Rh rhodium 
rt room temperature 
SET single-electron transfer 
TEMPO 2,2,6,6-tetramethyl-1-piperidinyloxy 
4-MeO-TEMPO 4-methoxy-2,2,6,6-tetramethyl-1-piperidinyloxy 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
UV ultraviolet 
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Figure 96 1H NMR and 13C NMR spectra of Δ-(R)-3. 
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Figure 97 1H NMR and 13C NMR spectra of Δ-RhO. 
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Figure 101 1H NMR and 13C NMR spectra of intermediate RhS-I. 
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6.6.2 CD Spectra of Enantiopure Rhodium Complexes  
 
Figure 102 CD spectrum of complex Λ-(S)-3 recorded in CH3OH (0.2 mM). 
 
Figure 103 CD spectrum of complex Δ-(R)-3 recorded in CH3OH (0.2 mM). 
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Figure 104 CD spectra of complexes Δ-RhO and Λ-RhO recorded in CH3OH (0.2 mM). 
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6.6.3 HPLC Spectra of Compounds 
 
 
 
Figure 105 HPLC trace for the racemic reference complexes Δ/Λ-RhO, Λ-RhO and Δ-RhO. HPLC 
conditions: Daicel Chiralpak IB (250 × 4.6 mm) HPLC column on an Agilent 1200 Series HPLC System. 
The column temperature was 25 °C and UV-absorption was measured at 254 nm. Solvent A = 0.1% 
TFA, solvent B = MeCN (Daicel Chiralpak IB, with a linear gradient of 30% to 41% B in 60 min, flow 
rate = 0. 6 mL/min). 
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Figure 106 HPLC traces (Daicel Chiralpak IC column) of rac-5a (reference) and (R)-5a.  
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Figure 107 HPLC traces (Daicel Chiralpak AD-H column) of rac-5b (reference) and (R)-5b.  
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Figure 108 HPLC traces (Daicel Chiralpak AD-H column) of rac-5c (reference) and (R)-5c.  
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Figure 109 HPLC traces (Daicel Chiralpak AD-H column) of rac-5d (reference) and (R)-5d.  
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Figure 110 HPLC traces (Daicel Chiralpak AD-H column) of rac-5e (reference) and (R,R)-5e.  
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Figure 111 HPLC traces (Daicel Chiralpak AD-H column) of rac-5f (reference) and (R,R)-5f.  
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Figure 112 HPLC traces (Daicel Chiralpak AD-H column) of rac-6 (reference) and (S,S)-6.  
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Figure 113 HPLC traces (Daicel Chiralpak AD-H column) of rac-10a'' (reference) and (S)-10a''.  
rac-10a‘‘ 
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Figure 114 HPLC traces (Daicel Chiralpak AD-H column) of rac-10a' (reference) and (S)-10a'.  
 
rac-10a‘ 
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Figure 115 HPLC traces (Daicel Chiralpak AD-H column) of rac-10a (reference) and (R)-10a.  
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Figure 116 HPLC traces (Daicel Chiralpak OD-H column) of rac-10b (reference) and (R)-10b. 
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Figure 117 HPLC traces (Daicel Chiralpak AD-H column) of rac-10c (reference) and (R)-10c. 
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Figure 118 HPLC traces (Daicel Chiralpak AD-H column) of rac-10d (reference) and (R)-10d. 
 
rac-10d 
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Figure 119 HPLC traces (Daicel Chiralpak AD-H column) of rac-10e (reference) and (R)-10e.  
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Figure 120 HPLC traces (Daicel Chiralpak AD-H column) of rac-10f (reference) and (R)-10f.  
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Figure 121 HPLC traces (Daicel Chiralpak AD-H column) of rac-10g (reference) and (R)-10g.  
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Figure 122 HPLC traces (Daicel Chiralpak AD-H column) of rac-10h (reference) and (R)-10h.  
 
rac-10h 
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Figure 123 HPLC traces (Daicel Chiralpak AD-H column) of rac-10i (reference) and (R)-10i.  
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Figure 124 HPLC traces (Daicel Chiralpak AD-H column) of rac-10j (reference) and (R)-10j.  
rac-10j 
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Figure 125 HPLC traces (Daicel Chiralpak AD-H column) of rac-10k (reference) and (S)-10k.  
 
rac-10k 
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Figure 126 HPLC traces (Daicel Chiralpak AD-H column) of rac-10l (reference) and (R)-10l.  
rac-10l 
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Figure 127 HPLC traces (Daicel Chiralpak AD-H column) of rac-16a (reference) and (S)-16a.  
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Figure 128 HPLC traces (Daicel Chiralpak AD-H column) of rac-16b' (reference) and (S)-16b'.  
rac-16b‘ 
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Figure 129 HPLC traces (Daicel Chiralpak AD-H column) of rac-16c' (reference) and (S)-16c'.  
 
 
  
rac-16c‘ 
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Figure 130 HPLC traces (Daicel Chiralpak AD-H column) of rac-16d' (reference) and (S)-16d'.  
 
rac-16d‘ 
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Figure 131 HPLC traces (Daicel Chiralpak AD-H column) of rac-16b (reference) and (S)-16b.  
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Figure 132 HPLC traces (Daicel Chiralpak AD-H column) of rac-16c (reference) and (S)-16c.  
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Figure 133 HPLC traces (Daicel Chiralpak AD-H column) of rac-16d (reference) and (S)-16d.  
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Figure 134 HPLC traces (Daicel Chiralpak AD-H column) of rac-16e (reference) and (S)-16e.  
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Figure 135 HPLC traces (Daicel Chiralpak IC column) of rac-16f (reference) and (S)-16f.  
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Figure 136 HPLC traces (Daicel Chiralpak AD-H column) of rac-16g (reference) and (S)-16g.  
rac-16g 
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1  
Figure 137 HPLC traces (Daicel Chiralpak AD-H column) of rac-16h (reference) and (S)-16h.  
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Figure 138 HPLC traces (Daicel Chiralpak AD-H column) of rac-18a (reference) and (S,R)-18a.  
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Figure 139 HPLC traces (Daicel Chiralpak AD-H column) of rac-18b (reference) and (S,R)-18b.  
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Figure 140 HPLC traces (Daicel Chiralpak AD-H column) of rac-18c (reference) and (S,R)-18c.  
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Figure 141 HPLC traces (Daicel Chiralpak AD-H column) of rac-18d (reference) and (S,R)-18d.  
rac-18d 
Chapter 6: Appendices 
250 
 
 
 
 
Figure 142 HPLC traces (Daicel Chiralpak AD-H column) of rac-18e (reference) and (S,R)-18e.  
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Figure 143 HPLC traces (Daicel Chiralpak AD-H column) of rac-20a (reference) and (S)-20a.  
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Figure 144 HPLC traces (Daicel Chiralpak OD-H column) of rac-26a (reference) and (R)-26a.  
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Figure 145 HPLC traces (Daicel Chiralpak OD-H column) of rac-26b (reference) and (R)-26b.  
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Figure 146 HPLC traces (Daicel Chiralpak OD-H column) of rac-26c (reference) and (R)-26c.. 
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Figure 147 HPLC traces (Daicel Chiralpak OD-H column) of rac-26d (reference) and (S)-26d.  
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Figure 148 HPLC traces (Daicel Chiralpak OD-H column) of rac-26e (reference) and (R)-26e.  
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Figure 149 HPLC traces (Daicel Chiralpak OD-H column) of rac-26f (reference) and (S)-26f.  
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Figure 150 HPLC traces (Daicel Chiralpak IC column) of rac-26g (reference) and (R)-26g.  
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Figure 151 HPLC traces (Daicel Chiralpak AD-H column) of rac-26h (reference) and (R)-26h.  
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Figure 152 HPLC traces (Daicel Chiralpak OD-H column) of rac-26i (reference) and (S)-26i.  
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Chapter 6: Appendices 
261 
 
 
 
 
Figure 153 HPLC traces (Daicel Chiralpak OD-H column) of rac-26j (reference) and (S)-26j.  
rac-26j 
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Figure 154 HPLC traces (Daicel Chiralpak OD-H column) of rac-26m (reference) and (R)-26m.  
rac-26m 
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Figure 155 HPLC traces (Daicel Chiralpak OD-H column) of rac-26n (reference) and (R)-26n.  
 
rac-26n 
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Figure 156 HPLC traces (Daicel Chiralpak OD-H column) of rac-26o (reference) and (R)-26o.  
rac-26o 
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Figure 157 HPLC traces (Daicel Chiralpak OD-H column) of rac-26p (reference) and (S)-26p.  
rac-26p 
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Figure 158 HPLC traces (Daicel Chiralpak OD-H column) of rac-26q (reference) and (R)-26q.  
rac-26q 
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Figure 159 HPLC traces (Daicel Chiralpak OD-H column) of rac-26r (reference) and (R)-26r.  
rac-26r 
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Figure 160 HPLC traces (Daicel Chiralpak OD-H column) of rac-26s (reference) and (R)-26s.  
 
rac-26s 
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Figure 161 HPLC traces (Daicel Chiralpak OD-H column) of rac-26t (reference) and (S)-26t.  
rac-26t 
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Figure 162 HPLC traces (Daicel Chiralpak AD-H column) of rac-26u (reference) and (R)-26u.  
rac-26u 
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Figure 163 HPLC traces (Daicel Chiralpak OJ-H column) of rac-26v (reference) and (R)-26v.. 
rac-26v 
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Figure 164 HPLC traces (Daicel Chiralpak IC column) of rac-26w (reference) and (R)-26w.  
rac-26w 
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Figure 165 HPLC traces (Daicel Chiralpak OD-H column) of rac-26x (reference) and (R)-26x.  
 
rac-26x 
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Figure 166 HPLC traces (Daicel Chiralpak OD-H column) of rac-26y (reference) and (R)-26y.  
rac-26y 
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Figure 167 HPLC traces (Daicel Chiralpak AD-H column) of rac-27 (reference) and (R)-27.  
rac-27 
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Figure 168 HPLC traces (Daicel Chiralpak AD-H column) of rac-28 (reference) and (R)-28.  
 
  
rac-28 
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6.7 List of Crystal Structure Data 
 
Figure 169 Crystal structure of Δ-(R)-3. ORTEP drawing with 50% probability thermal ellipsoids. 
 
Table 9 Crystal data and structure refinement for Δ-(R)-3. 
 
Crystal data: 
 
Identification code  w166_0m 
Habitus, colour  needle, yellow 
Crystal size 0.44 x 0.07 x 0.06 mm3 
Crystal system  Orthorhombic 
Space group  P 21 21 21 Z = 4 
Unit cell dimensions a = 13.919(6) Å = 90°. 
 b = 19.144(9) Å = 90°. 
 c = 28.616(11) Å  = 90°. 
Volume 7625(6) Å3 
Cell determination  9357 peaks with Theta 2.3 to 25.7°. 
Empirical formula  C81 H86 Cl6 N6 O8 Rh2 
Formula weight  1690.07 
Density (calculated) 1.472 Mg/m3 
Absorption coefficient 0.704 mm-1 
F(000) 3480 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.302 to 25.497°. 
Index ranges -16<=h<=16, -23<=k<=23, -33<=l<=34 
Data collection software  BRUKER APEX2 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 64188 
Independent reflections 14187 [R(int) = 0.0642] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  12148[II > 2(I)]  
Reflections used for refinement  14187 
Absorption correction Numerical 
Max. and min. transmission 0.96 and 0.76 
Flack parameter (absolute struct.)   -0.020(10) 
Largest diff. peak and hole 0.569 and -0.435 e.Å-3 
Solution  direct/ difmap 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  geom, constr 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 14187 / 114 / 996 
Goodness-of-fit on F2 1.024 
R index (all data) wR2 = 0.0682 
R index conventional  [I>2sigma(I)] R1 = 0.0358 
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Figure 170 Crystal structure of Δ-RhO. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion is omitted for clarity. 
 
Table 10 Crystal data and structure refinement for Δ-RhO. 
 
Crystal data:  
 
Identification code  w169_0m 
Habitus, colour  nugget, colourless 
Crystal size 0.51 x 0.24 x 0.17 mm3 
Crystal system  Orthorhombic 
Space group  P 21 21 21 Z = 4 
Unit cell dimensions a = 13.1445(5) Å = 90°. 
 b = 13.6427(6) Å = 90°. 
 c = 22.5166(8) Å  = 90°. 
Volume 4037.8(3) Å3 
Cell determination  9096 peaks with Theta 2.3 to 27.5°. 
Empirical formula  C39 H40 Cl2 F6 N4 O2 P Rh 
Formula weight  915.53 
Density (calculated) 1.506 Mg/m3 
Absorption coefficient 0.662 mm-1 
F(000) 1864 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.345 to 27.520°. 
Index ranges -17<=h<=17, -15<=k<=17, -29<=l<=29 
Data collection software  BRUKER APEX2 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 39009 
Independent reflections 9272 [R(int) = 0.0416] 
Completeness to theta = 25.242° 99.8 %  
Observed reflections  8540[II > 2(I)]  
Reflections used for refinement  9272 
Absorption correction Numerical 
Max. and min. transmission 0.90 and 0.75 
Flack parameter (absolute struct.)   -0.033(8) 
Largest diff. peak and hole 0.511 and -0.396 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 9272 / 168 / 590 
Goodness-of-fit on F2 1.033 
R index (all data) wR2 = 0.0579 
R index conventional  [I>2sigma(I)] R1 = 0.0287 
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Figure 171 Crystal structure of 5d. ORTEP drawing with 50% probability thermal ellipsoids. 
 
Table 11 Crystal data and structure refinement for 5d. 
 
Crystal data:  
 
Identification code  w189b_0m 
Habitus, colour  Needle, colourless 
Crystal size 0.45 x 0.08 x 0.05 mm3 
Crystal system  Orthorhombic 
Space group  P 21 21 21 Z = 4 
Unit cell dimensions a = 5.4571(2) Å = 90°. 
 b = 15.3289(6) Å = 90°. 
 c = 17.4084(9) Å  = 90°. 
Volume 1456.24(11) Å3 
Cell determination  4862 peaks with Theta 2.3 to 27.1°. 
Empirical formula  C14 H18 N2 O5 
Formula weight  294.30 
Density (calculated) 1.342 Mg/m3 
Absorption coefficient 0.103 mm-1 
F(000) 624 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.340 to 25.488°. 
Index ranges -6<=h<=5, -18<=k<=18, -21<=l<=21 
Data collection software  BRUKER APEX2 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
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Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 11088 
Independent reflections 2707 [R(int) = 0.0367] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  2478[II > 2(I)]  
Reflections used for refinement  2707 
Absorption correction Numerical 
Max. and min. transmission 0.99 and 0.95 
Flack parameter (absolute struct.)   0.3(4) 
Largest diff. peak and hole 0.146 and -0.203 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  geom, constr 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 2707 / 0 / 194 
Goodness-of-fit on F2 1.051 
R index (all data) wR2 = 0.0666 
R index conventional  [I>2sigma(I)] R1 = 0.0291 
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Figure 172 Crystal structure of racemic 5f to verify the relative configuration. ORTEP drawing with 50% 
probability thermal ellipsoids. 
 
Table 12 Crystal data and structure refinement for 5f. 
 
Crystal data:  
 
Identification code  w234b_0m 
Habitus, colour  prism,  colourless 
Crystal size 0.40 x 0.30 x 0.08 mm3 
Crystal system  Monoclinic 
Space group  P 21/c Z = 4 
Unit cell dimensions a = 10.1905(5) Å = 90°. 
 b = 11.5731(6) Å = 97.5045(16)°. 
 c = 17.4203(8) Å  = 90°. 
Volume 2036.88(17) Å3 
Cell determination  9754 peaks with Theta 2.4 to 27.5°. 
Empirical formula  C22 H26 N2 O4 
Formula weight  382.45 
Density (calculated) 1.247 Mg/m3 
Absorption coefficient 0.086 mm-1 
F(000) 816 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.118 to 27.536°. 
Index ranges -13<=h<=13, -15<=k<=15, -22<=l<=22 
Data collection software  BRUKER APEX2 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 47435 
Independent reflections 4679 [R(int) = 0.0370] 
Completeness to theta = 25.242° 100.0 %  
Observed reflections  3939[I > 2σ(I)]  
Reflections used for refinement  4679 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.99 and 0.93 
Largest diff. peak and hole 0.353 and -0.349 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2013 (Sheldrick, 2013) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 4679 / 0 / 258 
Goodness-of-fit on F2 1.122 
R index (all data) wR2 = 0.1143 
R index conventional  [I>2sigma(I)] R1 = 0.0381 
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Figure 173 Crystal structure of racemic 6 to verify the relative configuration. ORTEP drawing with 50% 
probability thermal ellipsoids. 
 
Table 13 Crystal data and structure refinement for racemic 6. 
 
Crystal data:  
 
Identification code  w283_0m_sq 
Habitus, colour  colourless, block 
Crystal size 0.47 x 0.11 x 0.08 mm3 
Crystal system  Triclinic 
Space group  P -1 Z = 2 
Unit cell dimensions a = 9.3288(4) Å = 70.7804(13)°. 
 b = 12.2132(5) Å = 76.9655(13)°. 
 c = 14.0156(5) Å  = 72.0469(13)°. 
Volume 1420.69(10) Å3 
Cell determination  9973 peaks with Theta 2.5 to 25.3°. 
Empirical formula  C27 H26 N6 O5 
Moiety formula  C27 H26 N6 O5 
Formula weight  514.54 
Density (calculated) 1.203 Mg/m3 
Absorption coefficient 0.085 mm-1 
F(000) 540 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
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Temperature  115(2) K 
Theta range for data collection 2.317 to 25.314°. 
Index ranges -11<=h<=9, -14<=k<=14, -16<=l<=16 
Data collection software  BRUKER APEX2 2014.1-1 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 31742 
Independent reflections 5175 [R(int) = 0.0337] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  4346[II > 2(I)]  
Reflections used for refinement  5175 
Absorption correction Numerical 
Max. and min. transmission 0.99 and 0.96 
Largest diff. peak and hole 0.411 and -0.205 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  CH riding model, NH located, iotropic ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2014 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 5175 / 0 / 349 
Goodness-of-fit on F2 1.037 
R index (all data) wR2 = 0.1163 
R index conventional  [I>2sigma(I)] R1 = 0.0426 
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Figure 174 Crystal structure of RhO-I. ORTEP drawing with 50% probability thermal ellipsoids. The 
hexafluorophosphate counteranion is omitted for clarity. 
 
Table 14 Crystal data and structure refinement for RhO-I. 
 
Crystal data:  
 
Identification code  w261_0m_sq 
Habitus, colour  needle, yellow 
Crystal size 0.26 x 0.06 x 0.03 mm3 
Crystal system  Orthorhombic 
Space group  P n a 21 Z = 4 
Unit cell dimensions a = 17.7761(6) Å = 90°. 
 b = 22.9437(8) Å = 90°. 
 c = 13.1111(4) Å  = 90°. 
Volume 5347.4(3) Å3 
Cell determination  9841 peaks with Theta 2.5 to 25.3°. 
Empirical formula  C51 H52 Cl4 F6 N4 O3 P Rh 
Moiety formula  C49 H48 N4 O3 Rh, F6 P, 2(C H2 Cl2) 
Formula weight  1158.64 
Density (calculated) 1.439 Mg/m3 
Absorption coefficient 0.615 mm 
F(000) 2368 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.113 to 25.329°. 
Index ranges -21<=h<=21, -27<=k<=27, -15<=l<=15 
Data collection software  BRUKER APEX2 2014.1-1 
Cell refinement software  SAINT V8.34A (Bruker AXS Inc., 2013) 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 56957 
Independent reflections 9643 [R(int) = 0.0497] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  8691[II > 2(I)]  
Reflections used for refinement  9643 
Absorption correction Numerical 
Max. and min. transmission 0.98 and 0.88 
Flack parameter (absolute struct.)   -0.015(8) 
Largest diff. peak and hole 1.123 and -0.508 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  SHELXS-97 (Sheldrick, 2008) 
 SHELXL-2014 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 9643 / 106 / 705 
Goodness-of-fit on F2 1.034 
R index (all data) wR2 = 0.0889 
R index conventional  [I>2sigma(I)] R1 = 0.0348 
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Figure 175 Crystal structure of an iridium enolate complex B. ORTEP drawing with 50% probability 
thermal ellipsoids. 
 
Table 15 Crystal data and structure refinement for an iridium enolate complex B. 
 
Crystal data:  
 
Identification code  w452_2_0m 
Habitus, colour  prism,  red 
Crystal size 0.180 x 0.040 x 0.020 mm3 
Crystal system  Monoclinic 
Space group  P21/n Z = 4 
Unit cell dimensions a = 14.5673(8) Å = 90°. 
 b = 13.2686(7) Å = 91.578(3)°. 
 c = 21.6394(13) Å  = 90°. 
Volume 4181.0(4) Å3 
Cell determination  9213 peaks with Theta 2.3 to 25.3°. 
Empirical formula  C51 H45 Ir N4 O3 
Moiety formula  C51 H45 Ir N4 O3 
Formula weight  954.11 
Density (calculated) 1.516 Mg/m3 
Absorption coefficient 3.242 mm-1 
F(000) 1920 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.264 to 25.306°. 
Index ranges -15<=h<=17, -15<=k<=15, -25<=l<=26 
Data collection software  BRUKER APEX2 2014.9-0 
Cell refinement software  BRUKER SAINT 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) 
 
Solution and refinement: 
 
Reflections collected 50910 
Independent reflections 7598 [R(int) = 0.0654] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  6059[I>2sigma(I) ]  
Reflections used for refinement  7598 
Absorption correction Numerical 
Max. and min. transmission 0.94 and 0.67 
Largest diff. peak and hole 1.311 and -0.851 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  SHELXS-97 (Sheldrick, 2008)  
 SHELXL-2014/7 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact) 
Data / restraints / parameters 7598 / 0 / 569 
Goodness-of-fit on F2 1.039 
R index (all data) wR2 = 0.0578 
R index conventional  [I>2sigma(I)] R1 = 0.0309 
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Figure 176 Crystal structure of (R)-10e. ORTEP drawing with 50% probability thermal ellipsoids. 
 
Table 16 Crystal data and structure refinement for 10e. 
 
Crystal data:  
 
Identification code  w445c_0m 
Habitus, colour  needle, colourless 
Crystal size 0.51 x 0.09 x 0.04 mm3 
Crystal system  Orthorhombic 
Space group  P212121 Z = 4 
Unit cell dimensions a = 9.2411(4) Å = 90°. 
 b = 11.5916(6) Å = 90°. 
 c = 23.1471(12) Å  = 90°. 
Volume 2479.5(2) Å3 
Cell determination  3967 peaks with Theta 2.5 to 25.2°. 
Empirical formula  C30 H24 Cl N3 O 
Moiety formula  C30 H24 Cl N3 O 
Formula weight  477.97 
Density (calculated) 1.280 Mg/m3 
Absorption coefficient 0.182 mm-1 
F(000) 1000 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.373 to 25.299°. 
Index ranges -10<=h<=11, -13<=k<=13, -27<=l<=27 
Data collection software  BRUKER APEX2 2014.9-0 (APEX2 2014) 
Cell refinement software  BRUKER SAINT (SAINT 2013) 
Data reduction software  SAINT V8.34A (SAINT 2013) 
  
Solution and refinement: 
 
Reflections collected 13057 
Independent reflections 4492 [R(int) = 0.0501] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  3776[I>2sigma(I) ]  
Reflections used for refinement  4492 
Absorption correction Semi-empirical from equivalents (SADABS 2014) 
Max. and min. transmission 0.99 and 0.91 
Flack parameter (absolute struct.)   0.00(4) 
Largest diff. peak and hole 0.191 and -0.221 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, riding model 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014, Sheldrick 2008)) 
 SHELXL-2014/7 (Sheldrick 2008) 
 DIAMOND (Brandenburg 2014) 
Data / restraints / parameters 4492 / 0 / 316 
Goodness-of-fit on F2 1.047 
R index (all data) wR2 = 0.0728 
R index conventional  [I>2sigma(I)] R1 = 0.0358 
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Figure 177 Crystal structure of (S)-16g. ORTEP drawing with 50% probability thermal ellipsoids. 
 
Table 17 Crystal data and structure refinement for 16g. 
 
Crystal data:  
 
Identification code  w875chiral_0m 
Habitus, colour  block, colourless 
Crystal size 0.45 x 0.36 x 0.22 mm3 
Crystal system  Monoclinic 
Space group  P21 Z = 4 
Unit cell dimensions a = 10.4418(6) Å = 90°. 
 b = 18.1671(9) Å = 106.238(2)°. 
 c = 12.1722(7) Å  = 90°. 
Volume 2216.9(2) Å3 
Cell determination  9854 peaks with Theta 2.3 to 27.5°. 
Empirical formula  C24 H18 Cl2 F3 N3 O 
Moiety formula  C24 H18 Cl2 F3 N3 O 
Formula weight  492.31 
Density (calculated) 1.475 Mg/m3 
Absorption coefficient 0.341 mm-1 
F(000) 1008 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.242 to 27.544°. 
Index ranges -13<=h<=13, -23<=k<=23, -15<=l<=15 
Data collection software  BRUKER APEX2 2014.9-0  
Cell refinement software  BRUKER SAINT [2] 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013)  
 
Solution and refinement: 
 
Reflections collected 71801 
Independent reflections 10210 [R(int) = 0.0299] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  9680[I>2sigma(I) ]  
Reflections used for refinement  10210 
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.93 and 0.87 
Flack parameter (absolute struct.)   0.017(7) 
Largest diff. peak and hole 0.293 and -0.372 e.Å-3 
Solution  Direct methods  
Refinement  Full-matrix least-squares on F2  
Treatment of hydrogen atoms  CH cal. positions, constr. ref., OH located, isotr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact)  
Data / restraints / parameters 10210 / 1 / 603 
Goodness-of-fit on F2 1.044 
R index (all data) wR2 = 0.0671 
R index conventional  [I>2sigma(I)] R1 = 0.0281 
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Figure 178 Crystal structure of 18a. ORTEP drawing with 50% probability thermal ellipsoids. 
 
Table 18 Crystal data and structure refinement for 18a. 
 
Crystal data:  
 
Identification code  w812_0m 
Habitus, colour  block, colourless 
Crystal size 0.26 x 0.20 x 0.19 mm3 
Crystal system  Orthorhombic 
Space group  P212121 Z = 4 
Unit cell dimensions a = 9.4488(4) Å = 90°. 
 b = 15.6639(6) Å = 90°. 
 c = 31.2528(12) Å  = 90°. 
Volume 4625.6(3) Å3 
Cell determination  9976 peaks with Theta 2.3 to 27.5°. 
Empirical formula  C53 H46 Cl2 F6 N6 O2 
Moiety formula  2(C26 H22 F3 N3 O), C H2 Cl2 
Formula weight  983.86 
Density (calculated) 1.413 Mg/m3 
Absorption coefficient 0.215 mm-3 
F(000) 2040 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.252 to 27.504°. 
Index ranges -9<=h<=12, -20<=k<=20, -40<=l<=31 
Data collection software  BRUKER APEX2 2014.9-0  
Cell refinement software  BRUKER SAINT  
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013)  
 
Solution and refinement: 
 
Reflections collected 23538 
Independent reflections 10598 [R(int) = 0.0221] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  9498[I>2sigma(I) ]  
Reflections used for refinement  10598 
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.96 and 0.91 
Flack parameter (absolute struct.)   0.018(17) 
Largest diff. peak and hole 0.275 and -0.374 e.Å-3 
Solution  Direct methods  
Refinement  Full-matrix least-squares on F2  
Treatment of hydrogen atoms  CH cal. positions, constr. ref., OH located, isotr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact)  
Data / restraints / parameters 10598 / 0 / 640 
Goodness-of-fit on F2 1.054 
R index (all data) wR2 = 0.0807 
R index conventional  [I>2sigma(I)] R1 = 0.0374 
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Figure 179 Crystal structure of rhodium intermediate RhS-I. ORTEP drawing with 50% probability 
thermal ellipsoids. Hexafluorophosphate counterion, hydrogen atoms and one CH2Cl2 molecular are 
omitted for clarity. 
 
Table 19 Crystal data and structure refinement for RhS-I. 
 
Crystal data:  
 
Identification code  w1280_0m 
Habitus, colour  cubic prism, yellow 
Crystal size 0.37 x 0.28 x 0.23 mm-3 
Crystal system  Triclinic 
Space group  P-1 Z = 2 
Unit cell dimensions a = 12.0250(5) Å α = 90.447(2)°. 
 b = 13.9944(6) Å β = 111.549(2)°. 
 c = 14.7168(7) Å γ = 101.223(2)°. 
Volume 2250.88(17) Å3 
Cell determination  9730 peaks with Theta 2.6 to 27.5°. 
Empirical formula  C44 H46 Cl2 F6 N4 O P Rh S2 
Moiety formula  C43 H44 N4 O Rh S2, F6 P, C H Cl2 
Formula weight  1029.75 
Density (calculated) 1.519 Mg/m3 
Absorption coefficient 0.691 mm-1 
F(000) 1052 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.244 to 27.557°. 
Index ranges -15<=h<=15, -17<=k<=18, -19<=l<=19 
Data collection software  APEX3 (Bruker AXS Inc., 2015)  
Cell refinement software  SAINT V8.35A (Bruker AXS Inc., 2015)    
Data reduction software  SAINT V8.35A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 56167 
Independent reflections 10388 [R(int) = 0.0229] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  9652[I > 2(I)]  
Reflections used for refinement  10388 
Extinction coefficient  X = 0.0030(2) 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.86 and 0.80 
Largest diff. peak and hole 1.024 and -0.604 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)   
 SHELXL-2014/7 (Sheldrick, 2014) 
 DIAMOND (Crystal Impact)   
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)   
Data / restraints / parameters 10388 / 0 / 560 
Goodness-of-fit on F2 1.054 
R index (all data) wR2 = 0.0550 
R index conventional  [I>2sigma(I)] R1 = 0.0226 
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Figure 180 Crystal structure of (R)-26t. ORTEP drawing with 50% probability thermal ellipsoids.  
 
Table 20 Crystal data and structure refinement for 26t. 
 
Crystal data:  
 
Identification code  w1272_0m 
Habitus, colour  needle, colourless 
Crystal size 0.44 x 0.08 x 0.08 mm3 
Crystal system  Monoclinic 
Space group  C2 Z = 4 
Unit cell dimensions a = 19.0297(14) Å α = 90°. 
 b = 8.3596(6) Å β = 104.557(2)°. 
 c = 18.4008(14) Å λ = 90°. 
Volume 2833.2(4) Å3 
Cell determination  9951 peaks with Theta 2.3 to 25.3°. 
Empirical formula  C30 H39 N3 O5 S 
Moiety formula  C30 H39 N3 O5 S 
Formula weight  553.70 
Density (calculated) 1.298 Mg/m3 
Absorption coefficient 0.158 mm-1 
F(000) 1184 
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Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.220 to 25.328°. 
Index ranges -22<=h<=20, -10<=k<=10, -22<=l<=22 
Data collection software  APEX3 (Bruker AXS Inc., 2015)  
Cell refinement software  SAINT V8.35A (Bruker AXS Inc., 2015)   
Data reduction software  SAINT V8.35A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 33859 
Independent reflections 5163 [R(int) = 0.0549] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  4655[I > 2(I)]  
Reflections used for refinement  5163 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.99 and 0.92 
Flack parameter (absolute struct.)   0.00(3) 
Largest diff. peak and hole 0.177 and -0.282 e.Å-3 
Solution  Direct Methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  CH calculated, OH located, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)  
 SHELXL-2014/7 (Sheldrick, 2014)  
 DIAMOND (Crystal Impact)  
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)   
Data / restraints / parameters 5163 / 193 / 450 
Goodness-of-fit on F2 1.093 
R index (all data) wR2 = 0.0777 
R index conventional [I>2sigma(I)] R1 = 0.0348 
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Statement 
 
gemäß § 10, Abs. 1 der Promotionsordnung der mathematisch-naturwissenschaftlichen 
Fachbereiche und des Medizinischen Fachbereichs für seine mathematisch- 
naturwissenschaftlichen Fächer der Philipps-Universität Marburg vom 15.07.2009 
 
Ich erkläre, dass eine Promotion noch an keiner anderen Hochschule als der Philipps- 
Universität Marburg, Fachbereich Chemie, versucht wurde und versichere, dass ich meine 
vorgelegte Dissertation 
 
Asymmetric Catalysis with Octahedral Chiral-at-Metal Iridium and 
Rhodium Complexes 
 
selbst und ohne fremde Hilfe verfasst, nicht andere als die in ihr angegebenen Quellen oder 
Hilfsmittl benutz, alle vollständig oder sinngemäß übernommenen Zitate als solche 
gekennzeichnet sowie die Dissertation in der vorliegenden oder ähnlichen Form noch bei keiner 
anderen in- oder ausländischen Hochschule anlässlich eines Promotionsgesuchs oder zu 
anderen Prüfungszwecken eingereicht habe. 
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